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Abstract
The intracellular protozoan parasite Leishmania causes leishmaniasis, a disease which is 
most prevalent in tropical and sub-tropical countries where it infects some two million 
people every year and kills around 60,000 of them. For decades pentavalent antimonial 
compounds have been the standard first-line drugs used to treat the disease and this 
remains the case despite increasing reports of drug-resistance. The mode of action of these 
drugs is not entirely understood, although it is generally accepted that in vivo reduction of 
the compounds from the pentavalent to a trivalent form is required for antileishmanial 
activity. The site of antimonial conversion and whether the reaction is catalysed by an 
enzyme remain controversial points. However, it was recently reported that L. donovani 
amastigotes were capable of reducing pentavalent antimonials to the trivalent form and that 
drug-resistant parasites were deficient in this activity, suggesting that a parasite enzyme 
did mediate drug toxicity. The identity of such an enzyme was investigated in this study.
Arsenical and antimonial compounds are similar and several classes of proteins that exhibit 
arsenate reductase activity have been previously identified in other organisms. Whether 
Leishmania possessed an enzyme akin to one of these was assessed by attempting to purify 
enzymes from parasite lysates and by searching the L. major genome database for similar 
sequences to the arsenate reductases. The latter approach was successful and a gene 
fragment was identified that shared similarity with omega glutathione S-transferases 
(oGSTs), a class of glutaredoxin-like GSTs which are capable of reducing pentavalent 
methylated arsenicals in vitro. The sequence of the complete L. major gene was elucidated 
by 5’ RACE, and was found to encode a protein tvfice the expected size with similar 3’ and 
5’ halves. The protein was named thiol-dependent reductase, or TDRl. Active recombinant 
protein was successfrilly produced and its biochemical activities were found to coincide 
with oGSTs: TDRl was capable of reducing pentavalent arsenical and antimonial 
compounds to trivalent species, and possessed thioltransferase and dehydroascorbate 
reductase activities usually associated with glutaredoxins. TDRl, which was shown to 
probably reside in the parasite cytosol but may also be secreted, was found to be more 
abundant in amastigote than promastigote forms, which correlates with the antileishmanial 
stage-specificity of pentavalent antimonials. L. major TDRl knockout mutants were 
generated, and the protein was also over-expressed in parasites. Both these genetic 
manipulations resulted in mutants with enhanced inactivity.
TDRl knockout parasites were more susceptible than wild type parasites to paraquat, 
which induces the production of intracellular superoxide. As its glutaredoxin-like in vitro
Ill
activities suggest, this implies TDRl has a role in protecting the parasites from oxidative 
stress, although re-expression of TDRl did not reinstate resistance. Whether TDRl has a 
role in susceptibility to pentavalent antimonials was investigated by studying the effect of 
the drug on L. major in macrophages. There appeared to be little difference in the effect of 
the drug on TDRl knockout, over-expressing and wild type parasites, although variation in 
inactivity to macrophages and the insensitivity of L. major to the drug complicated the 
situation.
Whether trivalent antimonials could be oxidised to non-trivalent species by hydrogen 
peroxide was assessed. This was indeed found to be the case, demonstrating that in 
principle antimonial metabolism may be more complex than straightforward reduction 
from the pentavalent to trivalent form. However, the physiological relevance of this finding 
is uncertain due to oxidation of the antimonials being inhibited by glutathione.
The dehydroascorbate reductase activity of TDRl was of interest as the presence of an 
enzyme capable of maintaining ascorbate in its reduced form may imply that this low- 
molecular weight thiol is important in the parasite. The recent identification of an 
ascorbate-dependant peroxidase in Leishmania added further credence to this hypothesis. 
Many organisms produce ascorbate de novo although, due to the loss of an important 
synthesis enzyme, humans cannot and have to scavenge ascorbate from their diet. If 
Leishmania does require ascorbate and rely on de novo production, enzymes that mediate 
synthesis could feasibly be exploitable drug targets. Whether Leishmania was capable of 
producing ascorbate and its importance in the parasite was investigated. The L  major 
genome database was searched for sequences similar to those of enzymes known to be 
involved in ascorbate synthesis in other organisms. Several candidate protein sequences 
were identified including that of one which is similar to L-gulono lactone oxidase (GLO), 
the enzyme that mediates the final step in ascorbate production in a variety of organisms 
and is the protein humans no longer possess. This L  major sequence was named LmGLO. 
L. major LmGLO knockout mutants were generated and the protein was also over­
expressed in parasites. While over-expression resulted in parasites being more infective, 
loss of LmGLO resulted in decreased infectivity, both in vitro and in vivo. In addition, 
LmGLO knockout promastigotes displayed a slight growth defect. Although these results 
need extending, they suggest that Leishmania parasites do indeed synthesise ascorbate and 
that this ability is important for optimal virulence and infectivity to mammals.
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1 Introduction
1.1 The Leishmania parasite
The genus Leishmania belongs to the family Trypanosomatidae, of the order 
Kinetoplastida, a reference to the unusual kinetoplast organelle that the parasite contains in 
its single mitochondrion. Over 20 species of the protozoan parasites are known to exist, 
which cause different manifestations of the disease leishmaniasis in a variety of 
mammalian hosts, such as canids and rodents, as well as humans. Leishmania parasites are 
most closely related to trypanosomatids such as Trypanosoma brucei and Trypanosoma 
cruzi, the causative agents of African sleeping sickness and Chagas disease, respectively. 
The vector responsible for spreading the eukaryotic Leishmania parasite is the female sand 
fly of the genus Phlebotomus in the old world and Lutzomyia in the new world. Leishmania 
parasites eause the disease leishmaniasis, which is most prevalent in tropical and sub­
tropical regions where the sand flies thrive, and in more than 80 countries the parasite is 
endemic.
1.1.1 The Leishmania life cycle
The parasite can exist in several different states during its life cycle, which is illustrated in 
figure 1.1. While in the sand fly vector they exist as promastigotes, transforming from 
procyclic to metacyclic forms. The motile promastigotes are an elongated oval shape with 
an anterior flagellum, approximately 10-20 pM in length, which replicate by asexual 
reproduction. The infectious metacyclic forms differ from procyclics in several ways: they 
have narrower bodies and longer flagella, are more motile, do not divide and have different 
biochemical compositions (Mallinson and Coombs 1989) and protein expression profiles 
(Nugent et al, 2004). As such, they are considered to be a distinct life-cycle stage. 
Following metacyclogenesis, the promastigotes migrate from the midgut to the proboscis 
of the insect vector, and are transmitted to the animal host when the sand fly bites. 
Thereafter the promastigotes are phagocytosed by host macrophages (and other cells 
(Bogdan et al, 2000)) where they transform to amastigote forms and proliferate, dividing 
again by binary fission, in the phagolysosome. Amastigotes are morphologically and 
biochemically distinct from promastigotes: they are much smaller (2-6 pm in diameter), 
immobile, ovoid forms lacking prominent flagella, and have very different protein 
expression profiles (Walker et al, 2006). Parasite-containing macrophages rupture and 
release the amastigotes, which then go on to infect more cells. Amastigotes are then taken 
up in a subsequent sandfly bite. Once in the vector, the amastigotes transform to procyclic
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promastigotes, recommencing the cycle. Leishmania promastigotes can be grown in 
culture, facilitating research into the parasites. In addition, amastigotes of some species can 
also be grown axenically (Gupta et al, 2001).
Intracellular amastigote
Transformation
Proliferation
Uptake
Uptake
Lysis/ \Phagolysosome bursting)
Attachment
MacrophageAttachment Mammalian host
Sandfly bite Sandfly biteSandfly
Amastigotes
MetacycHc 
promastigotes
FYocydic 
promastigotes
Migration 
to the 
mouthparts
fransformation
FYoliferation in the midgut
Figure 1.1: Life cycle of Leishmania. The amastigote (Intracellular In mammalian host) and 
promastigote (extracellular In Insect vector) life cycle stages are depicted. This Image Is taken from 
the website www.wehl.edu.au/medla/lmages/lelshmanla_cycle.glf.
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1.1.2 The Leishmania genome and regulation of gene expression
The genomes of several Leishmania species, which are diploid organisms, are currently 
being sequenced and the complete, annotated genome sequence of Leishmania major 
Freidlin was recently published (Ivens et al, 2005). Z. major has a 32.8 megabase haploid 
genome divided into 36 chromosomes and is predicted to contain 8272 protein-encoding 
genes and 911 RNA genes. In addition, the kinetoplast contains its own DNA (kDNA) 
which is the equivalent of mitochondrial DNA. However, kDNA is arranged in an unusual 
structure comprising catenated minicircles of which there are several thousand per 
kinetoplast, and maxicircles of which there are several dozen. Approximately 20 proteins 
are encoded by maxicircle kDNA, most of which are thought to be mitochondrial proteins 
involved in energy transduction,
Leishmania have an unusual method of gene expression with chromosomal protein- 
encoding genes being arranged in directional gene clusters (Myler et al, 1999) which 
undergo polycistronic transcription (Worthey et al, 2003). Accordingly, mRNA 
abundance does not necessarily reflect the level of a given protein in the parasites (Holzer 
et al, 2006; McNicoll et al, 2006), meaning that analysis of the expression level of 
Leishmania proteins by northern blotting is problematic. Like in other trypanosomatids, a 
conserved RNA sequence of 39 nucleotides, which is known as the splice-leader sequence, 
is trans-spliced onto the 5’ end of all Leishmania mRNAs; the 3’ end of most mRNAs are 
polyadenylated by trans-splicing also. These events are required for successful translation. 
Gene expression and resulting protein levels in trypanosomatids are thought to be mediated 
in several non-transcriptional ways: RNA degradation, control of translation and post- 
translational events are all thought to contribute, as reviewed in Clayton, 2002.
1.1.3 Redox regulation in trypanosomatids
upon infection of an organism, parasitic protozoa encounter high levels of reactive oxygen 
species due to the oxidative burst response of the host’s immune system and it is therefore 
of interest that trypanosomatids exhibit atypical mechanisms for dealing with oxidative 
stress. Distinctive thiol-based systems for regulating the redox environment have evolved 
in many protozoan parasites (reviewed in Muller et al, 2003b). In trypanosomatids these 
differences are underpinned by the presence of two unusual thiols that have been 
identified: ovothiol and trypanothione (T(SH)2). The precise function of ovothiol is not yet 
fully understood as, despite its abundance in Leishmania^ it is not known to participate in 
any enzymatic reactions and may simply act as a scavenger of reactive oxygen species
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(ROS) (Ariyanayagani and Fairlamb 2001). Meanwhile, T(SH)2  has a pivotal role in the 
thiol-based redox metabolism of Leishmania because it is responsible for keeping other 
thiols reduced. Although trypanosomatids also contain high levels of the almost ubiquitous 
thiol glutathione (GSH), they lack glutathione reductase which in other systems reduces 
glutathione disulphide (GSSG), the oxidised form of GSH. Instead they possess 
trypanothione reductase (TR), an essential enzyme in Leishmania (Tovar et al, 1998), 
which regenerates oxidised trypanothione (TS2) to the reduced T(SH)2 , which in turn 
reduces GSSG (Fairlamb et al„ 1985). Although this reaction occurs non-enzymatically, 
the Trypanosoma cruzi enzyme Tc52 is also able to catalyse the reduction of GSSG by 
T(SH) 2  (Montiez et al„ 1995). Ovothiol is also dependant on T(SH)2  for maintenance in 
its reduced state (Ariyanayagam and Fairlamb 2001).
T(SH)2  is comprised of two molecules of GSH that are linked by a molecule of spermidine, 
the conjugation of which is catalysed by trypanothione synthetase in L. major (Oza et al, 
2005), T brucei (Oza et al, 2003) and T cruzi (Oza et al, 2002). In the non-pathogenic 
insect trypanosomatid Crithidia fasiculata, which has been used as a model organism for 
investigating T(SH)2  synthesis, two enzymes were thought to regulate the formation of 
T(SH)2 : glutathionylspermidine synthetase and trypanothione synthetase (TS) (Tetaud et 
al, 1998). However, more recent findings have shown that only the latter enzyme is 
required for T(SH)2  synthesis (Comini et al, 2005) as is the case in pathogenic 
trypanosomatids. T(SH)2  participates in many enzymatic and non-enzymatic reactions 
including the reduction of dehydroascorbate (Krauth-Siegel and Ludemann 1996) and acts 
as a co-factor with trypanothione S-transferases (which have been postulated to replace 
glutathione S-transferases in trypanosomatids) in the detoxification of xenobiotics (Vickers 
et al, 2004). In addition T(SH)2  reduces tryparedoxin, a trypanosomatid-specific 
thioredoxin-like protein which reduces peroxiredoxins which in turn enzymatically 
detoxify hydroperoxides (Nogoceke et al, 1997). Peroxidases are thought to be of 
particular importance in some parasitic protozoa due to the absence of catalase (Muller et 
al, 2003b). The reducing equivalents for DNA synthesis are also provided by T(SH) 2  as it 
reduces ribonucleotide reductase (the enzyme required to synthesise nucleotide 
precursors), either directly or via tryparedoxin (Dormeyer et al, 2001).
Reflecting the diversity of the reactions T(SH)2  is involved in and its role in regulating the 
redox environment of the parasite, enzymes known to be involved in T(SH)2  synthesis and 
regeneration -  namely TR and TS -  are thought to be essential in trypanosomes. When 
RNAi was performed on T. brucei parasites resulting in reduced levels of TS, growth 
defects and increased sensitivity to oxidative stress, together with elevated levels of TR,
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were observed (Comini et al, 2004; Ariyanayagam et al, 2005). Attempts to create L. 
donovani TR null-mutants have been unsuccessful and both L. donovani and T. brucei 
parasites engineered to have reduced levels of the protein exhibited diminished viability in 
vivo (reviewed in Krauth-Siegel and Inhoff, 2003). These findings, coupled with the 
parasite-specific nature of the thiol, has lead to T(SH)2  metabolism being considered a 
valid drug-target and inhibitors of both TR and TS being sought. Indeed trivalent 
antimonial drugs, the reduced form of the most common first-line treatment against 
leishmaniasis, have been shown to inhibit TR in vitro (Cunningham and Fairlamb, 1995) 
and both the administered pentavalent antimonials and the trivalent form exert effects 
suggestive of inhibition of TR in vivo (Wyllie et al, 2004).
1.2 Leishmaniasis
The World Health Organisation collates epidemiological information on leishmaniasis and 
much of the forthcoming information was obtained from their relevant website at 
http://www.who.int/leishmaniasis/. Disease resulting from infection with the parasite 
LeishmaniahdiS three predominant forms: visceral, cutaneous and mucocutaneous 
leishmaniasis. Visceral leishmaniasis is the most severe form: symptoms include fever, 
diarrhoea, hepatosplenomegaly, pancytopenia, epistaxis, cachexia and peripheral 
lymphodenopathy, and, if left untreated, this form of the infection is almost always fatal. 
Visceral leishmaniasis affects many different bodily organs; macrophages become infected 
with parasites throughout the reticuloendothelial system and they ultimately reach the liver, 
spleen and bone marrow. The incubation period of the disease can be months or even 
longer, with death usually occurring in untreated sufferers approximately two years later. 
Infection with several species of Leishmania causes the visceral form of the disease; these 
include the old world species L. tropica, L. donovani, and L. infantum, andZ. chagasi in 
the new world (which is very similar to Z. infantum).
The least severe form of the disease is cutaneous leishmaniasis, a form that affects the skin. 
It causes isolated ulcers on exposed parts of the body, which are often disfiguring and 
leave scars. However, given enough time, spontaneous healing can occur which can result 
in leishmaniasis immunity in the patient. Cutaneous leishmaniasis is caused by infection 
with old world species Z. major, L. tropica and Z. aethiopica; and new world species Z. 
mexicana, Z. amazonensis, L. braziliensis, L. peruviana, Z. guyanensis and Z. panamensis. 
Z. aethiopica and Z. amazonensis can also cause a more severe form of the skin disease 
known as diffuse cutaneous leishmaniasis which requires treatment. As well as a lesion
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forming at the site of infection, chronic satellite lesions occur as the parasites metastasise 
to other areas of the skin.
The third distinct form of the disease, known as mucocutaneous leishmaniasis, also affects 
the skin but also facial mucosal tissue. A cutaneous infection can descend into the 
mucocutaneous variety months after the initial lesion has healed. Infection can lead to 
complete degradation of the nose, mouth and throat, which is both highly debilitating and 
disfiguring, and fatality can result from secondary infections. Mucocutaneous 
leishmaniasis is caused by infection with L. braziliensis and, less frequently, Z. 
panamensis', accordingly this form of the disease is only prevalent in the new world. 
Although each form of the disease is distinct, it should be noted that a cutaneous or 
mucosal infection can occasionally deteriorate into visceral leishmaniasis, and that 
sufferers of Z. donovani-màxiQQà visceral leishmaniasis can develop cutaneous lesions.
Leishmaniasis is prevalent in 88 countries worldwide and of these, declaration is 
obligatory in just 32. Infections are common in remote areas where access to medical care 
and facilities is limited. Consequently, incidence of the disease is under-reported and 
therefore it is difficult to determine the global burden and what the mortality rate is. It is 
currently estimated that there are approximately 50,0000 new cases of visceral 
leishmaniasis and 2 million new cases of cutaneous leishmaniasis each year; although in 
2001 only 600,000 cases were reported in total. Reportedly, 59,000 people died from 
visceral leishmaniasis in 2001. It was estimated that 2.4 million DALYs (disability- 
adjusted life years, the number of years lost to disability and premature mortality) were lost 
due to leishmaniasis (http://www.who.int/tdr/diseases/leish/). However, these numbers are 
subject to fluctuation due to epidemics: during an outbreak in Sudan in the early 1990s, 
Médecins sans Frontières reported that 100000 people died from leishmaniasis, which was 
more than 10% of the at-risk population.
As mentioned, leishmaniasis occurs where the sand fly vectors thrive: mainly in tropical 
and sub-tropical regions of Europe, Africa, Asia and Central and South America (figure 
1.2). Among these are 16 European countries; the remainder are developing nations, 
reflecting the nature of leishmaniasis as being a disease of the poverty-stricken. Over 90% 
of visceral infections reportedly occur in Bangladesh, Brazil, India, Nepal and Sudan and 
over 90% of reports of cutaneous disease are in Afghanistan, Brazil, Iran, Peru, Saudi 
Arabia and Syria. Unfortunately, the most recent comprehensive statistics on leishmaniasis 
epidemiology -  summarised in the 2002 World Health Report -  are from 2001, and 
therefore changes in the distribution and incidence of leishmaniasis in recent years are
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unknown. However, it is accepted that leishmaniasis is an increasing problem in many 
parts of the world (Desjeux, 2001). This is illustrated by the increase in cutaneous 
leishmaniasis cases in certain countries between the 1990s and the 2000s: in 1998 there 
were 21800 cases reported in Brazil but in 2002 the figure was 40000, while reported 
incidents of the disease in Kabul, Afghanistan rose from 14200 in 1992 to 65000 in 2002. 
The same is true of visceral leishmaniasis: the number of cases in north-eastern Brazil rose 
from 1840 in 1998 to 6000 in 2002. In recent years there has been an increase in the 
number of infections in Southern Europe, as is discussed below.
3. ^
Figure 1.2: Global distribution of leishmaniasis. Regions where the visceral form of the disease 
persists is in green and areas where the cutaneous and mucocutaneous forms exist are in red. The 
image is taken from the website http://www.wehi.edu.au/media/images/handman/world_map.jpg.
There are several reasons for the changing epidemiology of the disease (Desjeux, 2004). 
Immuno-compromised patients are at greater risk of developing clinical leishmaniasis (as 
opposed to passive infections that go undetected) than healthy individuals and this has 
resulted in HIV co-infection (Desjeux et al, 2001). This has been a particular problem 
with increasing infections of recurring visceral leishmaniasis in parts of Southern Europe
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including Spain, Italy, France and Portugal. However, improvements in HIV chemotherapy 
have led to a concomitant decrease in leishmaniasis in HIV sufferers in Europe (Lopez- 
Velez, 2003). In many developing countries HIV/leishmaniasis co-infection remains a 
growing problem. Another reason for the change in disease pattern is population migration: 
urbanisation and military unrest have both caused recent large-scale movement of people 
from uninfected areas, who lack innate immunity, to endemic regions. The challenges 
presented by the increasing prevalence and changing distribution of the disease mean that 
effective chemotherapy against leishmaniasis is imperative.
1.3 Chemotherapy and resistance
There are several Leishmania vaccine candidates currently under investigation that include 
the use of whole killed cells, live attenuated cells, recombinant Leishmania proteins and 
peptides and DNA vaccines (reviewed in Ghosh and Bandyopadhyay, 2003). However, no 
prophylactic is currently available and accordingly, effective chemotherapy is of utmost 
importance. Treatment of leishmaniasis is dependant upon several factors including the 
economic situation in the country where the infection has occurred, whether drug 
resistance is a problem in the area, and what form of leishmaniasis is present in the 
individual. Over 90% of cutaneous leishmaniasis infections heal over time and accordingly 
are often not treated (Davies et al, 2003) while visceral leishmaniasis is always treated if 
possible, due to infection being fatal. Mucocutaneous infections are usually treated as this 
form can be damaging also. There are several different chemotherapeutic options available 
to treat leishmaniasis, as well as promising new drug candidates. These are summarised in 
table 1.1, and discussed in this section. Widespread drug resistance has been reported in 
parts of Northern India to pentavalent antimonials and this has presented a finther 
challenge to leishmaniasis treatment; accordingly, issues surrounding drug resistance are 
addressed in this section. Appreciating why the drugs are toxic to the parasites is crucial in 
understanding how they develop ways to evade the toxicity and this is also discussed. 
Several promising new compounds are currently in the advanced stages of clinical trials 
and, as the potential future of leishmaniasis chemotherapy, these too are described.
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Type of 
leishmaniasis
Status of 
drug
Drugs available
visceral first-line pentavalent antimonials (sodium stibogluconate 
(Pentostam), meglumine antimoniate 
(Glucantime)); amphotericin B; pentamidine; 
miltefosine (India only)
clinical trials miltefosine; paromomycin; sitamaquine
cutaneous first-line pentavalent antimonials (sodium stibogluconate 
(Pentostam), meglumine antimoniate 
(Glucantime)); amphotericin B; pentamidine; 
miltefosine (Columbia only)
clinical trials miltefosine; paromomycin; azoles
Table 1.1: Drugs for leishmaniasis treatment. Table redrawn, with modifications, from a previous 
report (Croft et ai, 2006).
1.3.1 Pentavalent antimonials
There are two pentavalent antimonial compounds that have been used to treat leishmaniasis 
for over 60 years: sodium stibogluconate (Pentostam) and meglumine antimoniate 
(Glucantime), as well as generic varieties made in India and China. Antimonial compounds 
remain the standard first-line treatment for both visceral and cutaneous forms of 
leishmaniasis in almost all parts of the world, although emerging drug-resistance has 
resulted in the licensing of Miltefosine in some areas (see section 1.3.2). Pentavalent 
antimonials will be discussed in detail in section 1.4.
1.3.2 Miltefosine
Miltefosine (hexadecylphosphocholine) is a relatively new antileishmanial drug that has 
the major advantage of being administered orally. A member of a family of compounds 
called alkyl-lysophospholipids (ALPs), it was originally developed as an anti-cancer drug 
and was found to have an anti-proliferative effect on Leishmania in vitro and in vivo (Croft 
et at., 1987). It is active against many Leishmania species although there is variation in the 
sensitivity of these: L. donovani has been shown to be the most susceptible (Escobar et al, 
2002; Yardley et al, 2005). Currently in phase IV clinical trials, Miltefosine has been used 
successfully to treat visceral leishmaniasis with phase II clinical trial cuie rates of 95% and 
98% (Jha et al, 1999; Sundar et al, 1999) and has been licensed for use in India since 
2002. Following reports showing that Miltefosine was toxic against cutaneous 
leishmaniasis likely to be caused by L. panamensis (Soto et al, 2001), the drug has been
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recently licensed for use against this form of the disease in Columbia. A topical 
formulation of Miltefosine (Miltex) is also effective in treating cutaneous leishmaniasis 
(Schmidt-Ott et al, 1999). Miltefosine may be useful in treating infections of other 
parasites including Trypanosoma cruzi (Croft et al, 1996; Santa-Rita et al, 2000), 
Entamoeba histolytica (Seifert et al, 2001) Acanthamoeba spp. (Walochnik et al, 
2002).
The mode of action of Miltefosine has not been fully elucidated. Most work in this area has 
been carried out on cancerous mammalian cells as opposed to trypanosomatids and it is not 
known if the mechanism of toxicity in these is similar (Croft et al, 2003). It is known that 
Miltefosine induces apoptosis in cells (Konstantinov et al, 1998) and more recently this 
has been shown to occur in both L. donovani promastigotes (Paris et al, 2004) and 
amastigotes (Verma and Dey, 2004). The induction of apoptosis in mammalian cells has 
been attributed to several mechanisms. These include inhibition of phosphocholine 
biosynthesis by disrupting the translocation of CTPiphosphocholine-cytidylyltransferase 
(Geilen et al, 1992); stimulation of the stress-activated protein kinase/c-Jun NH2-terminal 
kinase (SAPK/JNK) pathway (Ruiter et al, 1999); disruption of signal transduction via 
inhibition of protein kinase C (Uberall et al, 1991) and stimulation of cellular ceramide 
formation (Wieder et al, 1998). However the role of inhibition of phosphatidylcholine 
synthesis in apoptosis has been recently questioned due to apoptosis being induced by 
Miltefosine in cells impaired in phosphatidylcholine synthesis by an alternative mechanism 
(van der Sanden et al, 2004). Significantly less research has been carried out into the 
affect of ALPs on trypanosomatids; the limited investigations that have been conducted 
were reviewed recently by Croft et al, 2003. The treatment of Trypanosoma cruzi with 
various ALPs including Miltefosine caused extensive blebbing of the flagellar membrane 
(Santa-Rita et al, 2000) and the affect of Miltefosine on parasite membrane lipids has been 
a focus of interest. It was originally shown that Miltefosine affected ether-lipid metabolism 
and glycosylphosphatidylinositol (GPI) anchor biosynthesis (Lux et al, 1996). The same 
group have since shown that the drug inhibits alkyl-specific-acyl-CoA acyltransferase, an 
enzyme involved in lipid-remodellihg (Lux et al, 2000). Recently it has been reported that 
laboratory-derived Miltefosine-resistant L. donovani promastigotes displayed altered 
membrane lipid composition (Rakotomanga et al, 2005).
Resistance to ALPs has so far only been observed in the laboratory, although this is 
expected to occur in the field in time due to several factors (Berman et al, 2006). The drug 
has a narrow therapeutic index and long half-life (Sundar, 2001b): both are factors 
considered to favour the emergence of resistance. In recent domiciliary clinical trials the
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relapse rate doubled as compared to supervised in-patient trials (Sundar and Murray,
2005), suggesting that non-supervised Miltefosine administration could result in conditions 
that would favour resistance. Moreover, the ease of generating resistance in the laboratory 
has given cause for concern (Seifert et ah, 2003). It has been suggested that in order to 
prevent Miltefosine resistance becoming problematic in the field, the drug should always 
be used in combination with a second unrelated antileishmanial compound such as 
paromomycin or amphotericin B (Bryceson 2001).
Several different mechanisms of Miltefosine resistance have been proposed in Leishmania, 
as reviewed in Croft et ah, 2006. Leishmania tropica engineered to over-express a P- 
glycoprotein-like transporter displayed more than nine times increased tolerance to 
Miltefosine than wild type parasites (Perez-Victoria et al, 2001), The engineered parasites 
showed a reduced accumulation ofbodipy-Cg-PC, a fluorescent analogue of miltefosine. 
The protein, which is a pump responsible for efflux and sequestration of compounds firom 
the cell, has also been implicated in resistance to antimonials in Leishmania (reviewed in 
Ullman 1995), However, the fact that Miltefosine has been used successfully to treat 
antimonial-resistant cases of leishmaniasis (Sundar et al, 1999) suggests resistance occurs 
via separate mechanisms. Recently it was shown that Miltefosine-resistant laboratory- 
derived L. donovani were deficient in uptake of the drug (Perez-Victoria et al, 2003a), An 
aminophospholipid translocase transporter was subsequently shown to mediate Miltefosine 
influx and different point mutations in the gene encoding the translocase, LDMT, were 
responsible for conferring resistance (Perez-Victoria et al, 2003b). Thirdly, as mentioned, 
the membrane-lipid composition and metabolism has been shown to be altered in resistant 
lines (Rakotomanga et al, 2005). The authors suggest that interactions between 
Miltefosine and the cell membrane may be important for parasite susceptibility to the drug 
at higher concentrations.
Despite the high efficacy of Miltefosine in treating leishmaniasis and the benefits of its oral 
administration, the threat of drug-resistance developing in the field cannot be ignored. 
Moreover, the drug may not be suitable for treating leishmaniasis caused by some species 
of Leishmania: an in vitro study has shown a lack of sensitivity to Miltefosine of L. 
braziliensis, L. mexicana and L. guyanensis clinical isolates (Yardley et al., 2005), while a 
cure rate of just 53% was achieved when the drug was used to treat cutaneous 
leishmaniasis (likely to be caused by L. braziliensis) in a clinical trial in Guatemala (Soto 
et al, 2004). The efficacy of Miltefosine in treating HIV-co-infected patients has also been 
questioned (Berman et al, 2006) after the majority of patients relapsed in one study 
(Sindermann et al, 2004). Although Miltefosine is well-tolerated, it is not suitable for
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treating pregnant females as it is teratogenic and must be administered with contraception 
to women of child-bearing age. These issues highlight the potential problems with 
Miltefosine, and suggest it is not necessarily the “wonder-drug” it has been hailed as.
1.3.3 Pentamidine
Pentamidine has toxic side effects but was originally extremely effective against infections 
of Leishmania and for several decades has been used as a second-line therapy for patients 
not responding to treatment with antimonials. However, pentamidine unresponsiveness has 
emerged (Giri, 1994) and in parts of India the cure-rate fell to less than 70% (Sundar, 
2001a). Accordingly, its use as an antileishmanial drug has diminished. Together with 
other diamidine compounds, pentamidine is also used to treat types of pneumonia and 
sleeping sickness as it is active against both T. brucei and Pneumocystis carinii.
The characterisation of pentamidine-resistance Leishmania strains developed in the 
laboratory has contributed to the understanding of how the drug may act on the parasite. 
Pentamidine-resistant L. donovani and L. amazonensis had lower levels of putrescine but 
higher levels of ornithine and arginine compared to wild type strains and lower levels of 
the enzyme omitliine decarboxylase. Moreover, the affinity of spermidine synthase for 
pentamidine was decreased in resistant strains and the enzyme had a higher affinity for 
putrescine (Basselin et al, 1997a). Pentamidine has also been found to inhibit arginine, 
putrescine and spermidine transport in Leishmania (Reguera et al, 1994; Kandpal et al, 
1996). Pentamidine-mediated alterations in polyamine synthesis or uptake may therefore 
be responsible for parasites’ susceptibility to the drug. Altered accumulation of 
pentamidine has been observed in drug-resistant L. mexicana, L amazonensis and L. 
donovani parasites (Basselin et al, 1997b; Basselin et al, 2002). Uptake of pentamidine is 
mediated by the P2 transporter in trypanosomes (reviewed by Bray et al, 2003) but this is 
not the case in Leishmania and the route of entry into the parasites remains unclear. 
However, increased efflux rather than decreased influx of the drug is responsible for 
reduced accumulation of pentamidine in resistant Leishmania (Basselin et al, 1997b). This 
has been attributed to resistant L. mexicana parasites not accumulating the drug in the 
mitochondrion as sensitive parasites do, therefore rendering the drug available for efflux 
(Basselin et al, 2002). This is thought to be due to reduced uptake into the organelle and 
recently a P-glycoprotein-like translocase, PRPl, has been identified that may mediate 
transport of pentamidine into the mitochondrion; part of PRPl was deleted in drug- 
resistant parasites (Coelho et al, 2003). Pentamidine is thought to adversely affect this 
organelle in Leishmania: treatment with the drug caused a decrease in the mitochondrial
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membrane potential (Basselin and Robert-Gero 1998), disintegrated the organelle (Croft 
and Brazil 1982) and altered kDNA minicircle structure (Basselin et al, 1998).
1.3.4 Amphotericin B preparations
Amphotericin B is a polyene antibiotic made by Streptomyces that interacts with sterols in 
plasma membranes, creating transmembrane channels which alter cells' permeability to 
cations, water and glucose and thus affecting the intracellular environment (Brajtburg and 
Bolard, 1996). Also an anti-fungal, it has a greater affinity for ergosterol (the predominant 
sterol in Leishmania) than cholesterol (the predominant sterol in mammalian cells) and 
therefore is more toxic to the parasite. However, dose-limiting renal toxicity in humans is a 
major problem and has resulted in the drug being a second line choice for treatment of 
leishmaniasis. In recent years, liposomal preparations of the drug have been developed in 
which the drug is delivered within a lipid bilayer (Ambisome) and these formulae are much 
less toxic to the host (Sundar et al, 2002). However, the expense of Ambisome has 
resulted in it being unavailable in poor regions where leishmaniasis is endemic.
Fungal infections have been reported that display drug resistance when treated with 
amphotericin B (Rrcmery and Barnes, 2002). However, Leishmania resistance is not a 
problem in the field: reports of multiple relapses after treatment with amphotericin B and 
Ambisome in immuno-compromised patients are likely to be due to patient immune status 
rather than acquired parasite resistance (Durand et al, 1998; Di Giorgio et al, 1999). 
Leishmania donovani promastigotes resistant to amphotericin B have been created in the 
laboratory by selection after increasing drug pressure (Mbongo et al, 1998). Analysis of 
these parasites revealed that amphotericin B uptake was decreased and efflux was 
increased, and that rather than the major sterol being the ergosterol lipid found in drug- 
sensitive parasites, an ergosterol precursor was present. However, the inability of these 
mutants to infect animals in vivo suggests that this lipid composition is not conducive to 
survival of Leishmania amastigotes and is therefore unlikely to be a problem in the field. 
The S- adenosyl-l-methionine-C24-d-sterol-methyltransferase (SCMT) enzyme which 
mediates méthylation of C-24 sterols was postulated to play a role in the phenotype and 
defective transcripts of SCMT were identified in amphotericin B-resistant parasites 
(Pourshafie et al, 2004). More recently, laboratory-derived. Amphotericin B-resistant L. 
mexicana parasites have been created that are insensitive to the drug in vitro and in vivo 
(Al-Mohammed et al, 2005). The parasites again had an altered sterol composition 
although they were infectious to animals, albeit causing attenuated disease symptoms. This 
may be cause for concern if such a situation occurs in the field.
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1.3.5 Drugs not yet licensed: paromomycin, azoles and 
sitamaquine
Paromomycin (aminosidine) is another antibiotic which has antileishmanial activity. The 
lack of published studies on mechanisms of action and resistance is perhaps surprising, 
given that it is currently in phase III clinical trials and is likely to soon be available as 
mainstream treatment for visceral leishmaniasis. Paromomycin is also useful in treating 
cutaneous leishmaniasis (el-On et al, 1992) although it is not as effective as antimonial 
treatment (Faghihi and Tavakoli-kia, 2003; Moosavi et al, 2005). The mode of action of 
the drug in parasites has not been well characterised, although in bacteria the compound 
inhibits protein synthesis by binding ribosomal RNA (Schroeder et al, 2000). 
Paromomycin has been shown to inhibit RNA and protein synthesis in L. donovani 
promastigotes and also affected lipid composition, membrane fluidity, and macromolecule 
uptake (Maarouf et al, 1998). In a separate study, the drug was reported to affect the 
Leishmania mitochondria and respiration (Maarouf et al, 1997). Parasites exhibiting drug- 
resistance to the compound have not yet been observed in the field, probably due to the 
limited use of paromomycin so far (Croft et al, 2006). However, there are reports of drug- 
resistant parasites having been created in the laboratory (el-On et al, 1991 ; Maarouf et al,
1998) which retained their inactivity. The mechanism of resistance has not been defined, 
although a decrease in the uptake of the drug was observed (Maarouf et al, 1998).
Cutaneous leislimaniasis has been treated successfully with itraconazole (Consigli et al,
2006) and ketoconazole (Salmanpour et al, 2001), oral formulations in clinical trials 
which inhibit ergosterol synthesis in the parasite. In addition, azoles may be useful in 
treating mucocutaneous leishmaniasis (Amato et al, 2000). However, the efficacy of these 
compounds is uncertain and one study showed that itraconazole was no better than the 
placebo in treating cutaneous disease caused by L. major (Nassiri-Kashani et al, 2005). No 
acquired resistance to azoles has been reported in the field although over-expression in L. 
major of squalene synthase, which has a role in mediating ergosterol biosynthesis, resulted 
in reduced sensitivity to itraconazole (Cotrim et al, 1999).
Sitamaquine (WR6026) is a second orally active drug which is currently in clinical trials 
for efficacy in treating visceral leishmaniasis (Yeates, 2002). Although the drug has the 
advantage of oral administration, the cure-rates of visceral leishmaniasis in a phase II 
clinical trial conducted in Brazil were unimpressive (Dietze et al, 2001) and toxic side- 
effects were observed. Sitamaquine was more effective at treating leishmaniasis caused by
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L. donovani in India and Kenya (Wasnnna et al, 2005). The mode of action is unknown 
and no studies have been published into sitamaquine-resistance in Leishmania.
1.4 Pentavalent antimonials
As mentioned, all forms of leishmaniasis are usually treated primarily with pentavalent 
antimonials. Herein these will be referred to as Sb(V), and when necessary the different 
drug compounds available will be referred to as SSG (sodium stibogluconate) and MGA 
(meglumine antimoniate). Meanwhile trivalent antimonials will be referred to as Sb(III) 
unless otherwise stated. Throughout this section, mechanisms which may confer resistance 
to antimonials are also discussed as resistance to antimonials is an increasing problem in 
the field (Sundar, 2001a).
Despite their prolonged use, many aspects of antimonial function -  including uptake, 
metabolism, detoxification and mechanism of action of the drug -  remain uncertain. The 
relatively low level of antimony in the environment has resulted in minimal contamination 
with this metal and subsequently antimonial poisoning is not a problem for humans. 
Therefore, little research has been carried out on the toxic effects of antimony in this aspect 
as well. On the other hand, arsenic - a metalloid (or semimetal) element similar to 
antimony - has been much more extensively characterised (probably due to its toxic effects 
often being seen in humans due to its abundance in the ground and contamination of 
drinking water) and more is known about its toxicology. Accordingly, it is often necessary 
to consider research carried out on arsenical compounds when analysing how antimonial 
compounds behave (Gebel 1997). The pentavalent form is known as arsenate (As(V)) 
while the trivalent form is arsenite (As(III)).
Promastigotes are not susceptible to Sb(V) although they are to Sb(III) (Ephros et al,
1999). As discussed in detail in section 1.4.3, it is generally accepted that Sb(V) is 
effectively a pro-drug and that reduction to a trivalent form is necessary for antileishmanial 
toxicity, although whether this reaction is carried out by the host cell or the parasite 
remains controversial. Accordingly, investigations into both Sb(V) and Sb(III) have been 
evaluated here.
The presence of the preservative chlorocresol in Sb(V) preparations has hindered research 
into the drugs, as chlorocresol itself has antileishmanial activity (Roberts and Rainey
1993). Specifically, studies into drug-resistance have been affected: unlike Sb(V), 
chlorocresol is toxic in vitro to promastigotes and therefore laboratory-derived Sb(V)-
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resistant Leishmania strains may actually be resistant to the preservative rather than the 
drug (Ephros et al, 1997). Accordingly, whether chlorocresol was present in Sb(V) 
preparations has been considered where possible when reviewing literature on antimonials.
1.4.1 Synthesis and structures
Both formulations of the pentavalent antimonials are synthesised with chelating agents 
which improve the solubility of the drugs. SSG is produced by reacting pentavalent 
antimony with gluconic acid. The result is a complex mixture of antimonial and 
carbohydrate species ranging in size and structure (Berman and Grogl, 1988). The mixture 
is assayed for its pentavalent antimony content and the drug is prepared using a standard 
amount. There has been some debate over whether the quality of each batch remains 
constant (Jackson et al, 1990) but fractionation of SSG by ion-exchange chromatography 
revealed that each fraction had similar activity against L. panamensis amastigotes. The 
antileishmanial activity of the drug is, however, probably due to several compounds in the 
preparation (Roberts and Rainey, 1993). Despite this, the main component of the 
polymeric structure has been proposed (figure 1.3A). The second antileishmanial form of 
pentavalent antimony is MGA, which is made by reacting pentavalent antimony with N- 
methyl-D-glucamine. Analysis of the drug revealed that it is composed of a number of 
compounds, although a major component was identified that had a molecular mass of 507 
atomic mass units, the structure of which was proposed by the authors (figure 1.3B) 
(Roberts et al, 1998). Despite the differing structures of the drugs and reports of 
Pentostam being used to treat Glucantime-resistant cases of leishmaniasis (Moreira et al, 
1992), few differences have been reported in their efficacy and treatment outcomes are 
similar.
1.4.2 Uptake of antimonials
How Sb(V) enters Leishmania is not well characterised. Studies using radioactive sodium 
stibogluconate showed that amastigotes accumulate the drug more quickly and to a higher 
concentration than either promastigotes or macrophages (Berman et al, 1987). The authors 
suggest that uptake of the compound could be due to non-enzyme mediated diffusion of the 
drug across the membrane due to macromolecule binding within the parasite. The 
observation that amastigotes accumulate approximately three times the amount of Sb(V) 
than promastigotes and macrophages could account for both the parasite- and stage- 
specificity of the drug. Using a more recently developed technique known as inductive 
coupled plasma mass spectrometry, similar results were obtained in L. tarentolae, L
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infantum and L. donovani’. amastigotes accumulated several times the amount of Sb(V) 
than promastigotes (Brochu et al, 2003). It was also observed in both studies that there 
was no competition between Sb(III) and Sb(V) for entry into the parasites, indicating that 
the drugs enter the cells by different mechanisms.
The uptake mechanism of Sb(V) has not been elucidated in other organisms (Tamas and 
Wysocki, 2001) although limited research has been carried out on pentavalent arsenicals. 
As(V) has a similar structure to inorganic phosphate and accordingly, they enter bacterial 
cells via the same transporters. In Escherichia coU, this is an ABC type ATPase complex 
formed by four separate proteins (reviewed in Gatti et al, 2000). Mutated phosphate 
transporters have been linked to increased arsenate tolerance in E. coli (Willsky and 
Malamy, 1980). In addition, in human cell lines, arsenate uptake is inhibited by phosphate 
(Huang and Lee 1996).
An aquaglycerolporin (AQPl) has been recently identified in Leishmania which mediates 
the uptake of Sb(III) (Gourbal et al, 2004). When AQPl was over-expressed in 
Leishmania species, the parasites became hypersensitive to Sb(III) and expression of the 
protein in resistant isolates induced sensitivity. Interestingly, over-expression of AQPl in a 
Sb(V)-resistant strain of L  donovani conferred sensitivity to Sb(V) as well as Sb(III), 
implying that reduction of the pentavalent drug to Sb(III) occurs, at least partially, in the 
macrophage (Gourbal et al, 2004). The expression of AQPl was also found to be 
decreased in Sb(V) resistant field isolates (Decuypere et al, 2005). AQPl is a member of 
the family of aquaporins -  channels which small, neutral solutes such as glycerol can pass 
through -  and similar proteins have been found in other organisms: Fpslp in S, cerevisiae 
(Wysocki et al, 2001) and GlpF in E. coli (Sanders et al, 1997) mediate Sb(III) uptake.
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Figure 1.3: Structures of pentavalent antimonial drugs used to treat leishmaniasis. A,
sodium stibogluconate. Image redrawn from previously reported image Croft etal., 2006. B, 
meglumine antimoniate. Image redrawn from previously published image Roberts et ai, 1998.
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1.4.3 Antimonial metabolism
1.4.3.1 Reduction of pentavalent antimonials
Although antimonials are administered in a pentavalent form, it is hypothesised that the 
drugs are reduced to a trivalent form, which is more toxic to Leishmania (Roberts et ah, 
1995; Sereno and Lemesre, 1997). It is not known why reduction occurs, although in other 
organisms it is the first stage in the detoxification of metalloid compounds: this will be 
discussed in section 1.4.5. Since the extra-cellular promastigote life-cycle stage of the 
parasite is not susceptible to Sb(V), two hypotheses have arisen: that reduction takes place 
in the host cell and that therefore only amastigotes are exposed to the toxic trivalent form 
(Sereno et al, 1998) or that reduction to the trivalent form is performed by the amastigotes 
parasites themselves in a stage-specific manner (Shaked-Mishan et al, 2001). Supporters 
of the concept that reduction is performed by the host point to the fact that mammalian 
Leishmania hosts are indeed able to reduce Sb(V): when pentavalent drugs were 
administered, Sb(III) was detected in both hamsters (Lugo de Yarbuh et al, 1994) and 
humans (Goodwin and Page, 1943). It was recently shown that over-expression of a Sb(III) 
transporter (AQPl) in Leishmania conferred sensitivity of the parasites to Sb(V) when 
incubated in macrophages (Gourbal et al, 2004). This suggests that at least a proportion of 
the pentavalent drug is metabolised to Sb(III) by the macrophage and that the subsequent 
uptake of the trivalent form accounts for the increased susceptibility to the drug. However, 
further investigation is required to show that that is indeed the case; in one recently 
published study Sb(V), unlike Sb(III), was not found to be toxic to macrophages and hence 
it was concluded that they are unable to mediate reduction of the drug (Wyllie and 
Fairlamb 2006). It has been shown that unlike intracellular amastigotes, axenically cultured 
Z. infantum amastigotes were not susceptible to Sb(V), suggesting that macrophages 
mediated Sb(V) reduction (Sereno et al, 1998). However, this observation has been 
challenged as several groups have shown that both L. mexicana and L. donovani axenic 
amastigotes are indeed sensitive to Sb(V) (Coombs et al, 1983; Callahan et al, 1997; 
Ephros et al, 1999; Goyard et al, 2003). Furthermore, it was recently found that the effect 
of Sb(III) on L. donovani promastigotes -  the simultaneous efflux of glutathione and 
trypanothione and the accumulation of oxidised thiols due to inhibition of trypanothione 
reductase -  was the same as the effect of Sb(V) on Z. donovani axenic amastigotes (Wyllie 
et al, 2004). These data imply that the macrophage is not required for the antileishmanial 
activity of Sb(V) and that therefore the parasites themselves can, at least in part, reduce the 
drugs. Compellingly, it has also been shown that Z. donovani parasites are indeed able to 
reduce antimonials and that amastigotes reduce Sb(V) to Sb(III) to a much greater degree
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greater degree than promastigotes (Shaked-Mishan et al, 2001). Furthermore, the reducing 
activity correlated with Sb(V) sensitivity as laboratory-derived, Sb(V)-resistant L, 
donovani amastigotes were unable to reduce the pentavalent compound.
The mechanism of Sb(V) reduction has not been fully elucidated. It is possible that the 
reaction is enzymatically controlled (Shaked-Mishan et al, 2001) but it has recently been 
shown that the reduction of pentavalent antimony can occur spontaneously in vitro upon 
reaction witli various thiols including glutathione, trypanothione and cysteine (Frezard et 
al, 2001; Ferreira Cdos et al, 2003; Yan et al, 2003a; Yan et al, 2003b). An acidic 
environment was required for these non-enzymatic reactions to occur, similar to that of the 
parasitophorous vacuoles which Leishmania amastigotes reside in in vivo. It is therefore 
possible that any reduction of Sb(V) that does occur in the macrophage is mediated non- 
enzymatically in this way. It was observed that the rate of Sb(V) reduction was greater 
upon reaction with the parasite-specific thiol trypanothione than with the ubiquitous 
glutathione (Ferreira Cdos et al, 2003) and, in theory, this could account for the greater 
toxicity of Sb(V) towards the parasites than the host cell. However it does not explain the 
stage-specificity of the drug as the levels of both trypanothione and glutathione are higher 
in promastigotes than in Sb(V)-sensitive amastigotes (Ariyanayagam and Fairlamb, 2001). 
It is also doubtful whether such reactions could proceed in the neutral intracellular parasite 
environment. Accordingly, enzymes that may have the ability to mediate the reduction of 
Sb(V) are discussed in the following section.
1.4.3.2 Arsenate reductases
Several enzymes capable of reducing arsenate have been characterised fi-om various 
prokaryotic and eukaryotic species. The number of categories of proteins known to 
mediate this reaction has doubled fi-om three to six in recent years, reflecting the relative 
lack of knowledge in the area, particularly in higher eukaryotic metalloid metabolism. It is 
possible that some or all of these enzymes are also able to reduce pentavalent antimonials 
although there are no reports of this activity being sought. Here, enzymes currently known 
to reduce arsenate -  which can therefore be thought of as potential Sb(V) reductases -  are 
described. The proteins are summarised in table 1.2,
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Enzyme Name Organisms found in In vivo evidence of 
role in arsenate 
metabolism?
ArsC (R773 plasmid) The gram-negative bacteria E. coli Yes
ArsC (pl258 plasmid) The gram-positive bacteria Suhtilis 
aureus and Bacillus subtilis.
Yes
Acr2p Yeast and plants: Saccharomyces 
cerevisiae, Arahidopsis thaliana, Pteris 
vittata.
Yes
Purine Nucleoside 
Phosphorylase (PNP)
Ubiquitous, but As(V) reducing activity 
characterised in mammalian enzymes 
(human, rat, calf, mouse, rabbit, 
hamster, guinea pig).
No
glyceraldehyde-3 - 
phosphate 
dehydrogenase 
(GAPDH)
Ubiquitous, but As(V) reducing activity 
characterised in mammalian enzymes 
(human and rat).
No
Omega GST (oGST) Variety of organisms including human, 
pig, S. mansoni, S. cerevisiae and 
Drosophila melanogaster. As(V) 
reducing activity found in human and S. 
cerevisiae enzymes.
No
Table 1.2: Arsenate reductases. All enzymes known to possess arsenate reductase activity, in 
vivo and in vitro (as indicated), are listed. Bacterial enzymes are in purple, the yeast and plant 
Acr2p is shown in blue, and mammalian enzymes are in red.
There are three main classes of microbial arsenate reductases known to exist which, 
although they perform the same function, are completely different enzymes 
(Mukhopadhyay and Rosen, 2002). The first of these, ArsC, is encoded for on the R773 
plasmid of E. coli and by part of the ars operon. The entire operon confers resistance to 
Sb(IIl) when over-expressed (Carlin et al, 1995), suggesting both compounds can be used 
as substrates by the encoded proteins. Unfortunately the authors did not assay 
susceptibility to Sb(V) so whether ArsC can reduce pentavalent antimonial compounds is 
unknown. ArsC uses reduced glutathione (GSH) to convert arsenate to arsenite via the 
following reaction:
H3ASO4 + 2GSH -► H3ASO3 + GS-SG + 2 H2O.
ArsC becomes oxidised when it catalyses the reaction and is reduced by E. coli 
glutaredoxin 2 (Shi et al, 1999). In turn, the oxidised glutaredoxin 2 is reduced by GSH 
which is converted to GSSG which in turn is reduced by glutathione reductase, with 
NADPH serving as the source of reducing potential (Liu and Rosen, 1997). The crystal 
structure of the complex has been elucidated and shows that the arsenate binds to the anion
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site of ArsC, which is made up of Arg60, Arg94, Argl07, and then forms a covalent 
arsenate thioester with Cysl2. After being reduced by glutathione and glutaredoxin, the 
Cysl2-S-arsenite intermediate hydrolyses and the arsenite is released (Martin et al, 2001). 
ArsC has low structural similarity to glutaredoxin and glutathione S-transferase.
Confusingly, the second class of arsenate reductases is also called ArsC, despite being 
unrelated to the type of enzymes described above. Found in several prokaryotic species, 
the protein is best characterised in Staphylococcus aureus and Bacillus subtilis and the 
crystal structures have been solved (Bennett et al, 2001; Zegers et al, 2001). Like ArsC 
arsenate reductase from E. coli, S. aureus ArsC is part of an operon encoded for on a 
plasmid, called pI258. The reaction is dependant on thioredoxin and thioredoxin reductase 
(as opposed to the former class which relies on glutaredoxin and glutaredoxin reductase)
(Ji and Silver, 1992; Ji et al, 1994). The catalysis is proposed to begin with Cys82 
attacking CyslO and forming a disulphide bond. CyslO donates its electron pair to the 
arsenate, which reduces it to arsenite. Cys89 attacks Cys82 to form a disulphide and 
regeneration of the CyslO thiolate occurs. Finally, ArsC is restored by thioredoxin and 
resumes its conformation. Similar mechanisms are present in the S. aureus and B. Subtilis 
proteins (Bennett et al, 2001; Zegers et al, 2001). As well as reducing arsenate, the pI258 
and the B. subtilis protein also function as tyrosine phosphatases and the crystal structures 
revealed that they have structural similarity to low molecular weight tyrosine phosphatases. 
The first step in the catalysis of arsenate reduction is analogous to that of tyrosine 
dephosphorylation (Bennett et al, 2001; Zegers et al, 2001).
The first eukaryotic arsenate reductase, Acr2p, was found in the yeast Saccharomyces 
cerevisiae almost a decade ago (Bobrowicz et al, 1997; Mukhopadliyay and Rosen, 1998). 
More recently, a similar enzyme has been identified in plants and A. thaliana Acr2p gene 
knockouts lacked the ability to reduce arsenate and accumulated the pentavalent metalloid 
(Duan et al, 2005; Dhankher et al, 2006). The & cerevisiae enzyme has been 
characterised (Mukhopadhyay et al, 2000; Mukhopadhyay and Rosen, 2001) although not 
to the extent of the previous two classes of prokaryotic arsenate reductases. Despite the 
fact it is not related to either of these two classes, Acr2p is related to protein tyrosine 
phosphatases albeit from a different class than that of the pI258 ArsC-related low 
molecular weight tyrosine phosphatases. One phosphatase of this class is CDC25a, which 
is involved in the human cell cycle and contains the HC(X)sR motif in its active site that is 
also present in the S. cerevisiae Acr2p. When the Acr2p site is mutated, the enzyme no 
longer has arsenate reductase activity in vitro (Mukhopadhyay and Rosen, 2001) 
suggesting they are likely to have common active sites. Conversely, Acr2p does not have
Joanne C. McGregor, 2006 Chapter 1 22
tyrosine phosphatase activity and lacks the phosphate binding GXGXXG motif of 
CDC25a. However, when this site is introduced by the addition of glycines into Acr2p, the 
enzyme gains this activity (Mukhopadhyay et al, 2003). It is hypothesised that this class of 
arsenate reductase evolved from protein-tyrosine phosphatases. Like E. coli R773 ArsC, 
the enzyme activity is glutaredoxin- and glutathione reductase-dependant (Mukhopadhyay 
et al, 2 0 0 0 ).
Until recently, the identity of an enzyme responsible for the reduction of arsenate in higher 
eukaryotes has remained elusive. Although the mechanism is still largely unknown, the 
activity has recently been attributed to purine nucleoside phosphorylase (PNP), an enzyme 
that normally uses phosphate to cleave purine nucleosides (inosine or guanosine) into bases 
(hypoxanthine or guanine) and ribose-1 -phosphate. In the presence of inosine and the 
endogenous ditliiol, dihydrolipoic acid (DHLP), or a synthetic equivalent such as 
dithiothreitol (DTT), calf spleen PNP was shown to reduce arsenate (Radabaugh et al, 
2002). The work was supported by observations that specific PNP inhibitors also inhibit 
rat liver cytosolic arsenate reductase activity, as do phosphate, the natural substrate of the 
enzyme, and guanine and hypoxanthine, the natural products of PNP which promote the 
reverse reaction (Gregus and Nemeti, 2002). Despite encouraging results showing that the 
rate of arsenate reduction in erythrocytes could be stimulated by the addition of exogenous 
DTT and inosine or guanosine, inhibition of PNP in both erythrocytes and rats with 
blocked excretory routes (to prevent clearance of the compounds) did not alter the base rate 
of arsenate reductase activity or the relative As(V) and As(III) levels (Nemeti et al, 2003). 
This suggests that an alternative mammalian enzyme may be responsible for reducing 
arsenate in vivo.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is the second mammalian enzyme 
purported to have a role in arsenate reduction (Gregus and Nemeti, 2005). Clearly the 
primary function of this enzyme is not to reduce metalloids: GAPDH catalyses the 
oxidative phosphorylation of D-glyceraldehyde-3-phosphate to 1,3-diphosphoglycerate 
which is a step in the glycolysis pathway. However, purified GAPDH reduced As(V) in the 
presence of GSH and NAD. Koningic acid (KA), a specific inhibitor of GAPDH, abolished 
arsenate reductase activity in erythrocytes (Gregus and Nemeti 2005). Furthermore, 
administration of (S)-alpha-cholorhydrin (ACH), which forms a GAPDH inhibitory 
metabolite, resulted in a significant reduction in arsenate reductase activity in rat liver 
(Nemeti et al, 2005). However KA failed to prevent arsenate reduction in rat liver 
cytosolic extracts and rats treated with ACH were capable of reducing arsenate despite the 
effect observed in the liver. These experiments were carried out with PNP inhibitors also
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present: the fact that arsenate reduction still occurs when both GAPDH and PNP are 
inhibited indicates that another protein is capable of mediating the reaction. Further 
analysis is clearly required to determine whether the two enzymes do have an in vivo role 
in mammalian arsenate reduction.
The sixth type of arsenate reductase, omega glutathione S-transferase (oGST), was first 
characterised as a methylated arsenical reductase (see section 1.4.3.3), Recently it has been 
reported that the protein is also able to reduce inorganic arsenate in vitro (Aposhian et al,
2004) although the details of this have not yet been published. Human oGST was the first 
to be characterised (Board et aL, 2000) and oGSTs fi*om a range of organisms including 
pig (Rouimi et al, 2001), Drosophila melanogaster (Kim et al, 2006) Schistosoma 
mansoni (Girardini et al, 2002), and S. cerevisiae (Garcera et al, 2006) have since been 
studied. The oGSTs have a molecular mass of around 27.5 kD and have 20 residue N- 
terminal extensions not present in other classes of GSTs. They are highly expressed in 
human liver, macrophage, glial and endocrine cells and were found to be localised in the 
nucleus (Yin et al, 2001). However, the pig oGST is reportedly cytosolic (Rouimi et al, 
2001). In S. mansoni, the protein was detected in all life cycle stages but expression was 
highest in the sporocysts (the parasitic stage of the intermediate host) and adult worms 
(parasitic stage in human) (Girardini et al, 2002), All of the known oGSTs share an active 
site motif of C-P-Y/F-A/V/S which resembles those of the monothiol glutaredoxins; 
moreover, oGST shares structural similarity with E. coli glutaredoxin 2 (Xia et al, 2001). 
Despite being classed as a GST, the in vitro activities of all oGSTs characterised so far 
correlate more closely with glutaredoxins: the proteins exhibit non-detectable or very low 
GSH and l-chIoro-2,4-dinitrobenzene (CDNB) conjugating activity -  the standard GST 
activity -  and liigher thioltransferase and dehydroascorbate activities -  characteristic of 
glutaredoxins (Board et al, 2000; Rouimi et al, 2001; Garcera et al, 2006). However, a 
second human oGST displays high GSH and CDNB conjugating activity (Wang et al,
2005), The role of oGST in metalloid reduction in vivo has not been unequivocally 
demonstrated, although naturally-occurring polymorphisms in oGSThsiVC been linked to 
arsenic-susceptibility in mammals (Schmuck et al, 2005) and alterations in excreted 
arsenical profiles in humans (Mamell et al, 2003).
1.4.3.3 Biomethylation
As described, the reduction of pentavalent arsenicals and antimonials creates more toxic 
trivalent forms of the metalloids. However, further metabolism of these compounds is 
possible and the in vivo transformation of arsenicals and antimonials from inorganic to
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organic molecules via the addition of methyl groups (biomethylation) is well documented. 
The biomethylation pathway involves alternating reduction and oxidative méthylation of 
arsenate (figure 1.4). A mammalian enzyme originally known as Cytl9 but more recently 
referred to as AS3MT is responsible for the methyltransferase activity (Lin et al, 2002; 
Wood et al, 2006). Although the recombinant protein is not thought to directly reduce 
pentavalent, methylated arsenicals, the reduction step was performed when either 
exogenous (DTT or tris(2-carboxyethyl)phosphine hydrochloride (TCEP)) or endogenous 
(thioredoxin, thioredoxin reductase and NADPH) reductants were present (Thomas et al, 
2004). However, at least one enzyme is capable of mediating reduction of the methylated 
arsenicals: oGST displays this activity in vitro (Zakharyan et al, 2001), along with the 
pentavalent inorganic arsenate reductase activity described in section 1.4.3.2.
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Figure 1.4: Putative pathway of biotransformation of inorganic arsenate. 1, arsenate 
reductase (ArsC (R773), ArsC (P1258), Acr2p, PNP, GAPDH, oGST); 2, arsenite methyltransferase 
(AS3MT); 3, MMA(V) reductase (oGST) 4, MMA(V) transferase. GSH, glutathione; SAM, S- 
adenosylmethionine; SAHC, S-adenosylhomocysteine. Figure redrawn from previously published 
image Zakharyan et a!., 2001.
Although many studies of biomethylation have addressed the méthylation of arsenicals in 
mammalian systems (Zakharyan et al, 1999), a similar process is known to occur in 
various microbes with antimonial species (reviewed in Bentley and Chasteen, 2002). 
However, whether the mechanism is similar for antimonials and arsenicals and if similar
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enzymes mediate the process is unknown. The purpose of the biomethylation pathway is 
not clear. Originally thought to be a detoxification pathway, this hypothesis has been 
discredited due to the greater toxicity of methylated, trivalent species than inorganic 
arsenite (reviewed in Thomas et al, 2001). The effects of methylated arsenicals include the 
inhibition of thioredoxin and glutathione reductase (Styblo et al, 1997; Lin et al, 1999), 
genotoxicity (Mass et al, 2001) and cytotoxicity (Petrick et al, 2000; Styblo et al, 2000).
The occurrence of biomethylation of antimonials may be important when investigating 
how antimonial drugs are metabolised by Leishmania. It is not known whether the 
parasites are capable of performing these reactions, or whether after reduction of the drug 
to the trivalent form no further metabolism takes place. However, the new data emerging 
concerning the toxicology of biomethylated intermediates and products suggests that if 
Leishmania can biomethylate antimonials, there could be important implications for how 
the drugs are lethal to the parasites.
1.4.3.4 Trivalent metalloid oxidation
Several species of bacteria capable of oxidising As(III) to As(V) -  effectively the reverse 
reaction to that mediated by the arsenate reductases -  have been identified including 
Alcaligenes faecalis (Philips and Taylor 1976), Thermus aquaticus (Gihring et al, 2001) 
and Agrobacterium tumefaciens (Kashyap et al, 2006). Two enzymes which mediate 
oxidation of the metalloid are the aoxA and aoxB proteins originally found in Alcaligenes 
faecalis (Anderson et al, 1992). The characteristics of these proteins, together with 
bacteria and archea which possess genes likely to encode similar enzymes, are reviewed in 
Silver and Phung, 2005. The two genes, which are part of a larger “arsenic detoxification” 
operon, encode a large subunit which contains a molybdenum-binding site and a smaller 
iron-sulphur subunit which contains a Rieske domain. Expression of the operon, which 
contains elements thought to regulate transcription of the encoded proteins, is upregulated 
m response to exposure to As(III) (Kashyap et al, 2006). When the sequence of either of 
the genes that encode aoxA or aoxB was disrupted in Cenibacterium arsenoxidans, the 
arsenite oxidase activity usually displayed by the bacteria was abolished (Muller et al, 
2003a). Reports of bacteria able to oxidise Sb(III) also exist (Lialikova 1974), although 
whether the proteins that mediate arsenate oxidation can also oxidise Sb(III) is unknown.
It was recently reported that As(III) could be oxidised to As(V) non-enzymatically upon 
reaction with hydrogen peroxide (H2O2) (Aposhian et al, 2003) and this has now also been 
shown to occur with Sb(III) (Quentel et al, 2004). It has been postulated that arsenite
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could be metabolised in such a way in vivo (Aposhian et al, 2003) although this may not 
be the case as an alkaline environment was required (Quentel et al, 2004). It is unknown 
whether non-enzymatic oxidation of trivalent metalloids can occur in vivo or whether 
enzymatic oxidation takes place in eukaryotic species. If either of these mechanisms are 
found to persist it would radically alter the field of metalloid metabolism in eukaryotes, 
which has so far been perceived as unidirectional (figure 1.4).
1.4.3.5 Arsenate metabolising-like enzymes in the trypanosomatids
Of all the different enzymes known to mediate metalloid metabolism in different 
organisms, homologues of only two -  Acr2p and oGST -  have been characterised in 
trypanosomatids: Leishmania Acr2p and the oGST-like Tc52 of 7! cruzi. In addition, an 
oGST-like enzyme, TDRl, has been identified in Leishmania, the characterisation of 
which is described in this thesis.
Leishmania major Acr2p (LmACR2) has only recently been described (Zhou et al, 2004). 
The purified protein was found to reduce both As(V) and Sb(V) to trivalent species in 
vitro. It was observed that the enzyme has a low specific activity when used in conjunction 
with glutaredoxin (required to keep LmACR2 reduced) and this observation has lead to its 
physiological relevance being questioned (Croft et al, 2006). However, Zhou et al, 2004 
propose that this may be due to tryparedoxin, a parasite-specific equivalent of 
glutaredoxin, being the enzyme that reduces LmACR2 in vivo. When the L. major gene 
was expressed in As(V)-sensitive E. coli, arsenate resistance was conferred. This was 
thought to be due to the fact that reduction is necessary for the detoxification of metalloids 
in bacteria. Moreover, when LmACR2 was over-expressed in L. infantum the transgenic 
parasites displayed slightly increased sensitivity to sodium stibogluconate. The existence 
of LmACR2 was reported during the investigation reported in tins thesis: its relevance is 
further discussed in chapter two.
The T, cruzi protein Tc52 (so called because of the species it is found in and its size, 52 
kD) is the only protein characterised from a trypanosomatid that shares significant amino 
acid identity with any GST (Schoneck et al, 1994) and is most similar to the omega GSTs. 
However, the protein has not been investigated in relation to metalloid susceptibility and so 
whether it shares the arsenate-reducing in vitro activity of oGST is unknown. Like oGST, 
Tc52 reportedly has no CDNB conjugating activity (Montiez et al„ 1995), but does 
possess dehydroascorbate reductase and thioltransferase activities which are characteristic 
of glutaredoxins (Montiez et al, 1997). These activities were strictly dependant on GSH
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and Tc52 was unable to use the parasite-specific thiol trypanothione (T(SH)2) as a 
hydrogen donor. In addition, Tc52 was found to enzymatically reduce oxidised GSH -  
glutathione disulphide (GSSG) -  using T(SH) 2  as the source of reducing potential 
(Schoneck et al, 1994; Montiez et al, 1995; Montiez et al, 1997). Trypanosomatids do 
not possess the glutathione reductase enzyme which reduces GSSG in other systems, and 
instead contain trypanothione reductase which regenerates oxidised T(SH)2 . Despite the 
similarities in activities between the two proteins, Tc52 is approximately 52 kD in size: 
double the size of omega GST. Analysis of the sequence showed that Tc52 consists of two 
similar halves which may have arisen fi-om a gene duplication event (Schoneck et al,
1994), and which both share sequence identity with oGSTs. However, the active site motifs 
in the N- and C- terminal halves of Tc52 are thought to be CPFC and SPFS, both of which 
differ from the equivalent oGST motifs (section 1.4.3.2). However, the C-terminal active 
site sequence was CPFS in T. marinkellei, a South American zoonotic parasite closely 
related to T. cruzi (Oury et al, 2005); this motif is more similar to that of oGST.
Tc52 is most highly expressed in the epimastigote and amastigote life cycle stages and has 
been localised to cytoplasmic organelles at the posterior end of the parasites, thought to be 
reservosomes (Ouaissi et al, 1995b). However, the protein has also been shown to be 
released into the culture media when the parasites are growing (Schoneck et al, 1994) and 
microscopic analysis of T. crwzz-infected heart sections showed that Tc52 localised to the 
parasite surface and aggregated in the host cell (Garzon et al, 2003). Secretion of Tc52 
from parasites correlates with another observed function of the protein: modulation of the 
host immune response. Tc52 has been shown to induce various immune responses 
including the inhibition of T-cell proliferation in which a C-terminal region is thought to be 
responsible (Borges et al, 2003), activation of macrophages characterised by increased 
expression of nitric oxide synthase and various chemokines (Fernandez-Gomez et al,
1998) and dendritic cell maturation and chemokine expression upon binding to these cells 
(Ouaissi et al, 2002). The immuno-regulatory role of Tc52 has also led to the protein 
being proposed as a vaccine candidate: immunised mice infected with T. cruzi parasites 
had significantly reduced mortality and parasitemia compared to non-immunised mice 
(Ouaissi et al, 2002).
Allaoui et al, 1999 attempted to create T. cruzi Tc52 null mutant parasites, although, 
because it proved impossible to knock out both alleles of the gene, the protein is thought to 
be essential. Parasites with only one copy of Tc52 remaining and a corresponding reduced 
level of Tc52, exhibited an impaired ability to undergo metacyclogenesis (Allaoui et al,
1999). Moreover, the intracellular trypomastigote forms did not proliferate as well as wild
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type parasites when incubated in macrophages. This effect was also apparent in vivo: 
parasitemia was lower in mice infected with the Tc52 single-copy parasites than with wild 
type parasites (Garzon et al, 2003). However, this observation has not yet been correlated 
with altered changes in the immune response of the host.
1.4.4 Modes of actions of antimonials
Although antimonials have been used for more than six decades to treat leishmaniasis, the 
mechanism of how they are toxic to cells remains unclear. Because toxicity of the drugs is 
thought to be mediated by reduction from the pentavalent to the trivalent from, it may be 
usefid to consider the effect of both forms of the drug on the parasite and accordingly both 
are discussed here.
L. infantum amastigotes exposed to the trivalent antimonial potassium antimonial tartrate 
(KAT) undergo a series of cellular changes including DNA fragmentation that result in 
apoptosis (Sereno et al, 2001) although the events that precede this remained ambiguous. 
Recently it was reported that treatment of intracellular L. donovani amastigotes with KAT 
resulted in parasite death characterised by DNA fragmentation and extrusion of 
phosphatidylserine (Sudhandiran and Shaha, 2003). High levels of reactive oxygen species 
(ROS) were produced before cell death but in the presence of an antioxidant, levels of ROS 
decreased and parasite survival increased. Following ROS production, a reduced parasite 
mitochondrial membrane potential and an elevated Ca^  ^level was also observed, which did 
not occur when the cells were treated with an antioxidant alongside KAT. Flufenamic acid, 
a non-selective cation channel blocker, also inhibited these effects. Together, these results 
imply that oxidative stress caused by treatment with KAT causes Ca^  ^influx through non- 
selective cation channels, and that this directly or indirectly leads to apoptosis 
(Sudhandiran and Shaha, 2003).
An additional observation regarding the activity of antimony is that Sb(V) (MGA and 
SSG) is capable of stabilising DNA-protein complexes in Leishmania promastigotes 
(Lucumi et al, 1998) and inhibits the relaxation of supercoiled DNA (Chakraborty and 
Majumder, 1988). These observations are associated with the inhibition of the enzyme 
topoisomerase I which is involved in breaking and rejoining DNA. Furthermore, much 
higher concentrations of meglumine antimoniate were required to induce the stabilisation 
of DNA-protein complexes in Sb(V)-resistant L. (viannia) panamensis parasites than in 
wild type parasites (Lucumi et al, 1998). However, whether Leishmania topoisomerase I is 
indeed an antimonial target is unclear as it was recently shown that Sb(V) but not Sb(III)
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inhibited the enzyme in L  donovani promastigotes (Walker and Saravia, 2004). However, 
given that the Leishmania topoisomerase I was inhibited to a greater extent than the human 
enzyme by Sb(V), the enzyme may yet prove to be a drug target.
Enzymes from other organisms purported to be inhibited by antimonials include protein 
tyrosine phosphatase in murine hemopoietic cells (Pathak and Yi, 2001), unspecified 
glutathione S-transferases in human erythrocytes (Poon and Chu, 2000) and S. mansoni 
phosphofructokinase (Su et al, 1996). In addition, it was shown that at least six proteins 
ranging in size from 14-68 kD were drug targets in L. mexicana amastigotes treated with 
radioactive SSG (Berman and Grogl, 1988). However, the identity of these proteins has not 
been elucidated. Glycolysis has also been proposed as a target of Sb(V) (Berman et al, 
1985) but again, clarification of how this occurs has not been forthcoming.
However, the most convincing evidence for how antimonials exert their effect on 
Leishmania concerns the modulation of the redox environment of the parasite. L. donovani 
trypanothione reductase has been shown to be inhibited in vitro by Sb(III) (Cunningham 
and Fairlamb, 1995). As mentioned, this enzyme regenerates oxidised T(SH)2 , the thiol 
found only in trypanosomatids, and the analogous human enzyme, glutathione reductase, 
was also inhibited. These experiments were performed in vitro and until recently it had not 
been shown whether trivalent antimonials have an effect in these enzymes in vivo.
However, it has recently been shown that Sb(III) effects the redox metabolism of L. 
donovani promastigotes in two distinct ways: treatment with the drug caused the rapid 
efflux of GSH and T(SH) 2  from the parasites, together with the intracellular accumulation 
of oxidised GSH and T(SH) 2  (Wyllie et al, 2004). The latter effect is thought to be due to 
continuing oxidative metabolism in the parasite coupled with inhibition of trypanothione 
reductase in vivo, which, due to the lack of glutathione reductase in parasites, effectively 
reduces both thiols. The observation that Sb(V) induces similar effects in amastigotes but 
not promastigotes adds further credence to the hypothesis that toxicity of Sb(V) is 
dependant upon amastigote-specific reduction of the drug to Sb(III). Interestingly, T(SH)2  
levels have been found to be elevated in As(III)-resistant L. tarentolae promastigotes 
(Mukhopadhyay et al, 1996), although this is thought to contribute to increased removal of 
metalloids from the parasites and will be discussed in section 1.4.5.
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1.4.5 Resistance mechanisms and exclusion of antimonials from 
Leishmania
Sb(III) and As(III) can form adducts with GSH and T(SH)z (Dey et al, 1996; Yan et al, 
2003a) and it is these forms which are thought to be extruded from cells (Dey et al, 1996; 
Legare et al, 2001). How these complexes are formed has not been completely elucidated: 
they can occur spontaneously in vitro (Dey et al, 1996; Yan et al, 2003a) although it has 
also been proposed that glutathione S-transferases (GSTs) may mediate their formation 
(Mukhopadhyay et al, 1996) and GST levels were found to be increased in As(III) 
resistant cells (Lo et al, 1992). Moreover, thiol levels, particularly T(SH)2, were also 
elevated in As(in)-resistant L. tarentolae promastigotes although the increase of T(SH)2  
alone is not sufficient to mediate resistance. Although formation and transport of the thiol 
complexes has not been directly demonstrated for pentavalent metalloids, it is hypothesised 
that this occurs upon reduction of the Sb(V) (Mukhopadhyay et al, 1996). When incubated 
with GSH, Sb(V) inhibited the transport of the trivalent metalloid-thiol adducts suggesting 
that this is indeed the case (Dey et al, 1996). Interestingly, expression of the thiol- 
synthesis genes encoding gamma-glutamylcysteine synthetase and ornithine decarboxylase 
were found to be elevated in Sb(V) resistant field isolates (Decuypere et al, 2005). These 
proteins were also more abundant than in As(III) resistant Leishmania (Grondin et al,
1997; Haimeur et al, 1999), resulting in increased levels of T(SH) 2  (Haimeur et al, 1999).
How the parasite actually eliminates the metalloid-thiol complexes has not been fully 
elucidated and, indeed, whether they are actually pumped out of the cell or sequestered in a 
parasite organelle is also uncertain. Pgpa, an ATP-dependant ABC transporter, has been 
shown to transport As(III) complexed with GSH (Legare et al, 2001). The location of 
Pgpa within the parasite was determined by expressing a GFP-fusion protein in L. 
tarentolae and rather than being plasma membrane bound, the protein was situated in an 
intracellular membrane. This lead to the hypothesis, that Pgpa transports trivalent 
metalloids bound to thiols into parasite vesicles (Legare et al, 2001). The fact that levels 
of Pgpa have been shown to be amplified in several different studies of antimonial- 
resistant Leishmania adds credence to this theory: MGA-resistant field isolates of L  
viannia were found to over-express Pgpa on an extrachromosomal amplicon (Anacleto et 
al, 2003) and Pgpa expression was increased in SSG-resistant L. donovani field isolates 
(Singh, 2006) and in L. infantum amastigotes (El Fadili et al, 2005). Moreover, in this 
latter study, L. panamensis amastigotes engineered to over-express Pgpa exhibited 
increased resistance to Sb(V) when incubated in amastigotes. However, in separate studies 
Pgpa has been show to not be the transporter responsible for transporting trivalent As(III)-
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thiol adducts from Leishmania'. amplification of Pgpa did not correlate with increased 
transport of the complexes (Dey et al, 1994) and membranes purified from a Pgpa 
knockout L. tarentolae strain were able to transport the complexes at the same level as 
those prepared from wild type cells (Dey et al, 1996).
Other transporters that may have a role in eliminating metalloids from Leishmania have 
been identified in other organisms. Acr3p, one of a cluster of three genes (one of which is 
the arsenate reductase Acr2p) found in yeast was found to be a membrane transporter 
involved in arsenite transport (Wysocki et al, 1997). Over-expression of Acr3p resulted in 
S. cerevisiae exhibiting increased tolerance to, and decreased accumulation of, arsenite. 
Accordingly, disruption of the acr3 gene resulted in increased sensitivity to arsenite and an 
increased cellular concentration of the trivalent metal was observed (Wysocki et al, 1997; 
Ghosh et al, 1999). In addition to this, expression of Acr3p is induced by arsenite 
(Wysocki et al, 2004). Another method of trivalent metalloid extrusion from cells was 
identified in E. coli and is via an ATP-dependant efflux pump called ArsAB. The ArsA 
subunit possesses the ATPase activity of the pump and is activated by arsenite or 
antimonite (Hsu and Rosen, 1989). Antimonite binding triggers a conformational change in 
ArsA and increases the activity of the ATPase 100 fold (Walmsley et al, 2001). The ArsB 
subunit is a transmembrane protein that is situated in the imier membrane of E. coli and 
translocates the substrate (Wu et al, 1992). No ArsB homologues are known in eukaryotes 
but S. cerevisiae does encode an ArsA homologue termed YdllOOp. The growth of 
mutants lacking this gene is impeded in the presence of arsenite and antimonite so it has 
been hypothesised that it may have a role in metalloid export (Tamas and Wysocki, 2001).
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Aims of this study
In this chapter it has been described that although pentavalent antimonial compounds have 
been used for decades to treat leishmaniasis, many aspects of how the drugs function are 
unknown. The principal aim of this investigation was to identify and characterise a 
Leishmania enzyme able to reduce pentavalent antimonial compounds and therefore 
mediate toxicity of the drug. Whether such a protein had an in vivo role in antimonial 
susceptibility, and therefore drug-resistance, would be assessed. The following list of 
objectives was set out in order for the aims to be met:
• Use the sequences of known arsenate reductases to search the L. major genome for 
similar genes which may encode an antimonial reductase
• Elucidate the complete open reading frames of any promising sequences
• Clone potential antimonial reductase genes found and produce soluble, active, 
recombinant protein
• Characterise the activities of the recombinant protein and raise antibodies to it
Investigate the in vivo spatial and temporal expression profile of any protein studied 
using the specific antibodies
Create Leishmania parasites that over-express the protein or lack it completely due 
to the corresponding gene being amplified or knocked out, respectively
Use the transgenic parasites to ascertain whether the protein identified has a role in 
susceptibility to pentavalent antimonial drugs and to study the physiological role of 
the protein in the cell
By using these approaches it was hoped that this investigation would yield a greater 
understanding of the Leishmania proteins involved in antimonial metabolism and their role 
in drug sensitivity. The findings are presented in chapters 3-5; chapter 6  contains an 
account of a related yet separate study, the aims of which are described in the introduction 
to the chapter.
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2 Materials and Methods
2.1 Parasites
2.1.1 Leishmania culture
L. major and L. mexicana promastigote cultures were grown and maintained in an identical 
manner. Parasites were cultured in HOMEM medium (GibcoBRL, Paisley) with 10% (v/v) 
heat inactivated foetal calf serum (HIFCS) at 25°C, with air as the gas phase and without 
shaking. L  infantum promastigotes were grown in the same way, except 20% (v/v) HIFCS 
was used and cultures were incubated at 27 °C. Cells were routinely sub-passaged after the 
parasites had existed in stationary growth phase ( ~ 2  x 1 0  ^cells/ml) for several days, so 
approximately every two weeks. New cultures were inoculated at 10 -^10  ^cells/ml 
depending on the intended purpose for the parasites.
L. mexicana amastigotes were also grown axenically according to the method described 
previously (Bates et al, 1992). Parasites extracted from lesions were deposited in 
Schneider’s Drosophila Medium (GibcoBRL, Paisley) (pH altered to 5.5 with HCl) with 
20% (v/v) HIFCS and 30 pg/ml gentamicin and incubated at 32 “C, again with air as the 
gas phase and without shaking. Cultures were routinely sub-passaged approximately once a 
week.
The densities of all cultures were determined by first diluting to approximately 1-2x10^ 
parasites/ml, then counting using an improved Neubauer haemocytometer (Weber 
Scientific, Hamilton, NJ, US).
2-1.2 Preparation of Leishmania from mice
When fresh cultures that had not been previously sub-passaged were required, L  major 
parasites were extracted from mouse footpads several weeks after parasite innoculation. 
Parasites were retrieved by first dissecting and then scraping the inside of the footpad, after 
which the collected material was deposited in a flask containing HOMEM medium with 
10% (v/v) HIFCS and gentamicin (Sigma, Poole, UK) at 30 pg/ml. Fresh cultures were 
then incubated at 25°C as above.
Leishmania major amastigotes purified directly from mouse lesions (Hart et al, 1981) 
were used to determine the expression of proteins in this particular stage of the life cycle.
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Parasites were grown in Balb/c mice and purified by S. Baillie and D. Laughland of the 
University of Glasgow.
2.1.3 Isolation of metacyclic forms of Leishmania major
L  major metacyclic promastigotes were isolated from stationary phase cultures by 
exploiting the fact that procyclic but not metacyclic parasites are agglutinated in the 
presence of peanut agglutinin (da Silva and Sacks, 1987). Cultures of known densities 
were pelleted by centrifugation at 1300 ^  for 10 minutes at 4 °C, washed in PBS and 
centrifuged again. Pellets were resuspended in PBS at a density of 1 x 10^  cells/ml and 
peanut agglutinin (Vector Laboratories, Burlingame, CA, US) was added to a final 
concentration of 100 pg/ml. After incubation for 30-60 minutes at room temperature the 
metacyclic-containing supernatant was removed and the parasite density was ascertained.
2.1.4 Leishmania harvest and lysis
Parasites were harvested by centrifugation at 1300 g for 10 minutes, washed twice in PBS 
and the resultant pellets were stored at -80 °C until required. Leishmania pellets were 
lysed by resuspending at approximately 1x10^ cells/ml in 1 x GST Bind/Wash Buffer 
(Novagen, Nottingham, UK) comprised of 4.3 mM Na2HP0 4 , 1.47 mM KH2PO4 , 137 mM 
NaCl and 2.7 mM KCl pH 7.3; with the addition of a cocktail of protease inhibitors and 
chelators: 2 mM ethylenediamine tetraacetic acid (EDTA), 10 pM (2»S',35)-3-(A-{(*S)-l-[A- 
(4-guanidinobutyl)carbamoyl]3-methylbutyl} carbamoyl)oxirane-2-carboxylie acid (E-64), 
2 mM 1,10-phenanthroline, 4 pM Pepstatin A and 1 mM phenylmethylsulfonyl fluoride 
(PMSF). The samples were kept on ice and immediately lysed by sonication at 20 pm on a 
cycle of 6  X 10 seconds on, 50 seconds off, using a Soniprep 150 MSE. Successful lysis 
was confirmed by analysing the samples microscopically and the samples were centrifuged 
at 1300 g for 20 minutes at 4 °C. The soluble fraction (supernatant) and the insoluble 
fraction (pellet, resuspended in sample buffer) were stored separately at -20 °C until 
required.
2.1.5 Leishmania mayor cryo-preservatlon
In order to preserve L. major parasite lines for long periods of time -  many years in some 
cases -  it was necessary to make stabilates of the parasites. L. major cultures in the 
stationary phase of growth were mixed in a cryotube vial (Nunc, Roskilde, Denmark) with 
a 1:1 mixture of glycerol and HIFCS in a proportion of 30% mixture and 70% parasites.
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The vials were deposited in an isopropyl alcohol bath at room temperature, which was then 
placed at -70 °C for at least 18 hours before transferring the vials to liquid nitrogen storage 
(-196°C). The isopropyl bath causes a gradual, uniform temperature decrease to occur, 
which improves parasite survival.
2.1.6 Bioassays for feishmanicidai activities
In order to determine L. major parasite viability following treatment with various 
compounds, and to calculate the resultant IC50 values of these compounds, two different 
assays were employed.
The acid phosphatase assay relies on Leishmania acid phosphatases converting the 
substrate j9-nitrophenyl phosphate to ^ -nitrophenol, which is yellow in colour and can be 
measured using a spectrophotometer at 405 nm (Bodley et al, 1995). The level of acid 
phosphatase activity is directly proportional to the amount of parasites present in the 
sample; therefore the assay can be used to analyse the efficacy of compounds on killing 
Leishmania or inhibiting parasite growth. L. major parasites were prepared with serial 
dilutions of the desired compounds in 96-well microtitre plates at a final density of 10^  
parasites/ml, with a volume of 200 pl/well. After incubation at 25 °C for 5-6 days, 20 pi of 
j9-nitrophenyl phosphate made up at a concentration of 40 mg/ml in 1 M sodium acetate pH 
5.5 with 1% Triton-XlOO, was added to each well and mixed by aspiration. The microtitre 
plates were subsequently incubated at 37 °C for 1-2 hours, depending on the progress of 
the assay as determined by appearance of the yellow p-nitrophenol. The absorbance of 
each sample at 405 nm as determined by reading the plates using a Titertek Multiskan 
MCC/340 spectrophotometer was used to calculate IC50 values using the Grafit (Erithacus, 
Staines, UK) IC 50 programme.
The Alamar Blue assay was also employed; this assay has the advantage of not interfering 
with the viability of the parasites, is very simple and is also easier to judge visually as the 
colour change involved is more pronounced than that seen in the acid phosphatase assay. 
Metabolically active Leishmania parasites can reduce alamar blue, of which the active 
ingredient is resazurin (O'Brien et al, 2000), to pink resofurin and the extent of reduction 
achieved is proportional to the number of parasites present (Mikus and Steverding 2000). 
Microtitre plates were seeded with Leishmania and the desired compounds as for the acid 
phosphatase assay described above. After incubation at 25 °C for 48 hours, 20 pi of alamar 
blue (Serotec, KidHngton, UK) or 5 mg/ml resazurin (Sigma, Poole, UK) was added to 
each well and mixed by aspiration. The plates were subsequently incubated for a further
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24-72 hours depending on the progress of the assay as determined by the appearance of the 
pink resofurin. The absorbencies of the samples at 550 nm, using a reference wavelength 
of 630 nm, were determined by reading the plates using a spectrophotometer and the IC50S 
were calculated as above.
2.1.7 L  mayor infectivity
Infectivity of L. major lines could be assessed by analysing how well they infected mice. 
One footpad of each mouse, in groups of up to six animals, was inoculated with either 5 x 
10^  L. major promastigotes in stationary phase, or 10^  L  major purified metacyclics, 
resuspended in 20 pi PBS. The thickness of each infected footpad, which was taken as a 
direct correlation of parasite burden, was measured on a weekly basis with the help of M. 
Dixon of the University of Glasgow.
Macrophages were also used to investigate the infectivity of X. major. The cells were 
extracted from the peritoneal cavity of CD-I mice by S. Baillie of the University of 
Glasgow and resuspended at a concentration of 5 x 10^  cells/ml in RPMI medium with 
10% (v/v) HIFCS and 30 pg/ml gentamicin. 200 pi of the cell-suspension was dispensed 
into each well of a chamber slide (VWR, Lutterworth) and incubated at 37 °C in 5% CO2 , 
95% air for 24-48 hours. Thereafter, stationary-phase L. major diluted in RPMI with 10% 
(v/v) HIFCS were added to the macrophages at a ratio of 2:1 or 3:1 and incubated as 
before. After 24 hours the parasite-containing media was removed, the cells were washed 
several times with media and 200 pi of fresh RPMI with 10% (v/v) HIFCS was added to 
each chamber. If drugs were being assessed for their antileishmanial ability, they were 
added to the media at this stage. After incubation for 2-3 days as before, the cells were 
washed and the media was replaced; the slides were incubated for a total of 5 days. The 
media was subsequently removed and the cells were fixed by flooding with methanol 
before being stained with 10% Giemsa stain (Sigma, Poole, UK). The proportion of 
infected cells, and/or the average number of L. major amastigotes infecting each cell, was 
determined microscopically. At least 150 cells from each chamber were analysed.
2.2 Molecular biology techniques
2.2.1 Isolation of genomic DNA from Leishmania
A pellet of 1-2 x 10* Leishmania promastigotes was resuspended in 400 pi of TELT buffer 
(50 niM Tris-HCl pH 8.5, 62.5 mM EDTA, 2.5 M LiCl, 4% (v/v) Triton X-100) (Medina-
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Acosta and Cross 1993). Trypanosomatid DNA is soluble in this solution and this property 
is exploited to separate the DNA from unwanted proteins. After five minutes of incubation 
at room temperature, 400 pi of 1:1 phenol-chloroform (v/v) mixture was added, to give a 
1:1 ratio of parasites in TELT buffer to phenol-chloroform, and the sample was mixed by 
inversion. The sample was then centrifuged at 13000 g for five minutes before the aqueous 
phase was removed and transferred to another microfuge tube. This was then repeated with 
phenol-chloroform being added to give a 1:1 ratio of DNA-containing aqueous phase to 
phenol-chloroform. After mixing and centrifugation as before, the aqueous phase was 
again removed and transferred to a fresh tube and chloroform was added to give a 1 :1  ratio 
of DNA-containing aqueous phase to chloroform. Again, the sample was mixed and 
centrifuged as before, and the aqueous phase was removed and transferred to a fresh tube 
for the DNA to be precipitated.
2.2.2 Ethanol precipitation of DNA
Despite commercial kits being used routinely to purify and concentrate DNA, for some 
procedures ethanol precipitations were also carried out. The volume of the initial sample 
was determined and 0.1 of the volume of 3 M sodium acetate pH 5.2 was added. The 
sample was thoroughly mixed and two volumes of ice-cold ethanol were added. Again the 
samples were well mixed by inversion and incubated at -20°C for at least 15 minutes. The 
sample was then centrifuged at 13000 g for 15 minutes at 4 °C and the supernatant 
discarded. If the DNA was required for in vivo purposes, all subsequent steps were 
performed under sterile conditions. The DNA pellet was washed twice with 70% (v/v) 
ethanol; after each wash the sample was centrifuged and the supernatant discarded as 
before. Finally, after the pellet had been air-dried until no liquid was visible, the DNA was 
resuspended in the desired volume of TE buffer (10 mM Tris-HCl pH 8 , 1 mM EDTA) and 
stored at 4 °C.
2.2.3 Isolation of RNA from Leishmania
A  pellet of 1-2 X 10^  promastigotes was resuspended in 1 ml of TRlzol® reagent 
(GibcoBRL, Paisley) and incubated at room temperature for five minutes. 200 pi of 
chloroform was added and the suspension was vigorously mixed before being incubated at 
room temperature for three minutes and then centrifuged at 12000 g for 15 minutes at 4 “C. 
The aqueous phase was then removed and transferred into a fresh microfuge tube into 
which 500 pi of isopropanol was added before mixing, and incubation at room temperature 
for 10 minutes. The sample was centrifuged at 12000 for 10 minutes at 4 °C and the
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supernatant was discarded leaving the RNA pellet intact. The pellet was washed twice with 
1 ml of 70% (v/v) ethanol; after each wash the sample was centrifuged for five minutes at 
12000 g  and the liquid discarded. The pellet was air-dried and, when no liquid remained, 
resuspended in 50 pi of double distilled water (ddHiO) which had been treated with 0.01% 
(v/v) diethylpyrocarbonate (DEPC) in order to remove any trace of RNAse activity.
2.2.4 Rapid amplification of cDNA ends (RACE)
Due to the L major genome not having been fully sequenced and, as a result, the database 
(www.genedb.org) being incomplete when this project commenced, it was necessary to 
perform 5’ RACE on the putative TDRl sequence in order to elucidate the entire gene. 5’ 
RACE was also attempted on putative genes designated LM16 and LM34 which were also 
thought to be sequences of interest.
Gene-specific cDNA was synthesised using reagents and according to the protocol from 
the kit ‘5’ RACE System for Rapid Amplification of cDNA Ends, Version2.0’ (Invitrogen, 
Paisley, UK). Briefly, (using the gene-specific primers OGSTl for TDRl, LM16 GSPl for 
LM16 and LM34 GSPl for LM34) cDNA was transcribed from total X. major RNA with 
SUPERscript II reverse transcriptase. After RNAse treatment to eliminate the RNA, the 
cDNA was purified using a Glassmax DNA Isolation Spin Cartridge. In Leishmania, 
almost all mRNAs have an identical 18 nucleotides known as the splice leader sequence 
spliced onto the 5’ end. Polymerase Chain Reaction (PCR) was performed to amplify the 
5 ’ end of the putative genes using a primer complementary to the splice leader sequence 
(SL primer) and second gene-specific primers (0GST2 for TDRl, LM16 GSP2 for LM16 
and LM34 GSP2 for LM34). For TDRl, the product of this reaction was used as a template 
in a second, semi-nested PCR using the SL primer and a third gene-specific primer, 
OGST3.
For the putative gene LM34 there was no STOP codon in the partial sequence so 3’ RACE 
was performed to elucidate the C-terminal of the gene. Total cDNA was synthesised from 
RNA, and the 3’ RACE procedure was executed using the kit ‘3’ RACE system for rapid 
amplification of cDNA ends’ (Invitrogen, Paisley, UK), according to the manufacturer’s 
instructions. Briefly, X. major RNA was incubated with AP primer (which has an oHgo-dt 
component) and total cDNA was synthesised using SUPERscript XI reverse transcriptase 
before treatment with RNAse to eliminate RNA. To amplify the 3’ end of the gene, 3’ 
RACE was performed on the cDNA using the supplied AUAP primer and the gene- 
specific primer LM34 3’ GSPl primer.
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2.2.5 Polymerase chain reaction (PCR)
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PCR was frequently used to amplify regions of Leishmania DNA. All oligonucleotides 
(primers) were synthesised by MWG biotech (Ebersberg, Germany) and were all manually 
individually designed. All primers used, their sequences and predicted melting 
temperatures, are displayed in table 2.1. Different annealing temperatures, numbers of 
cycles and elongation times were utilised depending on the PCR being performed; often 
these variables were initially optimised. A PTC-200 DNA Engine Thermal Cycler (MJ 
Research (BioRad), San Francisco, CA) was used to perform all reactions. Both the Taq 
(Promega, Southampton, UK) and the Expand High Fidelity (Roche, Lewes, UK) 
polymerase systems were used according to the manufacturers’ instructions.
RACE primers SEQUENCE 5’-3’ Tm C O
OGSTl AACAATCAGÇTGCGACTCGTG 55.3
0GST2 TACAGCCTCGCCCCTCG 54.3
0GST3 AATAGCGCAGGCACCGTATC 54.4
LM16GSP1 CCGTCCAAACCACTCC 45.4
LM16 GSP2 GCGCAAACTGCCGCACAAACG 65.1
LM34 GSPl GCGCTCGATCAGCG 46
LM34 GSP2 GCGCCAGCATGTCATGCAGC 62.1
LM34 3’ GSPl CCCTGCCGGTTCTCTACTGGTTTCG 64.5
LM34 3’ GSP2 GAGCTGCGCGAAATCAACC 55.7
AUAP PRIMER GGCCACGCGTCGACTAGTAC 54.7
AP PRIMER GGCCACGCGTCGACTAGTACTTTTTTTTTTTTTTT 68.7
SL PRIMER TAACGCTATATAAGTATCAGTTTC 65
TDRl primers
JOFLOGSTl TAGCGGCCGCTTACCCGCCCTGGGCCCTCCGTTG >75
JOFLOGST2 GACATATGGCCGCGCGCGCGCTAAAGCTGTACG >75
JOFLOGST3 TTGCGGCCGCTTACATTGGCGGCCTCTCCGGAAC >75
New TDRl o/e PI GACCCGGGATGGCCGCGCGCGCGCTAAAGC >75
New TDRl o/eP2 CTGGATCCTTACCCGCCCTGGGCCCTCC 74.7
TDR13’FLANKP1 CGCCCGGGAGGCTCACCGAGTGGGTCG >75
TDR13’FLANKP2 CGAGATCTCTTCACACGGGAGAGCACAGCCG 73.3
TDRIS’FLANKPI GCAAGCTTCAGGAACTCGCTGCGCAGTGATCC 74.9
LmGLO primers
TDR15’FLANKP2 GCGTCGACCGCAGCGGGCGCACCTCTCTAACG >75
L-gulo3’flankPl GACCCGGGGGTACCTAAGATTTTGTGC 65
L-gulo3’flankP2 GCAGATCTCCTCCCCCTCCTTGAGGTG 67.4
L-gulo5’flankPl GCAAGCTTGTGGGGTGCGGAGTTGAG 68.9
L-gulo5’flankP2 GAGTCGACGGTCAAGGTACAATGCAC 61.7
New L-gulo o/e PI GACCCGGGATGTCTGCTCATTCTGCGGCCCGTC >75
New L-gulo o/e P2 CTGGATCCTTACGGCGTGCACGCGGTGCTG >75
Table 2.1: Compendium of primers used, their sequences and Tm (melting temperatures). A,
adenine: T, thymine; C, cytosine; G, guanine.
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2.2.6 DNA gel electrophoresis
DNA fragments were resolved by electrophoresis on 0,5-1.5% (w/v) agarose gels 
containing 0.5 pg/ml of ethidinm bromide in 0.5 x TBE (45 mM Tris-borate, 1 mM 
EDTA). The percentage of agarose was dependent on the expected size of the DNA being 
analysed, with higher percentages being used for smaller fragments. Gels were run in 0.5 x 
TBE buffer. The 1 kb Plus DNA ladder (Invitrogen, Paisley, UK) was used and a 
transillumnator (UVP Laboratory Products, Cambridge, UK) was used to visualise the 
DNA.
2.2.7 DNA quantification
When it was necessary to calculate the concentration of DNA in a sample, serial dilutions 
were prepared which were then subjected to DNA gel electrophoresis alongside 0.6 pg of 1 
kb Plus DNA ladder. As 8 % of the mass is contained in the 1650 base pair (bp) band, 
approximately 48 ng of DNA are present in this band. The intensities of the bands 
containing the serial dilutions of the original sample were compared to the intensity of the 
1650 bp band and the approximate amount of DNA present, and hence the concentration in 
the sample, was determined.
2.2.8 Cloning of PCR products
PCR products were generated using Taq and Expand High Fidelity polymerases which 
both add an A (adenine) nucleotide to the 3’ end of the DNA fragment being synthesised 
(known as an A-overhang). The pGEM-T Easy vector (Promega, Southampton, UK) can 
be used to clone such fragments as it contains a T- (thymine) overhang at the 3’ end. PCR 
products were either isolated using a QIAquick gel extraction kit (Qiagen, Crawley, UK) 
after DNA gel electrophoresis, or purified using a QIAquick PCR purification kit (Qiagen); 
in both cases according to the manufacturer’s instructions. Approximately 150 ng of the 
purified product was ligated into 50 ng of the pGEM-T Easy vector using the supplied T4 
ligase, usually incubating overnight at 16 “C. Subsequently about 4 pi of the ligation was 
used to transform 50 pi DH5a competent cells (Invitrogen, Paisley, UK).
2.2.9 Subcloning of DNA fragments
Approximately 1-2 pg of donor and recipient plasmid DNA was digested with up to 50 U 
of the appropriate restriction enzymes in 100 pi. If digesting with more than one enzyme 
the most compatible buffer was used, as ascertained by the Promega restriction enzymes
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resource (www.promega.com/guides/re_guide/RESearch.asp?search=buffer). If there was 
no compatible buffer, after the first digest the DNA was recovered using a PCR 
purification kit (Qiagen) and the second digest was performed on the purified sample. The 
digested DNA Jftagments required were recovered by band extraction using a QIAquick gel 
extraction kit (Qiagen) after separation on an agarose gel. Ligations of the donor and 
recipient DNA were performed as described, before transformation into DH5a competent 
cells (Invitrogen).
2.2.10 Restriction digests
All restriction digests were performed using enzymes from Promega, Southampton, UK, 
according to the manufacturer’s instructions. For diagnostic digests approximately 250 ng 
of DNA was digested with 10-20 U of one or two enzymes in a total reaction volume of 20 
pi, usually for two hours at the temperature recommended by the manufacturer. Restriction 
digests of DNA intended for cloning were performed in larger volumes with additional 
enzyme and DNA (see section 2.2.9). These digests were performed overnight at the 
appropriate temperature. Typically the buffer supplied with the enzyme by the 
manufacturer was used; however, for digests with more than one enzyme a compatible 
buffer was sought (see section 2.2.9).
2.2.11 Ligations
Ligations of PCR products into the pGEM-T Easy vector (Promega) were performed using 
the supplied T4 ligase. For all other ligations the T4 DNA ligase from Roche Diagnostics, 
Lewes, UK, was used. Ligations were performed at a 3:1 (w/w) ratio of donor (insert) to 
recipient (plasmid) DNA using 2 U of ligase in a 20 pi volume. The reactions were usually 
incubated overnight at 16 "C although occasionally ligations were performed at room 
temperature for two hours. For a summary of vectors used, see table 2.2.
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Vector Origin Information and Application
pGEM-T Easy Promega, 
Southampton, UK
A commercially available vector that contains T- 
nucleotide overhangs for cloning PCR products.
pET28a(+) Novagen, 
Nottingham, UK
A commercially available E. coli expression 
vector used to express recombinant TDRl.
pGL345 Derivative of pXG 
vector (Ha et al, 
1996)
Contains cassette that can be used to create gene 
knockouts in Leishmania by homologous 
recombination. Hygromycin resistance marker.
pGL842 Derivative of pXG 
vector
As pGL345 but with blasticidin resistance 
marker.
pGL1033 Derivative of pXG 
vector
As pGL345 but with phleomycin resistance 
marker.
pGL102 Derivative of pXG 
vector
A Leishmania expression vector containing a 
neomycin resistance marker.
Table 2.2: Summary of vectors used, their origins and applications
2.2.12 Plasmid DNA extraction
Plasmid DNA was extracted from E. coli using Qiaprep Spin Miniprep and midiprep 
(when several micrograms of DNA were required) kits (Qiagen) according to the 
manufacturer’s instructions. The volumes of the bacterial cultures used were 3 ml and 35 
ml, respectively. The DNA obtained was stored at 4 °C for periods of up to several days, or 
-20 “C for longer-term storage.
2.2.13 DNA sequencing
DNA sequencing reactions were carried out both by the Molecular Biology Support Unit 
(University of Glasgow), and by GRI Genomics (Braintree, UK). Sequences were analysed 
using the Vector NTI programme, version 6.0 (Informax, Bethedsa, MA, US).
2.2.14 Competent cells
For routine cloning, ready-made Library Efficiency DH5a competent cells (Invitrogen) 
were used according to the manufacturer’s instructions.
For recombinant protein expression in E. coli, BL21(DE3) cells were made competent 
manually, being freshly prepared prior to use. 5 ml LB broth was inoculated with a single 
colony picked from a drug-free LB agar plate and was grown overnight at 37 °C. 
Thereafter 500 pi of this culture was used to inoculate 50 ml LB broth which was then
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grown again at 37 “C. The optical density (OD) of the culture at 600 nm was monitored 
until the value was between 0 . 6  and 0 .8 ; the culture was then cooled on ice for 1 0  minutes 
before being centrifuged at 2500 g for a further 10 minutes. The cells were resuspended in 
25 ml of ice-cold 0.1 M CaCL, chilled on ice for an additional 20 minutes and centrifuged 
at 2500 g for 10 minutes. The cells were finally resuspended in 2.5 ml of ice-cold CaCL 
and stored on ice (or overnight at 4 °C) until required.
2.2.15 Transformation of competent ceils
The antibiotics used for selection purposes when transforming bacterial cells were 
ampicillin, used at 100 pg/ml and kanamycin, used at 50 pg/ml. Both drugs were made up 
in water at lOOOx the working concentration, and stored at -20 “C. Transformations were 
spread onto LB agar (Sigma, Poole, UK) plates, which were made at 3.5% (w/v). Bacteria 
were grown in LB broth (1% (w/v) NaCl, 1% (w/v) Tryptone (Sigma), 0.5% (w/v) yeast 
extract (Sigma).
DH5a cells (Invitrogen) were transformed according to the manufacturer’s instructions, 
with 50 pi cells being used per transformation, 300 pi of the supplied SOC media being 
added after heat-shock and 140 pi of each reaction being spread on a LB agar plate 
containing the appropriate antibiotic. When pGEM-T Easy was the plasmid used for the 
transformation, a blue/white selection procedure was employed. 40 pg/ml isopropylthiol-p- 
D galactoside (IPTG) and 40 pg/ml 5-bromo-4-chloro-3-indolyl- isopropylthiol-p-D 
galactoside (X-gal) were added to the LB agar: resulting white colonies correspond to 
positive clones containing a DNA insert.
When BL21(DE3) cells were being transformed, just 1 pi of a DNA miniprep which had 
been diluted 1/10 was added to 100 pi of the competent cells. After being incubated for 30 
minutes on ice, the samples were heat-shocked at 42 “C for 90 seconds before being cooled 
on ice for two minutes. 900 pi of LB broth was added to each transformation and mixed, 
before being transferred to a universal tube so better aeration would be achieved when the 
samples were incubated at 37 °C for one hour while shaking at 250 rpm. Finally 100 pi of 
each was spread on a LB agar plate that contained the appropriate antibiotic drug.
2.2.16 Cryo-preservation of bacterial cultures
In order for cloned genes and constructs to be preserved, glycerol stocks of bacterial 
cultures carrying plasmids, which contained the DNA of interest, were made. A sterile
Joanne C. McGregor, 2006 Chapter 2 44
solution of 40% (v/v) glycerol, 60% LB broth was made. Bacterial cultures, grown 
overnight in LB broth containing the necessary antibiotics, were mixed with this solution 
in a 1:1 ratio (v/v) in 1.5 ml screw-cap tubes (Greiner Bio-one, Stonehouse, UK) and 
stored at -80 'C for up to three years.
2.2.17 Creation of transgenic L. mayor promastigotes
The method used to transfect and generate L  major parasites was broadly the same as the 
high-voltage protocol developed by Steve Beverley and colleagues (Robinson and 
Beverley, 2003).
For creating lines overexpressing a gene, the parasites were transfected with at least 2 pg 
of plasmid DNA that contained the gene of interest. However, to knock out a gene from 
Leishmania, linear DNA is used, comprising the 5* frank of the target gene, the 5’ frank of 
the DHFR gene, a drug resistance gene, the 3’ frank of the DHFR gene and the 3’ frank of 
the target gene (see figure 2.1). The gene-specific franks were cloned into the appropriate 
vector and the total construct excised from the plasmid by restriction digest. The digested 
sample was then subjected to gel electrophoresis and the desired DNA construct was 
purified by gel extraction. At least 5 pg of the purified DNA was used for each 
transfection. In both cases, the DNA to be used for transfecting the parasites was ethanol 
precipitated before use and resuspended in sterile TE buffer (10 mM Tris-HCl pH 8, 1 mM 
EDTA).
foreign DNA 5’ flank | DHFR [ OtHB  ^ I DHFR 3' flank
host DNA f 5’ flank Target gene ] 3‘ flankt 5’ flank Target gene 3’ flank
foreign DNAt 5’ flank | DHFR | Drug» I DHFR | 3 ' t e K
Figure 2.1 : Schematic diagram of target locus and constructs introduced when generating 
a gene knockout in Leishmania major. The diagram shows the two copies of the native locus 
from this diploid parasite and the constructs which replace the genes after two rounds of 
homologous recombination. The DHFR flanks are included in the constructs as the correct 
upstream and downstream elements for successful expression of the drug resistance gene.
When the transfections were to be performed, L. major promastigotes from the late 
log/early stationary phase of growth were centrifuged at 1300 g for 10 minutes at 4 °C, 
washed in ice-cold elecroporation buffer (120 mM KCL, 0.15 mM CaCL, 10 mM K2HPO 4 ,
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25 mM HEPES, 2 mM EDTA, 5 mM MgCL; pH 7.6) and centrifuged again under the 
same conditions. The parasites were then resuspended in the chilled electroporation buffer 
at a concentration of about 2x10^ cells/ml and kept on ice until required. The prepared 
DNA was deposited into a 4 mm Gene Pulse cuvette (BioRad, Hemel Hempstead, UK) and 
0.5 ml of the parasite was added; the sample was briefly aspirated to mix. The cuvette 
containing the mixture was electroporated twice at 25 pF, 1500 V (3.75 kV/cm) on the 
BioRad Gene Puiser II apparatus, with a 10 second interval between each pulse. The cells 
were then removed from the cuvette, transferred into 5 ml of HOMEM medium with 10% 
(v/v) HIFCS and incubated overnight at 25 “C. The following day the parasites were 
passaged into the medium containing the appropriate drug(s) (see table 2.3) for selection of 
successful transformants. 1 ml of the original culture was passaged into 5-10 ml of the 
fresh, drug-containing medium and the drug(s) were also added to the remainder of the 
original culture. In all cases, the passaged rather than the original culture contained 
transformants and was used for subsequent analysis.
For gene knockouts, it was desirable to obtain clones of successfully transformed parasites 
so a monoclonal culture could be created. This allowed the ensuing parasitic culture to be 
grown without the selection drugs, and ensured that all parasites within any culture were 
missing the gene. Clonal populations were obtained by both serial dilution of the original 
overnight culture from 1/2 to 1/1024 (v/v) in 24-well plates, and by dilution of the 
successfully transformed passaged culture so that 0 . 1  parasite was added to each well of a 
96-well plate. In both cases, the parasites were added to the plates with the appropriate 
antibiotic drugs and wells containing growing populations of parasites were accepted as 
clonal. When serial dilutions of the parasites were made, populations were accepted as 
clonal when the previous two wells did not contain growing populations.
Drug Working concentration Supplier
Blasticidin S Hydrochloride 1 0 - 2 0  pg/ml Invitrogen, Paisley, UK
Hygromycin B 50-100 pg/ml Roche, Lewes, UK
Neomycin 50 pg/ml Calbiochem, Nottingham, UK
Bleomycin 1 0  pg/ml Calbiochem, Nottingham, UK
Table 2.3: Antibiotic drugs used for selection of transgenic parasites.
2.2.18 Southern biot analysis
Southern blotting allows detection of specific sequences witliin genomic DNA and was 
employed to verify whether the LmGLO gene had been successfully knocked out of 
transgenic L. major parasites. Using a combination of Artemis and Vector NTI software, 
restriction enzymes were chosen that would generate different DNA fragment sizes
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depending on whether the intact WT locus was present, or whether homologous 
recombination had taken place and replaced the gene with DHFR flanking regions and a 
drug resistance marker. Parasite genomic DNA was extracted and digested to completion 
using the specific restriction enzymes and DNA fragments were separated on a 1% (w/v) 
agarose gel in 0.5 x TBE buffer. After electrophoresis for 6  hours at 70 V, the gel was 
incubated in 125 mM HCl for 20 minutes under gentle agitation, which results in the 
depurination of the DNA. Subsequently the gel was incubated for 30 minutes in 1.5 M 
NaCl, 0.5 M NaOH (for dénaturation of the DNA) and 30 minutes in 1.5 M NaCl, IM Tris, 
pH 7.5 (for neutralisation). These incubations were interspersed by 10 minute washes in 
ddH^O, and followed by a 20 minute pre-incubation in 20 x SSC (300 mM tri-sodium 
citrate, 3 M NaCl, pH 7.0). The DNA was then transferred overnight by capillary action 
onto Flybond N+ nylon membrane (Amersham) in 20 x SSC, using standard methods 
(Sambrook et al, 1989). The DNA was fixed onto the membrane by UV cross-linking 
(Spectrolinker XL-1000 UV linker, Spectronics Corporation, Westbury, NY, US). Until 
this point, all procedures were performed at room temperature.
The membrane was then pre-incubated at 65 °C for 4 hours in 20 ml Church Gilbert 
hybridisation solution (340 mM Na2HP0 4 , 158 mM NaH2P0 4 , 240 mM SDS, 1 mM 
EDTA) supplemented with 0.2 mg/ml salmon sperm DNA (Invitrogen, Paisley, UK) for 
the final 2 hours of the incubation. 30 ng of nucleic acid probe was prepared firom gel- 
purified restriction fragments using the Prime-It II Random Primer Labelling Kit 
(Stratagene, La Jolla, CA, US) according to the manufacturer’s instructions. With the 
dATP buffer firom the kit, 50 pCi of a32dATP (Perkin Elmer, Beaconsfield, UK) was used 
to label the A nucleotides of the probe. It was then purified using a Microspin S-200 HR 
column (Amersham, Chalfont St. Giles, UK) and boiled for 5 minutes before incubation on 
ice for 2 minutes. The membrane was hybridised by incubation with the labelled probe in 
20 ml of Church-Gilbert solution at 65 '’C overnight. The membrane was then washed 
twice under high stringency conditions in 2 x SSC, 0.1% (w/v) SDS, followed by 15 
minutes in 1 x SSC, 0.1% SDS and finally twice for 10 minutes in 0.1 x SSC, 0.1% SDS. 
All washes were performed at 65 °C, using pre-heated solutions. The membrane was then 
sealed in polythene and exposed to X-ray film for 1-14 days. Hybridisation signals were 
detected with an automatic film processor (X-Ograph imaging system Compact X4).
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2.3 Biochemical methods
2.3.1 Recombinant protein expression in E. coli
As mentioned, the bacterial expression plasmid pET28a(+) (Invitrogen) was used to 
express recombinant proteins; this vector adds an N-terminal His-tag to the expressed 
polypeptide. The proteins were expressed in the E. coli strain BL21(DE3).
The primers FLOGSTl and FLOGST2 were used to amplify the complete TDRl gene 
while the primers FLOGST2 and FLOGST3 were used to amplify the 5’ half of the gene. 
These constructs were cloned into pET28a(+) and the BL21(DE3) cells were transformed 
with the plasmids as described. Successfully transformed colonies were grown up 
overnight with kanamycin at 50 pg/ml and 500 pi of each was used to inoculate 50 ml of 
LB broth containing kanamycin as before. These were shaken at 37 “C and the ODgoo of 
the growing cultures was monitored. When the ODeoo had reached 0.6-0.9, the cultures 
were cooled on ice for several minutes before IPTG was added to a final concentration of 2 
mM. These cultures were grown overnight at 15 "C before being centrifuged at 3000 g for 
20 minutes at 4 “C. The pellets were resuspended in 5 ml of 20 mM Tris-HCl with 100 mM 
NaCl and lysed by sonication at 22 pm, on a cycle of 5 x 10 seconds on, 30 seconds off, 
using a Soniprep 150 MSE. 1 ml of each sample was then centrifuged at 13000 g for 20 
minutes at 4 °C and the supernatant (soluble fraction) was separated from the pellet 
(insoluble fraction). The pellet was resuspended in 0.5 ml of 1% SDS and both fractions 
were analysed by SDS-PAGE for protein expression. In order to achieve optimal 
expression of the proteins, trials were also conducted with different concentrations of IPTG 
and growth times.
2.3.2 Recombinant protein purification
Purification of recombinant TDRl from E. coli cells was performed by Alan Scott and Dr. 
Helen Denton, both University of Glasgow. Expression of TDRl was induced with 2 mM 
IPTG and cells were grown overnight and harvested as before, prior to resuspending in 
buffer A (20 mM Tris-HCl, 500 mM NaCl) containing 5 mM imidazole. The cells were 
lysed by sonication (a cycle of 10 x 30s at 22 pm) before centrifugation at 13000 g  for 30 
minutes at 4 “C and the soluble supernatant was collected. The soluble fraction was applied 
onto a 13 ml Ni^^-nitrilotriacetate BioCAD 700E workstation (PE Biosystems, Foster City, 
CA, US) that had been pre-equilibrated in buffer A containing 5 mM hnidazole. The 
column was washed with 100 ml containing 5 mM imidazole before washing again with 20
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ml of buffer A containing 50 mM imidazole. The His-tagged recombinant TDRl was 
eluted with 500 mM imidazole in buffer A. The fractions containing the majority of the 
eluted proteins were pooled and buffer-exchanged into buffer B (25 mM Tris-HCl, pH 7.9) 
using a PDIO column (Amersham, Chalfont St. Giles, UK) and applied to POROS 20 HQ 
column (4.6 mm x 100 mm) pre-equilibrated in buffer B. The column was washed with 5 
column volumes of buffer B and bound protein was eluted with 10 volumes of buffer B 
containing a 0-100% gradient of 2 M NaCl. Fractions containing protein were stored at -80 
“C.
2.3.3 His-tag cleavage
The pET28a(+) plasmid, used for expressing recombinant TDRl, adds an N-terminal His- 
tag and tlirombin cleavage site to the protein produced. The His-tag can be removed by 
incubating the purified recombinant protein with biotinylated thrombin, which can in turn 
be removed by adding streptavidin agarose to the sample and isolating the supernatant after 
centrifugation. This procedure was carried out using a Thrombin Cleavage Capture Kit 
(Novagen, Nottingham, UK) according to the manufacturer’s instructions. Briefly, 8  U of 
thrombin was added to 5 mg of TDRl in 1 x Thrombin Cleavage/Capture Buffer and 
incubated for 18 hours at room temperature. 16 pi of streptavldin-coated beads were added 
to the sample, incubated with gentle shaking for 30 minutes at room temperature and 
centrifuged for 5 minutes at 500 g. The supernatant was collected and buffer-exchanged 
into 25 mM Tris-HCl, pH 7.9 using a PDIO column (Amersham, Chalfont St. Giles, UK). 
The successful removal of the His-tag was confirmed by a decrease in size of the 
recombinant protein visible after SDS-PAGE.
2.3.4 SDS-PAGE
Proteins were separated according to their molecular masses under reducing conditions by 
SDS-PAGE. The protein samples were mixed with 25% volume of 5 x protein sample 
buffer (60 mM Tris-HCl pH 6 .8 , 12% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) (3- 
mercaptoethariol, 0,25% (w/v) bromophenol blue) and boiled for three minutes. The 
samples were resolved by electrophoresis on 8 -1 2 % polyacrylamide resolving minigels 
with 5% polyacrylamide stacking gels using the Mini-Protean II slab system (BioRad, 
Hemel Hempstead, UK), according to the manufacturer’s instructions. The proteins were 
then either detected by staining or transferred onto membranes for specific protein 
detection by western blotting.
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2.3.5 Detection of proteins on polyacrylamide gels
In order to observe proteins that had been resolved by SDS-PAGE, gels were routinely 
stained with 0.25% (w/v) Coomassie Brilliant Blue R250 in 10% (v/v) methanol and 
12.5% (v/v) isopropanol, usually overnight although occasionally for just 1-2 hours. Gels 
were destained with 1 0 % (v/v) acetic acid, 1 0 % (v/v) methanol, for several hours, usually 
with several changes of destain. Destained gels were visualised with a light-box 
(Hancocks, UK).
When increased detection of proteins was required, silver staining was employed. Gels 
were initially fixed in 40% (v/v) methanol and 10% (v/v) acetic acid for 30 minutes at 
room temperature, followed by two incubations for 15 minutes at room temperature in 1 0 % 
(v/v) ethanol and 5% (v/v) acetic acid. To oxidise the proteins, the gels were incubated in 
5% (v/v) glutaraldehyde solution, for five minutes at room temperature. The gels were 
washed twice in distilled water for five minutes at room temperature before reducing in 
0.4% (w/v) AgNOs for 20 minutes at room temperature. Gels were briefly washed in 
distilled water and developed in 0.02% (v/v) formaldehyde and 2.5% (w/v) NaiCOs. When 
the proteins became sufficiently visible the development was terminated in 5% (v/v) acetic 
acid; the gels were also stored in this solution.
2.3.6 Protein concentration determination
Protein concentrations in both cell lysates and purified recombinant protein samples were 
determined using the BioRad protein assay, based on the Bradford method (Bradford 
1976). Bovine serum albumin (Promega, Southampton, UK) was used as the protein 
standard; graphs and protein concentration calculations were made using Grafit software 
(Erithacus, Staines, UK).
2.3.7 Confirmation of axenic amastigotes by protease expression 
profile
Although it is possible to grow axenic amastigote-like forms of L. mexicana, it is necessary 
to confirm their similarity to amastigotes obtained from animals, rather than promastigotes 
grown in culture. This can be achieved by comparing the protease expression of the 
different parasite forms profile by gelatin SDS-PAGE (Bates et al, 1992).
SDS-PAGE was performed as described in section 2.3.4, except in addition the gels 
contained 0.2% (w/v) gelatin. Following electrophoresis, the gels were incubated for one
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hour at room temperature in 2.5% (v/v) Triton X-100 and then in 0.1 M sodium acetate pH 
5.0 with 10 mM DTT at 37 °C for 1.5 hours. The gels were stained in coomassie blue, as 
described in section 2.3.5.
2.3.8 Antibody production
Before the complete TDRl gene had been identified, the 3’ half of the gene was assumed 
to be the whole coding region and was cloned and expressed. The resulting N-terminal 
His-tagged, purified recombinant protein was unstable, but was used as an antigen to 
obtain antiserum from rabbit. This procedure was performed by the Scottish Antibody 
Production Unit (Carluke, UK), using standard methods. The antibody obtained was 
subsequently purified (see section 2.3.6).
Herein after it was decided a second anti-TDRl antibody should be generated, this time 
using the recombinant protein obtained upon expression of the whole gene. Again, N- 
terminal His-tagged, purified recombinant protein was used as the antigen, this time to 
produce antiserum in sheep. This procedure was performed by Diagnostics Scotland 
(Edinburgh, UK), using standard methods.
For production of an antibody raised against the putative LmGLO protein, the facility used 
was Biological Services, University of Glasgow. N-terminal His-tagged recombinant 
protein was produced and purified by Dr. Helen Denton and Dr. Gareth Westrop (both 
University of Glasgow); 50 pg protein diluted 1:1 (v/v) in Freund’s adjuvant (Sigma,
Poole, UK) in a final volume of 100 pi was inoculated into a rat. After one month, this was 
followed by two more similar booster inoculations.
2.3.9 Antibody purification
As described in the previous section two different anti-TDRl antibodies were raised, both 
of which were provided as crude serum. The first (rabbit) anti-serum did not recognise 
TDRl from Leishmania lysates on western blots although it did recognise many other 
Leishmania lysate proteins along with purified recombinant TDRl protein. These 
observations suggested that the anti-serum was not specific to TDRl but that it did contain 
anti-TDRl antibodies albeit at a low titre. Therefore, it was decided to purify and 
concentrate the anti-TDRl antibodies using recombinant TDRl.
The protocol for purifying the anti-TDRl antibody was optimised, so here only the 
optimised procedure involving an acidic column equilibration and final elution are
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described. 10 mg of purified recombinant TDRl in 2 ml 20 mM MOPS, pH 8.0, was 
incubated with 2 ml of Affi-gel 15 (BioRad, Hemel Hempstead, UK) overnight at 4 °C.
The incubation was centrifuged for one minute at 50 g and the supernatant (containing 
unbound protein) was removed before resuspending the gel in 3 ml of 20 mM MOPS, pH 
8.0.150 pi of 1 M ethanolamine, pH 8 . 0  was added (this blocks any uncoupled sites) and 
incubated for a further 1 hour at 4 °C. The sample was applied to a PD 10 column 
(Amersham, Chalfont St. Giles, UK) which was then washed with 10 ml each of; Tris-HCl, 
pH 7.5; Tris-HCl, pH 7.5 with 500mM NaCl; and glycine, pH 2.5, all at 100 mM. The 
column was then washed with Tris-HCl, pH 7.5, until the run-through was also pH 7.5, 
before 5 ml of heat-inactivated antiserum (heated to 65 "C for 20 minutes) was applied to 
the column; the run-through was re-applied twice to ensure optimal binding. The column 
was washed with 20 ml of 10 mM Tris-HCl, pH 7.5 with and without 500 mM NaCl. 
Finally, the bound antibodies were eluted in 6  ml of 100 mM glycine, pH 2.5.
2.3.10 Western blot analysis
Following separation by SDS-PAGE, proteins were transferred to Hybond-C nitrocellulose 
membrane (Amersham, Chalfont St. Giles, UK) by electroblotting in transfer buffer (20 
mM Tris, 15 mM glycine, 20% (v/v) methanol that had been pre-chilled to 4 °C. The 
transfer was performed using a mini transblot cell (BioRad, Hemel Hempstead, UK) for 45 
minutes at 100 V. A Seeblue protein standard (Invitrogen, Paisley, UK) was run alongside 
the protein samples; this can be visualised without staining. However, the membrane was 
stained with Ponceau S as this allowed observation of any air bubbles which could be 
marked, and confirmation of equal protein content between lanes when required. The 
membrane was blocked at 37 “C for 1 hour in 1 x TBS (20 mM Tris-HCl, pH 7.6, 13.7 mM 
NaCl) with 0.1% (v/v) Tween-20 and 5% (w/v) dried milk, before incubating overnight at 
4 °C with the appropriate primary antibody or antibodies in 1 x TBS with 0.1% (v/v) 
Tween-20 and 1% (w/v) dried milk. The following day the membrane was washed for 20 
minutes four times at room temperature with 1 x TBS with 1% (w/v) dried milk, before 
application of the secondary antibody in 10 x TBS with 1% (w/v) dried milk for two hours 
at room temperature. The membrane was further washed for 20 minutes three times in 1 x 
TBS with 1% (w/v) dried milk before rinsing briefly in lOx TBS and developing the blot. 
All secondary antibodies were HRP-conjugated so blots were developed manually by 
applying Supersignal West Pico substrate (Pierce, Cramlington, UK) and using Hyperfihn 
ECL (Amersham, Chalfont St. Giles, UK) to expose them, according to the manufacturers’ 
instructions. Films were developed and fixed using Kodak GBX developer/replenisher and 
fixer/replenisher (Sigma, Poole, UK), respectively.
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Antibody Source Type Dilution
rabbit anti-TDRl (1) Scottish Antibody Production 
Unit, Carluke, UK)
primary 1 / 2 0  (purified)
sheep anti-TDRl (2) Diagnostics Scotland, 
Edinburgh, UK
primary 1/4000
rat anti-L-GULO Biological services. University 
of Glasgow, UK
primary 1 / 1 0 0 0 -1 / 1 0 0 0 0
rabbit anti- 
Transketolase
Gifted by Dr. Mike Barrett, 
University of Glasgow, UK
primary 1 /2 0 0 0 - 1 / 1 0 0 0 0
rabbit anti-Cysteine 
Synthase
Gifted by Dr. Rod Williams, 
University of Glasgow, UK
primary 1/5000
anti-sheep IgG HRP 
conjugated
Santa Cruz Biotechnologies, 
CA, US)
secondary 1/5000
anti-rat IgG HRP 
conjugated
Pierce, Cramlington, UK secondary 1 / 2 0 0 0
anti-rabbit IgG HRP 
conjugated
Pierce, Cramlington, UK secondary 1 / 1 0 0 0 0
Table 2.4; Antibodies
2.3.11 Immuno-
used in Western Blots
-localisation of cellular protein
In order to analyse the distribution of TDRl in L. major, immuno-fluorescence was 
performed using the anti-TDRl antiserum produced in sheep, using an adapted method 
from one previously described (Field et al, 2004). Parasites were harvested by 
centrifugation at 1300 g for 10 minutes at 4 “C, washed in vPBS (Voorheis’ PBS: 137 mM 
NaCl, 3 mM KCl, 16 mM Na2HP0 4 , 3 mM KH2PO4 , 46 mM sucrose, 10 mM Glucose; 
pH7.6 (Nolan et al, 2000)), and resuspended at -2x10^ cells/ml in vPBS. An equal 
volume of 6 % (w/v) paraformaldehyde in vPBS was added and the mixture was incubated 
on ice for one hour. Five volumes of PBS was added and the parasites were harvested and 
washed as above, before resuspending at -2x10^ cells/ml in PBS. 200 pi of the parasite 
suspension was applied to a glass slide that had been pre-treated with 1 ml of 0 . 0 1  (w/v) 
poly-L-lysine solution (Sigma, Poole, UK) for five minutes and allowed to dry for > one 
hour at room temperature. The parasites were incubated for 15 minutes on the slide before 
the cells were permeabilised in 0.1% (v/v) Triton X-100 in PBS for 10 minutes at room 
temperature. Slides were washed at room temperature three times for five minutes in PBS, 
then blocked for one hour with 20% (v/v) HIFCS in PBS. The sheep anti-TDRl primary 
antibody was applied at various dilutions in PBS with 20% (v/v) HIFCS for one hour at 
room temperature before being washed three times in PBS as before. The secondary 
antibody (Alexa Fluor 488 donkey anti-sheep IgG, Molecular Probes, Paisley, UK) was
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applied at room temperature for one hour at a dilution of 1/500 in PBS with 20% (v/v) 
HIFCS along with 5 pg/ml 4’,6-diamidino-2-phenylindole (DAPI) stain. Slides were 
washed three times in PBS as before, dried and mounted with 1:1 (v/v) glycerol in PBS. 
Nail varnish was used to seal the edges of coverslips and slides were stored in the dark 
before analysis using an Axioplan Fluorescence microscope (Zeiss, Welwyn Garden City, 
UK) and Hamamstsu digital camera with Openlab software (Improvision, University of 
Warwick, UK).
2.3.12 Isolation of protein using S-hexyl-GSH agarose
It is possible to pull TDRl and other proteins out of Leishmania lysates by exploiting the 
fact they bind to hexyl-glutathione. Leishmania parasites were harvested, resuspended at 
-1 X 10^  cells/ml, lysed and centrifuged as before. The resultant soluble fraction was 
incubated with 100 pl/ml S-hexyl-glutathione sepharose (Sigma, Poole, UK) for two hours 
at room temperature with gentle mixing before centrifugation at 2500 g for one minute to 
sediment the sepharose. The sepharose pellet was vortexed and washed three times in 1 ml 
of 1 x GST Bind/Wash Buffer (composition as before, Novagen, Nottingham, UK), once in 
50 pi of 1 X GST Bind/Wash Buffer and once in 50 pi of 50 mM Tris-HCl, pH 8.0; the 
latter two washes were retained for analysis. Finally, bound proteins were eluted by adding 
50 pi of 10 mM S-hexyl-glutathione (Sigma, Poole, UK) in 50 mM Tris-HCl, pH 8.0, 
vortexing briefly, centrifuging as before and isolating the supernatant.
A similar method was also used to isolate TDRl from spent culture media. The method 
was broadly the same as described above except: 9 ml of spent media was filtered and 
mixed with 1 ml of 10 x GSH Bind/Wash Buffer and used rather than lysate; incubation 
with 100 pi of S-hexyl-glutathione sepharose was performed overnight at 4 “C and the final 
washing step was omitted.
2.3.13 BPR assay for measuring trivalent antimonials
The BPR assay can be used to detect trivalent antimonial species (Sblll). This method used 
was based on a procedure described previously (Frezard et al, 2001) and was employed to 
analyse whether H2O2 reacted with trivalent antimonials. Briefly, 200 pi of analyte solution 
comprising 20 mM sodium phosphate, pH 6 .8 , 0.1% (w/v) tartaric acid and 70 pM 
Bromopyrogallol Red (Sigma, Poole, UK) was added to 20 pi of sample in a microtitre 
plate. The absorbance was read at 540 nm using a Titertek Multiskan MCC/340 
spectrophotometer. Potassium antimonyl tartrate (0-0.5 mM in 20 pi), made up in the same
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buffer as the samples, was used to construct a calibration curve for each experiment 
performed and tests were conducted to confirm that none of the sample components 
interfered with the assay. Under the conditions used, this assay was shown to be specific 
for trivalent antimonial compounds and gave no reaction with sodium stibogluconate,
GSH, GSSG or H2O2 . The standard reaction mixture contained, in a volume of 1 ml, 100 
mM Tris-HCl, pH 8.0 (unless otherwise stated) and 1 mM Sblll in the form of potassium 
antimonyl tartrate (Sigma, Poole, UK). Potential inhibitors along with TDRl were also 
tested for their effect on the reaction; these were also present in the reaction mixture. The 
reaction, performed at room temperature, was initiated by tlie addition of H2O2, and 2 0  pi 
aliquots were removed at time-points between 2-180 minutes so the Sb(lII) content could 
be calculated using the BPR assay. Potassium antimonyl tartrate (0-0.5 mM in 20 pi), 
made up in the same buffer as the samples, was used to construct a calibration curve for 
each experiment performed.
2.4 Statistical analysis
Values were expressed either as mean ± standard deviation (SD) when the number of 
repetitions was more than two, or mean ± standard error (SE) when the number of 
repetitions was two. Significance levels were calculated by unpaired t-tests using the t-test 
function in the Microsoft Excel programme. Differences were considered significant when 
the p  value was <0.05.
2.5 Bioinformatic anaiyses
For trypanosomatid database mining and subsequent analysis, the website 
www.genedb.org was used extensively. The website www.ncbi.nlm.nih.gov and 
particularly the tblastn and tblastx BLAST search facilities were used for additional 
database mining and analysis. Examination of Leishmania DNA loci, generally of gene 
flanking regions, was performed using the Artemis programme.
The SignalP (version 3.0) programme (http://www.cbs.dtu.dk/services/SignalP/) was used 
to determine if genes of interest included any target signalling regions. The related targetP 
programme (version 1.1) was (www.cbs.dtu.dk/sevices/TargetP) was used to predict the 
subcellular localisation of proteins deemed to possess a signalling tag.
Vector NTI (version 6,0) software was used to organise, edit and analyse DNA and protein 
sequences as well as to facilitate the design of oligonucleotides. All sequence alignments
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and sequence similarity comparisons were made with alignX. Sequenced DNA was viewed 
and analysed using ContigExpress.
56
3 Pursuit of Leishmania genes and proteins 
involved in pentavalent antimonial activation
As discussed in chapter one, the toxicity of pentavalent antimonials, the standard first-line 
treatment against visceral leishmaniasis, is thought to be dependent on their reduction to 
trivalent forms. The site of the reduction remains controversial; the amastigote itself has 
been reported to reduce the drug (Ephros et al, 1999) although conflicting accounts 
regarding the lack of sensitivity that axenically grown amastigotes display to the drugs has 
lead to speculation that the host macrophage mediates reduction (Sereno et al, 1998). 
Whether reduction is enzymatically controlled is another contentious issue as pentavalent 
antimonials can be directly reduced to trivalent forms upon reaction with low molecular 
weight thiols such as trypanothione and glutathione in vitro (Frezard et al, 2001; Ferreira 
Cdos et al, 2003; Yan et al, 2003b). However, shortly before this work was initiated it 
was reported that L. donovani amastigotes possess antimonial-reducing activity which 
coincides with sensitivity to sodium stibogluconate (Shaked-Mishan et al, 2001). Drug- 
resistant parasites no longer had the capacity to reduce the pentavalent compound. 
Although providing no direct proof that the observed activity was enzymatic, the stage- 
specific nature of it combined with the apparent ability of the resistant parasites to dispense 
with drug-reducing activity suggested that that may well be the case.
No reports exist of proteins that specifically reduce or methylate antimonials; for this 
reason homologues of genes encoding proteins known to metabolise arsenate were 
pursued. Arsenate reductase (ars) opérons can confer resistance to antimonite when over­
expressed (Carlin et al, 1995) suggesting that both compounds can be used as substrates 
by the encoded proteins. The metabolism of arsenic, which is adjacent to and belongs to 
the same group as antimony in the periodic table, has been much more extensively studied 
(probably due to its toxic effects often being seen in humans) and more is known about its 
toxicology. Accordingly, it is often necessary to consider research carried out on arsenical 
compounds when investigating antimonials (Gebel, 1997). In addition to the reduction of 
inorganic, pentavalent metalloids, biomethylation has also been considered as a potential 
route of pentavalent antimonial drug metabolism. As reviewed in chapter one, the pathway 
is known to occur in a range of organisms and also involves reduction, albeit of methylated 
intermediates. Like arsenate reduction, biomethylation of metalloids yields more toxic 
products and may be considered as an activation pathway. As discussed, mammalian 
enzymes able to mediate biomethylation have recently been elucidated and, in addition, 
several different classes of arsenate reductases have been identified and characterised in
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eukaryotes and prokaryotes. This chapter details an investigation into whether genes 
encoding similar proteins to these, potentially involved in antimonial activation, are 
present in the L. major genome.
Sequencing of the Leishmania major genome has recently been completed (Ivens et al,
2005) but, together with those of other Leishmania species, the genomes have been 
elucidated over several years with more data being made gradually available. The 
databases -  all found at www.genedb.org -  have been frequently searched for sequences 
similar to the known arsenate-metabolising proteins; results of the most recent searches are 
summarised in this chapter. Moreover, genes and proteins potentially involved in 
antimonial reduction have been pursued by additional methods. These, along with the 
identification of one gene in particular, which is interesting because of both its significant 
homology to the inorganic arsenical and methylated arsenical reductase omega glutathione 
S-transferase (oGST) and its unusual sequence features, are also described.
3.1 Arsenate reductase homologues in L. major
Through frequent reviewing of available literature, several categories of proteins capable 
of reducing pentavalent arsenicals were identified. Three separate classes of microbial (two 
in bacteria and one in yeast) arsenate reductases had been previously characterised and 
during this investigation two mammalian proteins were found to be capable of reducing 
arsenate: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and purine nucleoside 
phosphorylase (PNP). In order to determine whether Leishmania may possess a protein 
capable of reducing pentavalent antimonials, the amino acid sequences of these arsenate 
reductase enzymes were used as enquiry sequences to search the L. major predicted protein 
database. Searches for L. major sequences were conducted using the omniblast feature at 
www.genedb.org and identified proteins were used as enquiry sequences to search known 
proteins of the original organism using the blastp facility found at 
http://www.ncbi.nlm.nih.gov/BLAST/. Alignments were performed using the alignX 
feature of vector NTI. The results of these blast searches and the ensuing analysis of the 
sequences identified are presented in this section and summarised in table 3.1.
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Enquiry sequence: 
organism, enzyme 
name, and amino 
acid length
Leishmania 
homologues, p/n 
scores and amino 
acid length
% identity, % 
conservation and 
observations on 
alignments
Single organism 
back BLAST results
E. coli R773 ArsC 
(1I9DA), 141 
amino acids
LmjF05.0150 0.94,
441 amino acids
11%, 33%. L. maj 
seq 240 amino 
acid N-term ext 
and small C-term 
ext.
Enq seq not 
significantly similar.
1. S. aureus pI258 
ArsC (AAA25638), 
131 amino acids
2. B. subtilis pI258 
ArsC (NP390455), 
139 amino acids
LmjFOl.0200
1.0.017, 2. O.Oe"* 
300 amino acids
1. 21%, 37%. 2. 
22%, 37%. L  maj 
seq has small N- 
term and larger 
C-term ext, plus 
insertion.
1. N/A 2. Best hit to 
enq seq.
S. cerevisiae Acr2p 
(NPO15526) 130 
amino acids
LmjF32.2740
0.011, 229 amino 
acids
16%, 31%. L. maj 
seq 99 amino acid 
N-term ext.
Best hit to enq seq.
Human PNP 
(NP000261)289 
amino acids
LmjF05.0830
7.1e‘*, 306 amino 
acids
21%, 42%. L. maj 
seq small C-term 
ext & small N- 
term deletion.
10“ hit to enq seq. 
Best is
methylthioadenosine
phosphorylase
(MTAP).
Human GAPDH 
(NP002037) 335 
amino acids
a. LnriF30.2970
2.3e'* , 361 amino 
acids
b. LmjF30.2980
5.3e‘*^ , 361 amino 
acids
c. LmjF36.2350
5.7e'  ^ ,215 amino 
acids
d. LmjF35.4750
9.3e'^\ 349 amino 
acids
a & b. 51%, 70%. 
Good similarity, 
c. 68%, 80%. L. 
maj seq 120 
amino acid N- 
term deletion, d. 
26%, 45%. Good 
similarity.
a & b. 2"^  hit to enq 
seq. Best is 
spermatogenic 
GAPDH.
c. Best hit to enq seq.
d. Best hit to enq seq.
Table 3.1: L. mayor sequences similar to arsenate reductases. Bacterial proteins are coloured 
in purple, yeast and plant Acr2p is shown in grey-blue, and mammalian sequences are in red. 
Abbreviations used are PNP -  purine nucleoside phosphorylase, GAPDH -  glyceraldehydes-3- 
phosphate dehydrogenase, L. maj -  L. major, seq -  sequence, ext -  extension, N-term -  N- 
terminal, C-term -  C terminal, enq -  enquiry.
3.1.1 Microbial Arsenate Reductases
The two unrelated classes of bacterial ArsC proteins are both encoded on extra- 
chromosomal plasmids, the most extensively investigated of each being the Gram-positive 
S. aureus pI258 ArsC and Gram-negative E. coli R773 ArsC. For clarification purposes 
these proteins will be herein referred to as pI258 ArsC and R773 ArsC. Together with 
Acr2p, first found in S. cerevisiae and for some time the only known eukaryotic arsenate 
reductase, these proteins comprise the group designated here as microbial arsenate
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reductases. It should be noted that recently Acr2p was identified in plants (Duan et al, 
2005; DhanJkher et al, 2006) and therefore can no-longer be thought of as purely a 
microbial enzyme. Although all three proteins have similarities with other enzymes, they 
have no other identified enzymatic capabilities and are classified specifically as arsenate 
reductases. This may be of importance when considering similar Leishmania sequences.
3,1.1.1 R773ArsC
The L. major genome was searched for sequences similar to the 141 amino acid E. coli 
R773 ArsC protein. The most similar (p/n value -  0.94) predicted protein, LmjF05.0150, 
was annotated as a hypothetical protein. Comprising 441 amino acids, it was predicted to 
be more than three times the length of R773 ArsC and have a 240 amino acid N-terminal 
extension as well as a smaller C-terminal extension, when the two sequences were aligned 
(figure 3.1). The regions of the sequences that did align shared just 11% identity and 33% 
conservation. When the amino acid sequence of LmjF05.0150 was used as an enquiry 
sequence in a blastp search of E. coli proteins, the original ArsC sequence was not found to 
be significantly similar. Other than trypanosomatid proteins, LmjF05.0150 is most similar 
to N0D3, a caterpillar protein involved in T-cell activation. The crystal structure of E. coli 
R773 ArsC has been previously solved (Martin et al, 2001); Arg60, Arg94, and Argl07 
are required to bind arsenate and the actual reduction is dependant on Cysl2. Of these 
residues, none were conserved when the sequence was aligned with that of LmjF05.0150 
although Arg60 and Argl07 aligned with the similarly basic amino acids Lys300 and 
Lys347, respectively. The low percentage similarity together with the high p/n value score 
given for the two proteins being related, imply that LmjF05.0150 is an unlikely R773 ArsC 
arsenate reductase, an observation supported by the lack of conservation between 
important residues and the large difference in predicted protein size. Other sequences 
identified in the search were less similar to R773 ArsC than LmjF05.0150 and 
unconvincing matches; these have not been detailed here.
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Figure 3.1: Alignment of E. coli R773 ArsC with the most similar L. mayor sequence, 
LmjFOS.OSIO. E. coli R773 -  E coli R773 ArsC. The residues known to be essential for arsenate 
binding and reduction in £. coli R773 ArsC are underlined in red; none of these residues are 
present in the L mayor sequence. Dashes indicate gaps in the alignment. Identical residues are 
printed in white on a black background and similar residues are printed in black on a grey 
background.
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3.1.1.2 pl258ArsC
Using the amino acid sequence of the S, aureus pI258 ArsC as the inquiry sequence, the L  
major genome was searched as above for similar proteins to this second class of ArsC 
reductases. Again the most alike (p/n = 0.017) protein, LmjFO1.0200, was annotated as 
being a hypothetical protein but was listed as exhibiting sequence similarities to low 
molecular weight phosphotyrosine protein (LMW PTPs) phosphatases. This was of interest 
as pI258 ArsC proteins are thought to have evolved horn genes encoding these enzymes 
(Zegers et al, 2001) and the B, subtilis pI258 ArsC displays low-level PTP phosphatase 
activity (Bennett et al, 2001). In order to determine whether LmjFO1.0200 was more 
similar to pI258 ArsC or LMW PTPs, the amino acid sequence was used to search the
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protein database at www.ncbi.nlm.nih.gov. Unfortunately the resultant list of alike proteins 
was divided between predicted arsenate reductases and LMW PTPs. One of these was the 
Bacillus subtilis pI258 ArsC, another experimentally confirmed pI258 ArsC (Sato and 
Kobayashi, 1998). This amino acid sequence was used to search for similar L. major 
predicted proteins and once again LmjFO1.0200 was the most alike. However, the p/n 
value was given as 9.0e’°^ , considerably smaller than when the S. aureus protein was used 
as the inquiry sequence. The sequence of LmjFO1.0200 was used as an enquiry sequence in 
a blastp search of B. subtilis proteins and the most similar was the pI258 ArsC. It is not 
possible to perform a single-organism search on the S. aureus genome at present.
Despite the improved p/n value, several factors suggested that the LmjFO 1.0200 protein 
may not necessarily be a pI258 ArsC. The L  major protein was predicted to contain 300 
amino acids, more than twice the number of the S, aureus pI258 ArsC (130) or the B. 
subtilis enzyme (139). Accordingly, when the three protein sequences were aligned (figure 
3.2), LmjFOl.0200 contained a small N-terminal extension and mid-sequence insertion as 
well as a C-terminal extension of almost 100 amino acids compared to the bacterial protein 
sequences. Of the areas that align, LmjFO 1.0200 shares identity with the S. aureus and B. 
subtilis pI258 ArsC proteins of 21% and 22% respectively, and conservation of 37% with 
both proteins. Several residues have been previously identified as being important for 
activity in both LMW PTP and pI258 ArsC enzymes: all known LMW PTPs contain a 
CXXXXXRS/T motif (Fauman et al, 1996) while a comparable CTGNSCRS motif is 
conserved between pI258 ArsC arsenate reductases (Bennett et al, 2001). In addition, 
Cys82, Cys89 and Asp 105 are all required for the B. subtilis pI258 arsenate reductase 
catalytic mechanism (Messens et al, 1999; Bennett et al, 2001). Although Cys82 and 
Cys89 are conserved in LmjFOl.0200 (Cysl55 and Cysl63, respectively), there is no 
corresponding aspartic acid. Furthermore, there is no intact CTGNSCRS or even 
CXXXXXRS/T motif: although the penultimate and final residues are conserved in Arg51 
and Thr52, the essential cysteine is absent. Due to the fact LmjFO1.0200 lacks the 
necessary amino acid requirements for both arsenate reductase and PTPase activity, it is 
unlikely to possess either of these enzymatic capabilities unless a modified or previously 
unidentified catalytic mechanism is involved.
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Figure 3.2; Alignment of S. aureus and B. subtilis ArsC with the m ost similar L. major 
sequence, Lmj FOI .0200. S. aur pl258 -  S. aureus pl258 ArsC, B. sub pi258 -  B. subtilis pl258 
ArsC. The residues known to be essential in the S. aureus and B. subtilis sequences are 
underlined in blue and the essential motif is underlined in red. Although the L mayor sequence 
contains a cysteine residue which aligns with the Cys89 of the known pl258 ArsC sequences and 
contains another which aligns adjacent to the Gys82 residue, it lacks an aspartic acid residue that 
aligns with Asp 105 and the essential CTGNSCRS motif. Dashes indicate gaps in the alignment. 
Identical residues are printed in white on a black background, conserved residues are printed in 
white on a grey background and similar residues are printed in black on a grey background.
3.1.1.3 Acr2p
Acr2p -  the third category of microbial arsenate reductases -  was first identified in S. 
cerevisiae, and the 130 amino acid sequence of the yeast protein was used here to search 
the L major genome for similar predicted proteins. Once more the most similar sequence 
was that of a hypothetical protein, LmjF32.2740, and the p/n score given was 0.011. 
Predicted to comprise 229 amino acids, it was again a considerably larger protein than its 
microbial counterpart, S. cerevisiae Acr2p, and when the two sequences were aligned 
(figure 3.3) LmjF32.2740 was expected to have a 100 amino acid N-terminal extension.
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The sections of the two proteins that did align shared 16% identity and 31% conservation. 
When LmjF32.2740 was used as an enquiry sequence to search the S. cerevisiae database, 
the most similar protein was Acr2p. As discussed in chapter 1, Acr2p proteins share 
sequence similarities (including the essential HCXXXXXR motif) with Cdc25a protein 
tyrosine phosphatases, a separate class of phosphatases from the pI258 ArsC-related low 
molecular weight tyrosine phosphatases. This motif was also found in LmjF32.2740:
His 176, Cysl77 and Argl83, respectively. Meanwhile the Cdc25a protein GXGXXG 
motif required for phosphatase activity is absent in both the Z. major and S. cerevisiae 
Acr2p proteins.
LmjF32.2740 has recently been characterised and exhibits arsenate reductase activity in 
vitro (Zhou et al, 2004); the protein has been designated LmACR2. In addition when 
LmACR2 was over-expressed in L. infantum the transgenic parasites displayed increased 
sensitivity to Pentostam; a similar phenotype was also observed when the Leishmania gene 
was expressed in E. coli. Although it appears that LmACR2 is the first example of an 
arsenate reductase in Leishmania, the protein that has been characterised is significantly 
shorter than LmjF32.2740. The possible reasons for this, and the potential implications, are 
discussed in section 1.5 of this chapter.
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Figure 3.3: Alignment of 5. cerevisiae Acr2p with the m ost similar L. ma/or sequence, 
LmjF32.2740. S. cev Acr2p S. cerevisiae Acr2p. The motif known to be Important in the S. cerevisiae protein which Is also preset In the L mayor sequence is underlined in red. The residue 
that has previously been reported as the start methionine of the Leishmania protein (Zhou et al. 
2004) Is underlined in blue. Dashes Indicate gaps in the alignment. Identical residues are printed in 
white on a black background and similar residues are printed In black on a grey background.
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3.1.2 Mammalian arsenate reductases
As detailed in chapter one, the two recently identified mammalian enzymes capable of 
reducing arsenate in vitro -  purine nucleoside phosphorylase (PNP) and glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH) -  may not be responsible for in vivo arsenate 
reductase activity. It is therefore within this context that Leishmania proteins with similar 
sequences to the mammalian arsenate reductases are evaluated: even very similar proteins, 
likely to be present due to the highly conserved sequences of these enzymes due to their 
important cellular roles, are treated with caution.
3.1.2.1 PNP
The sequence of the 289 amino acid human PNP was used to search the L. major genome 
for similar predicted proteins. The most significant homologue -  with a p/n score of 7.1e'^ 
-  was that of LmjF05.0830, a predicted protein annotated as a methylthioadenosine 
phosphorylase (MTAP) although this is inferred from homology rather than experimental 
evidence. At 306 amino acids LmjF05.0830 is similar in size to human PNP and the 
proteins share 21% identity and 42% conservation. When LmjF05.0830 was used as an 
enquiry sequence in a blastp search of human proteins, nine sequences were more similar 
to the Leishmania protein than the PNP, with the most alike being a MTAP. LmjF05.0830 
is considerably more similar to this class of phosphorylase than to PNP (figure 3.4): the 
identity between the human protein (identification number NP002442) and the L. major 
sequence is 34%. Accordingly, the annotation in the database describing LmjF05.0830 as a 
MTAP can probably be regarded as accurate as the amino acid sequences are so closely 
related. It is interesting to note that there are no predicted proteins annotated as, or 
displaying significant homology to, mammalian PNP included in the L major genome.
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Figure 3.4: Alignment of Human PNP and MTAP sequences with the m ost similar L  major 
sequence, LmjF05.0830. The L mayor sequence is more similar to human MTAP (identification 
number NP002442) than to PNP. Dashes indicate gaps in the alignment. Identical residues are 
printed in white on a black background, conserved residues are printed In white on a grey 
background and similar residues are printed In black on a grey background.
3.1.2.2 GAPDH
Using the sequence of the 335 amino acid human GAPDH protein as the inquiry sequence, 
the L. major genome was searched for similar proteins to this second class of mammalian 
putative arsenate reductases. Four Z. major protein sequences were found to share 
significant similarity with human GAPDH and are all annotated as such. The first two of 
these four homologues, LmjF30.2970 and LmjF30.2980, will be considered together as 
they are tandemly arrayed and their sequences differ by just one amino acid. Both 361 
amino acid proteins, which are similar in size to the human homologue, share 51% identity 
and 70% conservation with human GAPDH; these high values are reflected in the p/n 
scores which are 2.3e"^  ^for LmjF30.2970 and 5.3e'^  ^for LmjF30.2980. The predicted 
proteins are annotated as glycosomal GAPDHs and are >95% similar to an experimentally
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characterised L. mexicana glycosomal GAPDH (Hannaert et al., 1994). The glycosomal 
location of both these proteins together with the cytosolic location of the third L  major 
GAPDH has also been experimentally proven (Hannaert et al, 1992).The third L. major 
GAPDH, LmjF36.2350, is just 215 amino acids long: over 120 amino acids present at the 
N-terminus of the human and other L. major GAPDH proteins are absent. However the p/n 
score is highly significant -  -  and the identity and conservation between the
aligning regions of LmjF36.2350 and human GAPDH are 6 8 % and 80%, respectively. The 
predicted protein, which is annotated as a cytosolic GAPDH, appears to be a partial 
GAPDH. However when the upstream DNA sequence was retrieved and translated, it too 
aligned with human GAPDH and proved to be the missing N-terminal part of the protein,
A putative start methionine codon at the point in the sequence that would result in the 
missing portion being translated was also in frame, although a downstream stop codon 
prevented this sequence from being included in the LmjF36.2350 open reading frame. 
Whether a mutation has caused a stop codon to appear and for either a truncated protein to 
be translated or for LmjF36.2350 to have effectively become a pseudo-gene (perhaps 
possible due to degeneracy between the L  major GAPDH enzymes), or whether this is a 
straightforward error in the sequencing, is unclear. If the latter is true LmjF36.2350 is a 
strong contender to be a third L. major GAPDH and possible arsenate reductase. The 
fourth L  major GAPDH-like protein, the 349 amino acid Lmj35.4750, is less similar to the 
human enzyme with a p/n score of 9.3e'^\ However this is a relatively significant value 
and the Leishmania sequence, which is annotated as a GAPDH, shares 26% identity and 
45% conservation with the human protein. When each of the sequences of the L. major 
proteins similar to GAPDH were used as enquiry sequences in blastp searches of the 
human protein database, the most similar to each was GAPDH. All four L. major predicted 
GAPDH sequences aligned with the human GAPDH sequence are shown in figure 3.5.
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Figure 3,5: Alignment of human GAPDH with the most similar L. mayor, sequences, 
LmjP30.2970, LmjF30.2980, LmjF35.4750 and LmjF36.2350. LmjF30.2970 and LmjF30.2980 are 
almost identical in sequence. Dashes indicate gaps In the alignment. Identical residues are printed 
In white on a black background, conserved residues are printed in white on a grey background and 
similar residues are printed in black on a grey background.
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3.2 Analysis of omega glutathione S-transferase-iike 
genes in L. major
In section 3.1, the presence in L. major of amino acid sequences similar to known arsenate 
reductase proteins was investigated. However, as is discussed in chapter one, reduction is 
not the only form of metalloid metabolism known to occur in vivo: biomethylation of 
arsenicals, and indeed antimonials, is also possible. Although most studies of 
biomethylation have focused on the méthylation of arsenicals in mammalian systems 
(Zakharyan et al, 1999), a similar process is known to occur in various microbes with 
antimonial species (reviewed in Bentley and Chasteen, 2002). The mammalian enzyme 
AS3MT is responsible for the methyltransferase activity (Lin et al, 2002; Wood et al,
2006). A search for similar enzymes to AS3MT in the L. major predicted proteins database 
yielded one significant (p/n score ~ 7.1e‘^ )^ homologue, LmjF35.4250, although the protein 
sequence is much more similar to, and is annotated as, 3-demethyIubiquinone-9,3- 
methyltransferase, a methyltransferase involved in the synthesis of ubiquinone.
Meanwhile human enzyme MMA(V) reductase (which enzymatically reduces methylated 
pentavalent arsenicals as opposed to inorganic arsenate) has recently been identified as 
oGST (Zakharyan et al, 2001). oGST sequences have since been identified in a wide range 
of organisms and have a conserved C-P-Y/F-A/V/S motif at their predicted active sites 
(figure 3.6). The role of oGST in arsenic metabolism in vivo remains unclear although 
naturally-occurring polymorphisms in oGSThmc been linked to arsenic-susceptibility in 
mammals (Schmuck et al, 2005) and alterations in excreted arsenical profiles in humans 
(Mamell et al, 2003). More recently oGST has been reported to reduce arsenate, as well as 
MMA(V), in vitro (Zakharyan et al, 2005) -  an observation that effectively adds a new 
class of proteins to the rapidly increasing number of arsenate reductases described earlier 
in this chapter. In this section an investigation of L. major genes and proteins similar to 
oGST is presented.
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Figure 3.6; Alignment of various oGST amino acid sequences. oGST-llke sequences have now 
been discovered In a diverse range of organisms. The sequences all share the predicted active site 
motif of C“P“Y/F"A/SA/ situated at position 31-33 of human oGSTI (underlined in red). The 
Identification numbers for the oGST sequences are as follows: chicken, XP421747; human 1, 
NP004823; human 2, NP899062; mosquito, AAP13482; mouse, NP034492; pufferflsh, AAL08414; 
schistosome, AA049385. Dashes Indicate gaps In the alignment. Identical residues are printed in 
white on a black background, conserved residues are printed in white on a grey background and 
similar residues are printed in black on a grey background.
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3.3 Omega GST-like sequences in the L. major genome
In order to identify Leishmania genes or proteins similar to oGST, the amino acid sequence 
of human oGST 1 (identification number NP004823) was used as an inquiry sequence to 
search the L. major databases available at www.genedb.org. This search was initially 
performed in 2003 when the L. major genome had not been fully sequenced. Several 
sequences, deemed 1ml 6, lm33 and lm34 based on the Leishmania chromosomes they 
mapped to, displayed significant similarity to oGST, including in the active site motif 
(figure 3.7). As stated the sequencing of the genome at this time was incomplete and the 
databases not yet annotated; for each fi*agmentary oGST-like sequence the specific codon 
that translated to the start methionine was ambiguous. Furthermore lm34 lacked an in- 
firame stop codon. Unfortunately analysis of the surrounding sequences in silico to 
elucidate the open reading frames was impossible due to the non-assembled condition of 
the genome. Consequently it was necessary to perform rapid amplification of cDNA ends 
(RACE) on the sequences -  5’ RACE on all three sequences and 3’RACE on lm34 - in  an 
attempt to reveal the complete genes. This was successful for the sequence lm33, as 
detailed later in this chapter.
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Figure 3.7: Alignment of L. mayor oGST-like sequences with human 0GSTI. All sequences are 
fragmentary; Im33 has a putative start methionine at position 8 but tm16 and lm34 do not, while 
Im34 also lacks an in-frame stop codon. However all sequences contain the conserved C-P-Y/F- 
AA//S active site motif present in oGSTs (underlined in red). Dashes indicate gaps in the alignment. 
Identical residues are printed in white on a black background, conserved residues are printed in 
white on a grey background and similar residues are printed in black on a grey background.
3.3.1 !m16 and Im34: analysis of two oGST-like sequence 
fragments
As mentioned, RACE was performed on the fragmentary 1ml 6 and lm34 sequences to 
discover the positions of the relevant start and stop codons and hence elucidate the 
complete open reading frames. Frustratingly, despite repeated attempts, the reactions did 
not yield any products of the expected size; accordingly the DNA that was sequenced was 
found to be non-specific and unrelated to the sequences being analysed. Furthermore, 
attempts to amplify 1ml 6 and lm34 by standard PCR also proved to be unsuccessful. At 
this point the sequences were used as inquiry sequences in tblastx searches of the translated
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database at www.ncbi.nlm.nih.gov. Both sequences, particularly 1ml 6, were found to share 
very high similarity with proteins from rod-forming, gram-negative bacteria 
Photobacterium profundum and Pseudomonas fluorescens (figure 3.8). This was 
unexpected as the sequences of oGST-like sequences are not particularly highly conserved 
between species (figure 3.6). The high level of similarity between the Leishmania and 
bacterial sequences, together with the experimental difficulties encountered when trying to 
amplify the genes, lead to the hypothesis that 1ml 6 and lm34 may not be L. major genes 
and may have been included in the genome database due to bacterial contamination in the 
sequencing material. Therefore no further analysis of 1ml6 and lm34 was attempted at this 
time. Due to the fact that neither sequence appears in the now completed L. major genome, 
the hypothesis was likely to have been correct and the decision to terminate investigation 
into these sequences justified.
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Figure 3.8: Alignment of Im16 and Im34 with bacterial amino acid sequences. A -  im34 
aligned with Photobacterium profundum sequence. B -  Im16 aligned with Pseudomonas fluorescens sequence. The high level of similarity coupled with the failure to amplify the supposed Leishmania sequences from parasite DNA suggested the Im16 and Im34 may be bacterial. The 
sequences no longer appear in the L. major genome database. Dashes indicate gaps in the 
alignment. Identical residues are printed in white on a black background and similar residues are 
printed In black on a grey background.
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Genes annotated as glutaredoxins and thioredoxins in the L  
mayor genome
Previously oGST has been shown to share amino acid sequence similarity (including the 
proposed active site motif), and enzymatic activities with glutaredoxins and thioredoxins 
(Board et al, 2000) and structural identity with E. coli glutaredoxin 2 (Xia et al, 2001). 
Indeed recombinant oGST is more similar to glutaredoxins in activity than to other classes 
of GSTs. Whether glutaredoxins or thioredoxins are also capable of directly reducing 
pentavalent metalloids -  either inorganic or methylated -  has never been explored. Such an 
activity could explain the previous observation that the transformation of arsenite to 
dimethylarsinate, which involves the reduction of methylarsonate, was possible in vitro 
with just the arsenical-methylating protein AS3MT, thioredoxin, thioredoxin reductase and 
NADPH present (Thomas et al, 2004). The likenesses between methylarsonate-reducing 
oGST and these proteins, coupled with the possibility that they may directly reduce 
arsenicals, was the basis for analysing the L  major predicted proteins database for 
glutaredoxins and thioredoxins.
There are five L .major predicted proteins annotated as being putative glutaredoxins 
although in all cases the function has been inferred from homology rather than being based 
on experimental analysis. They are LmjF14.1480 (311 amino acids), LmjF20.1010 (107 
amino acids), LmjF05.0310 (180 amino acids), LmjF27.0810 (109 amino acids), and 
LmjFO 1.0110 (195 amino acids). The largest of these predicted proteins, LmjF14.1480 is 
annotated as being a putative glutathione S-transferase or glutaredoxin. Two L. major 
predicted proteins, LmjFO1.0270 and LmjF35.1250, are also annotated as being putative 
thioredoxins (again, function inferred from homology). When the amino acid sequences of 
these predicted proteins were used as inquiry sequences for blastx (translated sequence 
versus protein database) searches at www.ncbi.nlm.nih.gov, all were most similar to 
predicted or experimentally characterised glutaredoxins or thioredoxins, again with the 
exception of LmjF14.1480 which was most similar to prostaglandin E synthase 2. These 
proteins have been previously found to possess glutathione S-transferase activity; 
accordingly LmjF14.1480 is treated as such here and is discussed in section 3.4 of this 
chapter.
The L  major amino acid sequences were compared to those of glutaredoxins 1-5 (grxl-5) 
and thioredoxins 1 and 2 (trxl and trx2) of the fission yeast Schizosaccharomyces pombe, 
and aligned using alignX (figures 3.9 and 3.10). The thioredoxin-specific motif WCGPCK 
is present in just one of the L. major predicted thioredoxins, LmjFO1.0270, and this protein
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also shares the highest level of sequence identity with trxl and trx2 of S. pombe. Even 
more strikingly, LmjFO1.0270 is 56% identical to T. brucei brucei thioredoxin which has 
been experimentally characterised (Reckenfelderbaumer et al, 2000). However, the second 
predicted thioredoxin, LmjF35.1250, does not contain the aforementioned motif but does 
possess a comparable N-terminal WCEFCT sequence (figure 3.9). In addition the predicted 
protein has a CGFT motif which is similar to, and aligns with, the CGFS active site motif 
of the S. pombe glutaredoxins grx4 and grx5 (figure 3.10). X pombe grx4 also contains an 
N-terminal thioredoxin-like motif, WAAPCK, potentially responsible for cellular nuclear 
localisation rather than thioredoxin or glutaredoxin-like activities (Molina et al, 2004). 
LmjF35.1250 shares considerably liigher levels of identity with grx4 and grx5 -  20% and 
28%, respectively -  than with trxl (11%) and trx2 (8%). It is reasonable to conclude that 
LmjF35.1250 is a monothiol glutaredoxin tliat contains a thioredoxin-like motif, rather 
than an actual thioredoxin protein.
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Figure 3.9; Alignment of S. pombe trx1 and tnc2 with the annotated L. major irx sequences, 
LmjFOI.0270 and LmjF35.1250. The trx-specifio motif is present in LmjF01.0270 but not 
LmjF35.1250 (underlined in red). The grx-like motif in LmjF35.1250 Is underlined in blue. Dashes 
Indicate gaps in the alignment. Identical residues are printed in white on a black background, 
conserved residues are printed in white on a grey background and similar residues are printed in 
black on a grey background.
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Of the annotated glutaredoxins (with the exception of LmjF14.1480), all aligned with S. 
pombe glutaredoxins and had similar active site motifs to them (figure 3.10). Only one, 
LmjF27.0810, had a conventional glutaredoxin dithiol active site (C-P-Y-C). This protein 
also shared highest levels of identity, in both cases 35%, with the S. pombe dithiol 
glutaredoxins grxl and grx2. The predicted active sites of the remaining L. major putative 
glutaredoxins contain just one cysteine: C-A-F-S (LmjFOl.OllO), C-R-F-T (LmjF05.0310) 
and C-Q-F-S (LmjF20.1010). LmjF20.1010 shares 24% sequence identity with both grx4 
and grx5 but the aligned sequence is 28% identical to grxl. However, because of the single 
cysteine residue in the active site motif of these L. major predicted proteins, all three of 
them are likely to be monothiol glutaredoxins. Two of them, LmjFO 1.0110 and 
LmjF05.0310, are predicted to have N-terminal signalling tags and when the amino acid 
sequences were entered into targetP they were both predicted to be mitochondrial proteins.
In summary, L. major is likely to contain one thioredoxin, one dithiol glutaredoxin and 
four monothiol glutaredoxins, up to three of which may localise to cellular organelles, such 
as the mitochondria, or be secretory proteins. Although their primary role is unlikely to be 
metabolising metalloids in the parasite, investigation into whether any of these predicted 
proteins are capable of reducing and hence activating pentavalent antimonial drugs would 
be worthwhile. However, these have not been analysed in this study due, in part, to the 
presence of sequences sharing considerable similarity to those of the verified mammalian 
arsenical reductase oGST in the L. major genome, as described previously.
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Figure 3.10: Alignment of S. pombe grxl, grx2, grx3, grx4 and grx5 with the annotated L. 
mayor grx sequences, LmjF27.0810, LmjF20.1010, LmjFOI.0110 and LmjFG5.0310; plus 
LmjF35.12S0. The trx-like motif present in S. pombe grx4 is underlined in red. The predicted grx 
active sites, including monothiol and dithiol motifs, are underlined in blue. Dashes indicate gaps in 
the alignment. Identical residues are printed in white on a black background, conserved residues 
are printed in white on a grey background and similar residues are printed in black on a grey 
background.
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3.4 Analysis of S-hexyi-GSH-binding proteins in 
Leishmania
Glutathione S-transferases (GSTs) are a diverse family of detoxification enzymes present 
in most life forms that catalyse the conjugation of glutathione (GSH) to both endogenous 
and exogenous electrophillic compounds. They have been implicated in a wide range of 
cellular reactions (Hayes et al, 2005) including drug-resistance, notably to anti-cancer 
compounds (Townsend and Tew, 2003). It is thus possible that GSTs could be involved in 
directly detoxifying antimonial compounds. However, the recently discovered involvement 
of mammalian oGST in arsenical reduction (Zakharyan et al, 2001) was the most 
compelling reason to look for GSTs in Leishmania.
In 2002 several known GST sequences were used as inquiry sequences in searches of the 
various Z. major genome and proteome databases. With the exception of the oGST-like 
sequences described previously, and with LmjF14.1480 being more similar to 
prostaglandin E2 synthase, there were no highly significant similar sequences to any of the 
classes of GST used in the searches. Prostaglandin E2 synthases are members of the 
MAPEG (Membrane Associated Proteins in Eicosanoid and Glutathione metabolism) 
family which include microsomal, membrane-bound GSTs. Many of these proteins 
catalyse the conjugation of l-chloro-2,4-dinitrobenzene with GSH (Bresell et al, 2005), 
generally considered as being the standard GST activity. Therefore it is plausible that 
LmjF14.1480 could function as a cellular GST and, despite the associated problems in 
analysing membrane-bound proteins, could be an interesting candidate for investigation. 
Flowever, Z major sequences encoding cytosolic GSTs (like oGST) remained elusive. The 
abundance of cytosolic GSTs in most life-forms suggested that GST-encoding genes would 
be present in the Z. major genome; the lack of them found at this time was explained by 
the difficulty in identifying GSTs due to the highly divergent nature of proteins belonging 
to this large, diverse super-family (Sheehan et al, 2001), Therefore attempts were made to 
isolate GST proteins directly fi*om Leishmania parasites using biochemical methods.
3.4.1 Isolating Leishmania proteins using S-hexyi-GSH sepharose
It has been reported that pig oGST binds to S-hexyl-glutathione (S-hexyl-GSH) and that 
this property can be exploited to purify the protein from cellular extracts (Rouimi et al, 
2001). This approach, together with mass-spectrometric analysis of the recovered proteins, 
was used here in an attempt to find novel Leishmania GSTs. S-hexyl-GSH sepharose was 
used as oGSTS were of specific interest due to their in vitro arsenate reductase activities.
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Briefly, Leishmania parasites were harvested and lysed and the soluble fraction was 
incubated with S-hexyl-GSH. Bound proteins were subsequently eluted from the sepharose 
and analysed by SDS-PAGE; consistently appearing bands were analysed by mass- 
spectrometry so their identity could be ascertained.
3.4.2 The range of Leishmania proteins isolated using S-hexyl- 
GSH sepharose is reproducible
Before pursuing the identity of S-hexyl-GSH binding-proteins by mass spectrometric 
analysis it was important to optimise the elution conditions to enhance yield and 
reproducibility. Large cultures of Leishmania promastigotes were harvested so that each 
sample contained at least 1x10^ parasites, a volume sufficient for the resultant eluted 
proteins analysed by SDS-PAGE to be visible following silver-staining. Both the amount 
of S-hexyl-GSH used in the elution buffer and the pH of the elution buffer were varied in 
order to determine whether bound proteins could be eluted gradually from the sepharose 
(figure 3.11 A and 3.1 IB). However, it was found that this approach yielded similar protein 
compositions in each elution and therefore the number of elutions performed in subsequent 
experiments was limited. Using large volumes of parasites and silver-staining the SDS- 
PAGE gels did, however, provide confirmation that reproducibility in proteins eluted 
between different samples could be achieved (figure 3.11 A). Several proteins were eluted 
in the range of 20-30 kD (figure 3.1 IB): these were of particular interest as cytosolic GSTs 
from other organisms are around this size.
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Figure 3.11: Silver-stained SDS-PAGE gels of Leishmania proteins eluted from S-hexyl-GSH 
sepharose. A1 and A2 -  L. infantum proteins eluted with increasing concentrations of S-hexyl- 
GSH as lat)elled above the gel images. hex-GSH = S-hexyl-GSH. A1, 1.8 x 10® parasites used; A2, 
2.6 X 10® parasites used. All elutions were performed in 50 mM Tris-HCI, pH 8.0. Protein molecular 
masses are indicated to the left of the gel image in kD (kilodaltons). B -  L. major proteins eluted 
with different S-hexyl-GSH concentrations and high pH buffer, as lat>elled above as before. Final 
wash performed in bind/wash buffer pH 7.3. All elutions performed in Tris-HCI pH 8.0 except for 
final elution performed in same buffer but at pH 9.5 as indicated. Ladder shown is benchmark 
protein ladder; protein sizes are shown as t>efore. Proteins eluted from the S-hexyl-GSH sepharose 
are indicated with red arrows.
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3.4.3 Similar proteins are isolated from different species of 
Leishmania with S-hexyl-GSH sepharose
As well as achieving reproducibility between S-hexyl-GSH binding-proteins recovered 
from different L. major samples, it was desirable to ascertain whether similar proteins 
could be detected from different Leishmania species. A final wash with elution buffer 
without S-hexyl-GSH was introduced that was performed with the same volume as the 
elutions. This was to ensure that the proteins detected were being eluted specifically by the 
S-hexyl-GSH in the buffer, rather than by a non-specific effect due to the change in buffer 
and pH: proteins that were either only present or were more abundant in the elution 
samples were of interest as they were being specifically eluted by the S-hexyl-GSH. In 
each species -  L. major, L. infantum and L. mexicana -  one or two proteins were identified 
that met these criteria (figure 3.12). Moreover the proteins detected were of comparable 
sizes suggesting that the same proteins could be isolated from different Leishmania species 
using S-hexyl-GSH sepharose. A protein of approximately 30 kD, similar in size to oGST, 
was isolated from both L. major and L. infantum.
kD
50
36
22
L. major L. Infantum L. mexicana
Figure 3.12: SDS-PAGE analysis of S-hexyl-GSH binding-proteins in different species of Leishmania. For each different species (as labelled below the gel images) the proteins in the final, 
low-volume wash and either one or two different elutions have been subjected to SDS-PAGE; the 
proteins have been visualised by silver-staining. Protein molecular weights are indicated to the left 
of each gel image in kD (kilodaltons). Proteins more abundant in the eluted fractions than in the 
washes have been identified and marked with arrows: L major, green arrows, L infantum, blue 
arrows, L mexicana, red arrow. Similarly sized proteins were detected in each species.
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3.4.4 Identification of proteins isolated from Leishmania with S- 
hexyl-GSH sepharose
Using L  infantum parasites the experiment was repeated, again using low-volume washes 
with the different buffers so that proteins eluted by specifically by S-hexyl-GSH could be 
recognised. This time the gel was stained with coomassie rather than silver nitrate as the 
former is compatible with mass spectrometry while the latter is not. Following resolution 
by SDS-PAGE, three proteins were visible that were significantly more abundant in the 
eluate as compared to the final wash (figure 3.13). These protein bands were excised and 
the contents of the approximately 30 kD protein band were analysed by mass spectrometry. 
Unfortunately the proteins identified did not correspond to any of the putative GST 
sequences already identified by searching the Leishmania genome databases. The most 
significant match was to pyroline-5-carboxylate reductase which at 28.7 kD is similar in 
size to the band excised for analysis. Alpha-tubulin, a commonly found contaminant due to 
its abundance in the cell, was also detected. The failure of this technique to identify any 
GSTs in Leishmania was, with hindsight not entirely unexpected: aside from those 
predicted proteins mentioned elsewhere in this chapter, no GSTs exist within the now 
fully-sequenced L. major genome.
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Figure 3.13: Coomassie-stained gel of L. infantum S-hexyl-GSH-blnding proteins. The
different fractions, as labelled at>ove the gel image, have been subjected to SDS-PAGE analysis. 
Wash 3, low-volume wash at pH 7.5; wash 4, low-volume wash at pH 9.5; eluate, proteins eluted 
with 10 mM S-hexyl-GSH, pH 9.5. Protein molecular weights are indicated to the left of the gel 
image in kD (kilodaltons). Proteins that were more abundant in the eluate are marked with arrows. 
The red arrow indicates the -30 kD band that was excised and analysed by mass spectrometry.
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3.5 Identification and analysis of TDR1 {Êm33)
In section 3.3, the discovery of three oGST-like sequences in the L. major genome was 
described. Two of these -  1ml 6 and lm34 -  were shown to be probable bacterial sequences 
and no longer appear in the genome. Like 1ml 6 and lm34 the third sequence -  called lm33 
after the chromosome the sequence was consigned to -  was fragmentary and molecular 
analysis was required to elucidate the complete coding sequence. That investigation and 
subsequent identification of the gene is described in this section.
3.5.1 Identification of the complete TDR1 gene
5’RACE was performed on the lm33 in order to locate the position of the start methionine. 
The sequence had originally been identified due to its similarity to human oGST and the 
complete gene was predicted to be of a similar size to the human sequence: approximately 
723 nucleotides. The position of the internal primer determined that the 5’RACE reaction 
should yield a product of 200 base pairs plus the unknown 5’ untranslated region, likely to 
be about another 100-200 base pairs. Unexpectedly, gel electrophoresis revealed four 
distinct products of approximately 450 base pairs, 950 base pairs, 1100 base pairs and 2200 
base pairs (figure 3.14A). Although the smallest was most likely to be the desired product, 
all four bands were excised and ligated into the pGEM T-easy vector. Clones of the vector 
containing each of the three smallest products were obtained and the DNA was harvested 
and sequenced.
Surprisingly, sequencing revealed that the smallest product in the reaction was non-specific 
(did not contain any of the lm33 sequence) while both the 950 and 1100 base pair products 
contained the known sequence of lm33. Indeed, these two products transpired to be almost 
identical, differing only in the lengths of their untranslated N-terminal regions 
corresponding to two different transcripts. Both products contained approximately a further 
625 base pairs of additional coding sequence as well as the 200 base pairs previously 
predicted. As a result the lm33 coding sequence contained a large N-terminal extension 
when compared to those of mammalian oGSTs; the complete gene was 1353 base pairs 
long as opposed to the 723 base pairs of human oGSTl. The entire lm33 gene, including 
the variant 5’ untranslated regions, and resultant amino acid sequence is shown in figure 
3.14B. The gene was named TDRI, an acronym for thiol-dependant reductase 1, alluding 
to the activity of the protein it encodes. Analysis of the TDRl amino acid sequence showed 
that the newly-revealed N-terminal half of the protein was also similar to oGST and 
consequently the two halves of TDRl were similar to each other (figure 3.15).
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1 AACTAACGCT ATATAAGTAT CAGTTTCTGT ACTTTATTGC CGAGCACCAC AGCAAGGAGG TCCCCTGCAG
71 CCCTTTAGTG TCCGCTCCCC CTCGTCCACC TTCTTTTCCG TCTCGACTTG TTTTTCTGCT CTCCCACACG
141 GGCTCTCACC GTCTGTGGCT CTCCCCCGTT AGAGAGGTGC GCCCGCTGCG TGTGTGTGTG TGCGTGTGTG
2 11 TGTGTGTGTG TTGCTGCTGA AGCTTTCCGC TTATCTTGGC ACCGTTGGCC CACCACTGAA CCACTGAGTG
M A A R A L K L 'ï  V S A T C P F C H R
2 81 CCTGGCGTGT CGGGGATGGC CGCGCGCGCG CTAAAGCTGT ACGTGTCGGC GACGTGCCCG TTCTGTCACC
• V E I V A R E K Q V S Y D R V A V G L Fl E E M
351 GCGTGGAGAT CGTTGCGCGG GAGAAGCAGG TCTCCTACGA TCGGGTTGCT GTTGGGCTTC GCGAGGAGAT
• P Q W Y K Q I N P R E T V P T L 1S V G N A E K
421 GCCGCAATGG TACAAGCAGA TCAACCCGCG TGAGACAGTG CCGACGCTGG AGGTCGGCAA TGCGGAGAAG
R F V E E S M L I A Q Y L I3 N S G A P A G A L M
491 CGGTTTGTGT TCGAGTCGAT GCTGATCGCG CAGTACCTGG ACAACAGTGG CGCGCGCGCG GGTGCGCTGA
• G A S S A G R H Q I E F F L A Q V G D E I  A A
561 TGGGTGCCTC GTCGGCGCAA CGACACCAGA TTGAGTTCTT CCTCGCCCAG GTCGGCGATT TCATTGCTGC
• A H G L L R D P L S G E K R K A ^ D D N A A Y
631 TGCGCACGGG CTACTCCGCG ACCCGCTGAG TGGTGAGAAG CGCAAGGCCG TGGATGACAA CGCGGCGTAC
V D G Ij L A A N O T T G P 't  Y C D G E F T M A D
701 GTGGACGGGC TGCTCGCGGC GAACCAGACG ACGGGGCCAT ACTACTGCGA CGGCGAGTTC ACGATGGCGG
• V A L V P F L V R L K P A L M Y Y A G Y D V F
771 ACGTTGCGCT TGTGCCGTTC CTGGTGCGAC TGAAACCTGC TCTGATGTAC TACGCCGGGT ACGACGTGTT
• C K A P R M K V L W A A A A Q R 'r S V R E T S
841 CTGCAAGGCG CCACGAATGA AGGTGCTGTG GGCœCTGCT GCTCAACGCA CATCTGTGCG TGAGACGTCG
P T A ; L Q C I E N Y R H L /  P E S A P M M G A N
911 CCGACGGCGG CACAGTGCAT CGAGAACTAC CGCCACCTGG TTCCGGAGAG CGCGCCAATG ATGGGCGCCA
• G G H V L Y S N L E C P F V D R A R L A C E L
981 ATGGCGGGCA CGTGCTGTAC AGCAATCTTT TCTGTCCTTT TGTGGACCGC GCACGCCTCG CGTGTGAGCT
• R K F Q V H 1 V E V P L H P E P ]E W Y K Y I  N
105 1 GCGCAAGTTC CAGGTGCACA CGGTGGAGGT GCCGCTGCAT CCAGAGCCQG AGTGGTACAA ATATATCAAT
P R D 1? V P A L F T P S G ] E A V H E S Q L I  V Q
112 1 CCCCGCGATA CGGTGCCTGC GCTATTTACG CCGAGCGGCG AGGCTGTACA CGAGTCGCAG CTGATTGTTC
• Y I  D C V A T E G I A L V P R G D A E K E Y E '
1191 AGTACATCGA CTGCGTGGCG ACGGAGGGTA CTGCGCTGGT GCCGCGTGGG GACGCGGAGA AGGAGTACGA
• V G F F V E N A G Y F V G G L M :S W I  I R G G
126 1 GGTGGGTTTC TTCGTGGAAA ACGCTGGGTA TTTCGTTGGA GGACTGATGT CGTGGATCAT CCGTGGTGGC
E D A K A E L Q W A A G E ] L E Q Q L A K H P F G
1 3 3 1 GAGGATGCGA AGGCTGAGCT TCAGTGGGCT GCTGGCGAGC TCGAGCAGCA GCTGGCGAAA CACCCGTTTG
• E G P F F G G K R M N A G D V A I  L P F L V R
1401 GTGAGGGCCC CTTCTTCGGC GGCAAGAGGA TGAACGCTGG CGATGTGGCC ATTCTACCTT TCCTGGTCCG
• A K A F M P E F S G G Y D L F A 1H F P L L N V
1 4 7 1 TGCAAAGGCG TTTATGCCGG AGTTTAGTGG CGGGTACGAT CTCTTCGCCC ACTTTCCGCT GCTGAATGTG
L A E A G M A A P E A K A '/  F R T L E E Y K E H
1541 CTGGCAGAGG CTGGCATGGC GGCACCGGAG GCGAAGGCGG TGTTTCGTAC ACTCGAGGAG TACAAGGAGC
• I R Q R Q R R A Q G; G *
1 611 ACATCCGTCA GCGTCAACGG AGGGCCCAGG GCGGGTAA
Figure 3.14: Elucidation of the complete TDR1 (im33) open reading frame. A -  the amplified 
products of the 5’ RACE reaction subjected to gel electrophoresis. Sizes in bp (base pairs) are 
indicated to the left of the image. Four distinct bands were visible, labelled 1-4, which were excised, 
cloned and sequenced. Bands 2 and 3 were the amplified Im33 transcripts. 8 -  the Im33 (now 
called TDR1) open reading frame. The spliced-leader sequence is shown in red and the N-terminal 
untranslated sequence exclusive to the longer transcript (band 2 in part A of this figure) is shown in 
blue. The three letter amino acid codes are shown for the translated part of the sequence which 
encodes 450 amino acids rather than the 241 predicted. Where codons extend over two lines, dots 
are shown at the end and beginning of lines to represent this.
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h u m a n  o G S T ( 1 )T D R l  C - t e r m ( 1 )T D R l  N - t e r m ( 1 )C o n s e n s u s ( 1 )
h u m a n  o G S T ( 5 2 )T D R l  C - t e r m ( 3 4 )T D R l  N - t e r m ( 3 4 )C o n s e n s u s ( 5 2 )
h u m a n  o G S T ( 1 0 0 )T D R l  C - t e r m ( 8 2 )T D R l  N - t e r m ( 8 5 )C o n s e n s u s ( 1 0 3 )
h u m a n  o G S T ( 1 5 1 )T D R l  C - t e r m ( 1 3 1 )T D R l  N - t e r m ( 1 3 3 )C o n s e n s u s ( 1 5 4 )
h u m a n  o G S T ( 1 9 4 )T D R l  C - t e r m ( 1 8 2 )T D R l  N - t e r m ( 1 8 3 )C o n s e n s u s ( 2 0 5 )
Ie i f k :|Y
WGNKEgMgdNgSolV V L K  E PEWYK I N P R D T V P  L E  1 0 3
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  5 1|MR^»£|Tf4,i;:;.iLKaj.jGIRHEV i<3HVaiNL^»^p|Ai;’'ACELSKSQVt^ TM |A R A L K l | f / S A T j | J | c 'H § V E I ^ ] A R E |Q V S : Y p R  MA G A IK L Y S  F C P F  DR RLV K K I  HD
102 EAYPG cM te MAPV H ES L I  QYLD AA1 5 3
i N S M — L iY j  FTPSli—
EG E
K K L |P D D P Y E K f |C [  K M I L i L i S K V P g L V G ^ F L R | Q N K E D Y ^ L | E i F R K E F  ;G T L § V PR --G D H E K E Y E V G M V E N A k ]Y [ '‘VGGLMj |WI 1 R G G E D A |^ |L Q W A AAG^ J mG A S# RHQlgjljAdvgDgiA&HÜL^DPLSgEgR^VDbNÀ  ALM A  A  QKH l E F F L  N G F I A A I  S IK D  AG K E D 1 5 4  2 0 4
ITKT , E V fT N K K T | INS I  SI ^ I|Y L |W § W F E |^ S |M K L N E # ----------GEf I 'QQ0AKHPFGEp^gKRMNAGgglg^AgFMPEF%G^L^j 
M YVDG|LARNQ[ lT[ .H y Y C D G E F T H A g ^ 'L V g g g g ' iPALMYYA'A LED  L T G P F F G G  IS M A D V A IL P F L V R L K A  L L  FAG YDLF2 0 5  2 5 2D |T |K l i l j W M i P 4 K E D |T |S |L L T S E K D W Q G F L E L Y L ; Q N |P E A C D Y G L  AiHlLpB^E|GMAA| ’EAKi^ VFRtlLEEYjKlHllQRQRI^ QGjS-------
cKA|RMSwa?^QRTSiRE!r,SPi#^ -----H PKLKVL AAA PSVKAL T DW E I R  L S A
Figure 3.15: The N- and 0- terminal halves of TDR1 are both similar to human oGST and to 
each other. Dashes indicate gaps in the alignment and the predicted active site motifs in both the 
N- and C- terminals are underlined in red. Identical residues are printed in white on a black 
background, conserved residues are printed in white on a grey background and similar residues 
are printed in black on a grey background.
Comparisons of the amino acid sequences using the vector NTI alignX function showed 
that human oGST shares 19% identity with the N-terminal half of TDRl and 22% identity 
with the C-terminal half, while the halves are 28% identical to each other. It is interesting 
that despite their similarity, the two halves contain different predicted active site motifs: C- 
P-F-C in the N-terminal, and C-P-F-V in the C-terminal.
3.5,2 Tc52: Identification of a TDR1 homologue in T. cruzi
Using TDRl as an inquiry sequence allowed detection of a similar sequence of comparable 
length in the Trypanosoma cruzi database (TcOO. 1047053503419.30) and more recently in 
that of T. infantum (LinJ33.0270) (figure 3.16). When aligned as before, these sequences 
were shown to share 45% and 96% identity with TDRl, respectively. Die predicted active 
site motifs are conserved in the N-terminal halves but the T .cruzi motif differs in the C- 
terminal: the cysteine residue at position 240 and the valine residue at position 243 in 
TDRl are both replaced by serine residues in the T. cruzi protein. The Leishmania 
sequences are identical in these regions. Interestingly, no full-length sequences
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homologous to TDRl appear in the T. brucei, T. vivax, T. congolense, or T. gamhiense 
predicted protein databases.
L .  i n f .  T D R l  (1L .  m a j .  T D R l  (1T .  c r u .  T C 5 2  ( 1C o n s e n s u s  (1
L .  i n f .  T D R l  ( 5 2L .  m a j .  T D R l  ( 5 2T .  c r u .  T C 5 2  ( 5 0C o n s e n s u s  ( 5 2
L .  i n f ,  T D R l  ( 1 0 3L .  m a j .  T D R l  ( 1 0 3T .  c r u .  T C 5 2  ( 9 9C o n s e n s u s  ( 1 0 3
L .  i n f .  T D R l  ( 1 5 4L .  m a j .  T D R l  ( 1 5 4T .  c r u .  T C 5 2  ( 1 5 0C o n s e n s u s  ( 1 5 4
L .  i n f .  T D R l  ( 2 0 5L .  m a j .  T D R l  ( 2 0 5T .  c r u .  T C 5 2  ( 2 0 1C o n s e n s u s  ( 2 0 5
L .  i n f .  T D R l  ( 2 5 6L .  m a j .  T D R l  ( 2 5 6T .  c r u .  T C 5 2  ( 2 5 2C o n s e n s u s  ( 2 5 6
L .  i n f .  T D R l  ( 3 0 7L .  m a j .  T D R l  ( 3 0 7T .  c r u .  T C 5 2  ( 3 0 3C o n s e n s u s  ( 3 0 7
L .  i n f .  T D R l  ( 3 5 7L .  m a j .  T D R l  ( 3 5 7T .  c r u .  T C 5 2  ( 3 5 4C o n s e n s u s  ( 3 5 8
L .  i n f .  T D R l  ( 4 0 8L .  m a j .  T D R l  ( 4 0 8T .  c r u .  T C 5 2  ( 4 0 5C o n s e n s u s  ( 4 0 9
YVSAT F H E V R Q SYDR A G R EE-M n M iK Q R M B IV lfT tk M  MAARALKLYVSATC P F C H RVEIV AREKOVSYD RVAVGLREEM PQW YKQ INP 5 2  1 0 2
IP-R E TV PT LE V G N A D K R FM FE SM LIA Q Y L D N S G A P A G A LM G S SA A Q R H Q IEF F 1 0 3  1 5 3AQV P Ë KAQV F
LAQVGDFIAAAHGLLRDPLSGEKRKAVDDNAAYVDGLLAANQTTGPYYCDG1 5 4 2 0 47 R t ,K  A M A
iSgEgMVggACFRgvgSgC^glgHEFTMADVALVPFLVRLKPALMYYAGYDVFCKAPRMK 2 0 5  _ _ _ _I I #  i |i ii|i III ii|iisVL|<PE^Y§IGFKRKHT|HVTW#AP|YB|VfKYS|
.. ÏVTSÎ LWAAAAQRTSVRET 2 5 5
ENYRHL E APMMGANC H YS L F C  V A CE RKi
SPTA A Q C IE N Y R H L V PE SA PM M G A N G G H V L Y SN L FC P F V D R A R L A C E L R K F  2 5 6  3 0 6
Q IiirQ L H IV E V P L H P  P E W Y K Y IN P R D T V P A L F T P S G E A V H E S Q L IV Q Y ID C V A T  3 0 7  3 5 7
y p R G  EKE E G EVE AG VGGLM W I|HgPAL-LPKjHl>Glillsi7ES|V|)BTpM^EG SA LV PR G D A E K E Y E V G FFV E N A G Y FV G G LM SW IIR  GGEDAKAELQWAA3 5 8  4 0 8
         —   -
1^SH|AHSLy|^aHI«CT|pLTE|QHL G ELEQ Q LA K H PFG EG PFFG G K R M N A G D V A IL PFLV R A K A FM PEFSG G Y D LF 4 0 9  4 5 1
K M N # # # 0 5 # M A 0 K g F S g s g S S ; r ^ T  F l g p ' S S - -  A H FPL L N A L A E A G M Â S PE Â K A V F R T L E E Y K E H IR  RQRRAq ’ G
Figure 3.16: Alignment of TDRl with similar sequences from L. infantum and T. cruzi.
Dashes indicate gaps in the alignment and the predicted active site motifs in both the N- and 0- 
terminals are underlined in red. Identical residues are printed in white on a black background, 
conserved residues are printed in white on a grey background and similar residues are printed in 
black on a grey background. L. inf. TDR1, L  infantum sequence (LlnJ33.0270): L. maj. TDR1, L major sequence {LmjF33.0240); T. cru. TC52, T. cruzi sequence (TcOO. 1047053503419.30).
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3.5.3 Amplification and cloning of TDRl
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Before the complete TDRl open reading frame (ORF) was elucidated. Dr. Helen Denton 
of the University of Glasgow had cloned the 3’ half of the coding sequence into the 
pET28a(+) vector which allowed expression of the C-terminal region of TDRl with an N- 
terminal His-tag. Therefore, following the discovery of the remainder of the gene, it was 
decided to clone both the 5’ half of the coding sequence (5’TDRl) as well as the full- 
length TDRl ORF. Both sequences were amplified from L major genomic DNA (figure 
3.17A) and sub-cloned into pGEM T-Easy before being cloned into pET28a(+) 
(represented in figure 3.17B). The production of recombinant TDRl and 5’TDRl is 
presented in chapter four.
B f1 origin Vo/I (167) f1 origin NoA (167)
6HIS-N-TDR1
6HIS-TDR1
Kan Kan Ndd (853)
pET28a+TDR1
6655 bp
pET28a+N-TDR1
5985 bp
lad
lad
Figure 3.17: Amplification of TDRl and 5TDR1, and expression constructs for production of 
recombinant protein. A -  ethidium bromide-stained gel showing the products of PCR amplification 
using primers JOFLOGST1 and JOFLOGST2 to amplify TDR1 and JOFLOGST1 and JOFLOGST3 
to amplify N-TDR1, as latielled above the image. Sizes in kb (kilo bases) are indicted to the left of 
the image. B -  schematic representation of the pET28a(+) plasmids constructed for the expression 
of TDR1 and N-TDR1. 6-HIS-TDR1/6-HIS-N-TDR1, the cloned ORFs with N-terminal His-tags; the 
restriction sites used to clone these into the vector are also shown. Lad, lac repressor gene; f1 
origin, origin of replication of the f1 phage; kan, kanamycin resistance gene.
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3.6 Discussion
In this chapter the most similar Leishmania proteins to different classes of known arsenical 
reductases have been elucidated and described. The three types of microbial arsenate 
reductases, which are well characterised in other organisms (Rosen, 2002), are not well 
represented in Leishmania; the most similar predicted proteins to both S. aureus pI258 
ArsC and E. coli R773 ArsC are poor homologues of these proteins and lack residues 
essential for arsenate reductase activity. A more convincing potential arsenate reductase is 
LmjF32.2740, a Leishmania enzyme similar to S. cerevisiae Acr2p. This enzyme, which 
has been characterised and designated LmACR2, has been shown to reduce metalloids in 
vitro and increase sensitivity to pentavalent antimony when over-expressed in L. infantum 
(Zhou et al, 2004). As described, the protein designated LmjF32.2740 in the geneDB 
database comprises 229 amino acids, 99 amino acids more than S. cerevisiae Acr2p; 
accordingly only 130 amino acids of the two proteins are similar and align. However Zhou 
et al, reported that LmjF32.2740 (LmACR2) is just 128 amino acids long, ignoring the 
non-aligned 101 amino acid N-terminal extension. There is no published account of 
experimental evidence (5’ RACE, western blots) that would confirm an error in the 
database of the size of the predicted protein. Furthermore, residues 13-35 of the complete 
229 amino acid sequence of LmjF32,2740 are predicted to be a transmembrane targeting 
sequence and a possible cleavage site exists between residues 35 and 36. When the 
LmJFS2.2740 amino acid sequence was entered into a protein localisation prediction 
programme, target?, it was predicted to be a secretory protein. Clearly the predicted size of 
the LmjF32.2740 protein may be wrong: this could simply be an inaccuracy in the database 
and the protein may indeed comprise just 128 amino acids. However, the existence of the 
signal peptide near the beginning of the predicted 229 amino acid sequence suggests 
otherwise. Zhou et al also found that LmACR2 is monomeric. This is in contrast to S. 
cerevisiae Acr2p which fonns a homodimer and is suggestive of either a different catalytic 
mechanism or, as discussed, a discrepancy in the amino acid sequence of the recombinant 
protein.
If the complete LmACR2 protein does include an additional 101 amino acids at its N- 
terminal, there could be resulting implications for the published activities of LmACR2. It 
is possible that the full-length protein is more active and stable, possibly adopting a 
different quaternary structure from that of the monomeric formation found previously 
(Zhou et al, 2004); indeed like S. cerevisiae Acr2p it may prove to be a dimer. In this case 
both the in vitro metalloid reductase activity of the recombinant protein and the degree of 
increased sensitivity to Pentostam achieved when the protein was over-expressed in L.
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infantum may be improved by the inclusion of the additional residues. Conversely, if the 
wild-type protein is targeted to a particular organelle, is a membrane-embedded protein or, 
as predicted by target?, secreted from the cell, it may be entirely unable to reduce 
pentavalent metalloids in vivo. Further experimental evidence is required to clarify the 
situation.
The absence of proteins significantly similar to bacterial arsenate reductases in Leishmania 
is perhaps unsurprising. These proteins, together with eukaryotic Acr2p, apparently arose 
separately by convergent evolution as a detoxification response to being exposed to arsenic 
(Mukhopadhyay and Rosen, 2002) and have no other known functions other than reducing 
arsenate. This is not the situation with recently identified mammalian proteins capable of 
reducing arsenate; oGST, PNP and GAPDH all display other enzymatic activities and their 
ability to reduce arsenate may be incidental.
For this reason the fact L. major does not appear to possess a protein likely to be a PNP 
was unexpected. PNPs catalyze the cleavage of ribonucleosides and deoxyribonucleosides, 
in the presence of inorganic orthophosphate (Pi) to generate the purine base and 
ribose(deoxyribose)-1 -phosphate and in many organisms have a key role in the purine 
salvage pathway (Bzowska et al, 2000). This pathway is essential in trypanosomatids as 
they are incapable of synthesising purines and instead salvage nucleosides and nucleobases 
from their host (reviewed in Landfear et al, 2004). Despite blast searches not detecting 
any sequences similar to mammalian PNPs in Leishmania, a sequence annotated as a 
nucleoside phosphorylase-like protein is present in the L  major genome (LmjFlO.lOlO). 
Analysis of this sequence showed that it was similar to the hexameric bacterial PNPs, 
which share function and topology with the trimeric PNPs found mainly in mammals, but 
are otherwise unrelated (Pugmire and Ealick, 2002). It is as yet unknown if bacterial PNPs 
can reduce arsenate in vitro; therefore whether LmjFlO.lOlO could potentially reduce and 
activate pentavalent antimonials drugs is also unclear.
As explained, the role of PNP and GAPDFI in arsenate metabolism remains unclear. The 
situation is complicated by the fact that most of the in vivo work in regard to these 
enzymes as arsenate reductases has been performed on rats, the suitability of which has 
been questioned (Aposhian and Aposhian, 2006). However, the differences between 
arsenic metabolism in rats and humans are not necessarily relevant when assessing the role, 
if any, of these enzymes in unicellular Leishmania. If PNP does reduces metalloids in vivo 
it may contribute to their detoxification; therefore the absence of a similar protein in 
Leishmania could be related to their susceptibility to pentavalent antimonials. However
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this is not in keeping with the findings of Shaked-Mishan et a l,, in which parasites 
incapable of reducing Pentostam were less, rather than more, sensitive to the drug. 
Likewise, if the arsenate reducing activity of GAPDH is shown to be relevant in vivo, 
antimonial susceptibility could be explained by the presence of several Leishmania 
GAPDH proteins metabolising pentavalent antimonials into more toxic trivalent forms.
The situation will remain unclear until more is known about both the role of these proteins 
and how antimonials are toxic to Leishmania. Although the arsenate-reducing capacity of 
these mammalian enzymes observed in vitro has been described as ‘fortuitous’ (meaning 
the proteins have other functions and that the reducing activity may be coincidental and 
thus not relevant in vivo) (Waalkes and Liu, 2002) it is intriguing that potential metalloid 
reductases continue to be identified. Presumably the dynamic nature of the field of 
metalloid metabolism in other organisms reflects the situation in Leishmania: additional, as 
yet unidentified proteins may well be involved in antimonial reduction together with the 
ones examined here.
The most similar L. major proteins to all known classes of arsenate reductases have been 
described and the sequences analysed. Most of the proteins presented here are unlikely to 
function as arsenate reductases due to their low similarity to the enzymes including lack of 
essential residues or because they are more like other classes of proteins. Whether 
LmACR2, the Leishmania Acr2p capable of reducing pentavalent antimonials, has an N- 
terminal region previously unreported must be established for its in vivo role to be 
clarified. Of all the remaining predicted and known proteins described here the GAPDH 
homologues are perhaps the most promising as potential novel Leishmania arsenate 
reductases; the high level of conservation between their amino acid sequences and those of 
the mammalian enzymes may be indicative of a common function. However it is important 
that the arsenate reductase activity exhibited by mammalian GAPDH be verified in vivo. 
The fact that GAPDH was not implicated in metalloid metabolism until very recently, 
together with the continued uncertainty surrounding the true role of this enzyme in the 
reduction of arsenate, are the foremost reasons why the L. major enzymes were not 
investigated as part of this study.
At one time thioredoxins were thought to be absent from trypanosomatids due to their lack 
of thioredoxin reductase, required to reduce thioredoxin in other organisms. However the 
discovery and characterisation of a classical thioredoxin in T. brucei brucei 
(Reckenfelderbaumer et al, 2000) which can be reduced directly by trypanothione 
(Krauth-Siegel and Schmidt, 2002) disproved this theory. The presence of glutaredoxin- 
like sequences in Leishmania is of interest as no typical glutaredoxins have been
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previously described in any trypanosomatid. As described, Leishmania are likely to 
possess just one thioredoxin; this is probably the situation in other trypanosomatids. 
Thioredoxin is not essential in T. brucei brucei (Schmidt et al, 2002) ^vhich has led to the 
authors’ speculation that tryparedoxin, another small dithiol protein found in parasites with 
similar activities to thioredoxin, could be able to perform the cellular functions of 
thioredoxin. Certainly, degeneracy between glutaredoxins and thioredoxins is known to 
exist in other organisms (Potamitou et al, 2002). The discovery of thioredoxin and 
putative glutaredoxins, as well as there being several proteins annotated as tryparedoxins, 
suggest degeneracy could also occur between these proteins in Leishmania. Indeed the 
similarities between glutaredoxins and oGSTs mean that degeneracy between these and 
TDRl may occur in Leishmania; this may be important for analysis of TDRl knock out 
parasites, as detailed in chapter five.
No canonical, cytosolic GSTs have been found in Leishmania by either biochemical 
methods or by searching the genome. This is perplexing as GSTs are found throughout 
nature in a wide range of organisms (for review see Hayes et al, 2005). The recent 
discovery that elongation factor IB from a variety of trypanosomatids display 
trypanothione S-transferase activity (Vickers and Fairlamb, 2004; Vickers et al, 2004) 
may help explain the apparent absence of GSTs in Leishmania: trypanothione S- 
transferases could, in part, carry-out the functions usually performed by GSTs. However, 
given the range of GSTs found in most organisms, with their different sub-cellular 
localisations and subtrate specificities, it seems unlikely that just one protein could replace 
them. The absence of GSTs in Leishmania and the other trypanosomatids remains 
intriguing. Although oGSTs are functionally more similar to glutaredoxins than to other 
GSTs, they do exhibit low-level CDNB-conjugating activity typical of GSTs (Board et al, 
2000); TDRl is therefore a candidate for fimctioning as a cellular GST.
The elucidation of the complete sequence of TDRl revealed several interesting features. 
TDRl has two halves that are similar to each other and it is therefore possible that the 
TDRl gene is a product of a smaller, ancestral gene that became duplicated. The 
differences between the two putative active sites of the protein are also intriguing as that in 
the C-terminal half contains just one cysteine (like GSTs and monothiol glutaredoxins) 
while the equivalent motif in the N-terminal half is has two cysteines (as glutaredoxins and 
thioredoxins do). Furthermore, these also differ from the predicted active site motifs from 
T. cruzi Tc52, the only known full-length homologue of TDRl and may be suggestive of 
different functions. Although TDRl was originally discovered because of its similarity to 
mammalian oGST which reduces methylated arsenicals, the biomethylation pathway is
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probably not present in Leishmania. There are no reports of biomethylated species having 
been detected in parasites treated with antimonial compounds and no AS3MT homologue 
(the methyltransferase implicit in this pathway) was detected in the L major genome. 
However the recent observation that human oGST can reduce pentavalent inorganic 
arsenate as well as methylated forms (Aposhian and Aposhian, 2006) suggests that TDRl 
could be capable of reducing antimonial drugs. The role of TDRl as a metalloid reductase 
and in antimonial susceptibility will be investigated in the forthcoming chapters.
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4 Analysis of TDRl : characterisation of 
recombinant protein and expression profile in 
Leishmania
It chapter three it was demonstrated that the Leishmania major genome contains an 
unusual gene, TDRl, which comprises two similar halves. When translated, both the 5’ and 
3’ halves of TDRl share sequence similarity with omega GSTs but also with other classes 
of GSTs, glutaredoxins and thioredoxins, as well as the only known full-length homologue, 
Trypanosoma cruzi Tc52. Although the sequences of translated TDRl and Tc52 protein 
(which has been characterised to some extent (Montiez et al, 1995; Femandez-Gomez et 
al, 1998; Ouaissi et al, 2002)) are considerably similar, it is notable that the predicted 
active site regions are not identical.
As discussed in chapter one, the effectiveness of pentavalent antimonials drugs used to 
treat leishmaniasis is likely to be dependent upon their reduction to a trivalent form 
(Shaked-Mishan et al, 2001), a process which could be mediated by an arsenate reductase­
like protein in Leishmania, However it seems likely that, with the exception of the recently 
identified L. major ACR2-like protein (Zhou et al, 2004) and GAPDH, other known 
classes of arsenate reductases are not represented in the Leishmania genome. TDRl was 
originally of interest due to its resemblance to omega GST (oGST), a recently discovered 
protein capable of reducing methylated arsenical compounds (Zakharyan et al, 2001), and 
thus we hypothesised that it may be involved in the activation of pentavalent antimonials.
The work detailed in this chapter includes the production of recombinant TDRl so that its 
in vitro functions, including whether it was able to reduce pentavalent metalloids, could be 
analysed. In addition the protein was assayed for its ability to mediate the oxidation of 
Sb(lll). Furthermore, production of recombinant TDRl would allow other interesting 
information to be gathered. There is no known quaternary structure data on Tc52, whereas 
human oGST forms a dimer (Board et al, 2000) and glutaredoxins can be monomeric or 
dimeric (Kelley et al, 1997; Noguera et al, 2005). Other important considerations 
included the expression profile and sub-cellular localisation of TDRl. Pentavalent 
antimonials are toxic solely to the amastigote form o ïLeishmania (Ephros et al, 1999); 
temporal variations in the level of a potential antimonial reductase could help explain this 
phenomenon. Insight into the position of TDRl within the cell or the knowledge of 
whether it is released -  as is proposed to be the case with Tc52 (Ouaissi et al, 1995a; 
Ouaissi et al, 1995b) -  would also help establish a role for the protein.
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4.1 Production of TDRl
4.1.1 Expression of TDRl and 5’ TORI in E. coli
Following the elucidation of the entire TDRl open reading frame by database mining and 
3’ RACE, the gene had been cloned into the pET28a(+) expression plasmid. In addition, 
the 5’ half of the gene (5 ’TDRl) was cloned into the same vector. The 3’ half of the gene 
( i  ’TDRl) had already been cloned into the expression vector by Dr. Helen Denton. The 
intention was to express the full-length TDRl together with the 3’ and 5’ truncated 
proteins in order to analyse the individual halves of TDRl and so clarify whether they had 
separate functions or if they were both required for a functioning protein Thereafter the 
plasmids were transformed into E. coli BL21(DE3) cells which were grown up to the 
appropriate density and treated with 2 mM IPTG to initiate protein expression. The cells 
were grown overnight at 15 'C before harvesting and lysing the cells, separating the 
soluble and insoluble cellular fractions in the process. SDS-PAGE analysis confirmed that 
the transformed cells were expressing proteins of 52 kD and 27 kD corresponding to the 
translated sizes of TDRl and 5’TDRl, respectively. However, although approximately 
50% of TDRl being expressed was present in the soluble fraction, it appeared that all of 
the 5’TDRl was insoluble (Figure 4.1). 3’TDRl had been previously expressed and 
purified under similar conditions by Dr. Helen Denton and although it was partially 
soluble, the recombinant protein was highly unstable end therefore unsuitable for analysis.
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Figure 4.1: SDS-PAGE analysis of TDRl and 5’TDRl expression in £. coli soluble and 
Insoluble fractions. Protein expression was induced and the cells were grown overnight at 15 °C. 
1 ml of each was harvested and the insoluble and soluble fractions were separated by 
centrifugation following lysis by sonication. The insoluble pellet fractions were resuspended in a 
volume of 0.5 ml; 10 pi of each sample was mixed with 2 pi of 5 x protein sample buffer and loaded 
onto the 10% polyacrylamide gel for SDS-PAGE analysis. The gel was subsequently stained with 
coomassie blue. The 52 kD full length TDRl is indicated with the uppermost red arrow and is 
present in both the soluble (supernatant) and insoluble (pellet) fractions while the 27 kD 5TDR1 
indicated with the lower red arrow is completely insoluble. In the left hand lane the Benchmark 
molecular weight marker is visible and sizes are indicated to the left in kD (kiloDaltons).
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In order to obtain soluble 5’TDRl, a range of induction conditions and expression times 
were attempted by varying the IPTG concentration and bacteria growth period, 
respectively. The insoluble nature of the expressed protein may be due to inclusion bodies 
forming; a less vigorous production rate or a decrease in the amount of protein being made 
by the bacteria could prevent this. Unfortunately, none of the modified conditions yielded 
any soluble matter (Figure 4.2) and the decision was made to continue working solely on 
the full-length TDRl.
Supernatant Pellet
Time(h) 1 4 16 1 4 16 1 4 16 1 4 16 1 4 16 1 4 16
kD
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IPTG 0 O.ImM 2mM 0 0.1 mM 2mM
Figure 4.2: Varying expression conditions in an attempt to obtain soluble 5TDR1. Protein 
expression was not induced or induced with 0.1 mM or 2 mM IPTG and the cells were grown at 15 
“C for 1, 4 or 16 hours. 1 ml of each sample was harvested, resuspended in 250 pi and the 
insoluble and soluble fractions were separated by centrifugation following lysis by sonication. The 
insoluble pellet fractions were resuspended in a volume of 100 pi; 16 pi of each sample was mixed 
with 4 pi of 5 X protein sample buffer and loaded onto the 10% polyacrylamide gel for SDS-PAGE 
analysis. The gels were subsequently stained with Coomassie blue. Although more protein was 
produced with increased cell growth time and IPTG, the 27 kD 5TDR1, indicated with the red 
arrow, is only present in the insoluble pellet fractions. In the left hand lane of each gel the 
Benchmark molecular weight marker is visible and sizes of the standards are indicated to the left of 
the figure in kD (kiloDaltons).
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4.1.2 Purification of recombinant TDRl
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TDRl was purified from cellular lysates by Alan Scott and Dr. Helen Denton of University 
of Glasgow. The His-tagged recombinant protein was primarily purified from soluble E. 
coli lysates using a 13 ml -nitrilotriacetate affinity column and a BioCAD 700E 
workstation. Although only His-tagged proteins should be eluted, small quantities of 
contaminants can persist in the eluate from nickel-agarose columns and for this reason 
further purification was deemed necessary. E. coli glutaredoxin 2 is known to possess 
similar activities to oGST (Vlamis-Gardikas et al., 1997); its presence in the purified 
TDRl samples could obscure subsequent analysis. Following buffer exchange into 25 mM 
Tris-HCl, pH 7.9, the pooled TDRl-containing fractions were applied to a HQ column. At 
this pH, E. coli glutaredoxin 2 (pi 9.17), but not TDRl (pi 6.3), was excluded from 
binding; TDRl was eluted with a NaCl gradient and collected.
A yield of approximately 20 mg of protein was obtained from one litre of original bacterial 
culture. Recombinant TDRl was found to be >95% pure as determined by SDS-PAGE and 
could be stored in elution buffer for periods of at least six months without deterioration. 
Unlike the truncated forms of TDRl that were produced, full-length TDRl was moderately 
soluble, stable and, as was later demonstrated, active (figure 4.3).
TDR1 
Full length CPFC
MTçmmwwmpar 'i'T*; w WWW
CPFV ] SolubleActiveStable
TDR1
C-terminal CPFV
Soluble
Active
Unstable
TDR1
N-terminal CPFC Insoluble
Figure 4.3: Schematic diagram representing the forms of recombinant protein produced and 
their properties. The predicted active site motifs are included on each similar half of the TDR1 
protein. Only full-length recombinant TDR1 was soluble and stable.
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4.1.3 Cleavage of the His-tag from recombinant TDRl
To facilitate purification, the pET28a(+) plasmid confers an N-terminal His-tag, 
comprising six histidine residues to the protein being expressed. Between the His-tag and 
the open reading frame lies a thrombin cleavage site, included so the His-tag can be 
removed from the recombinant protein after it has been successfully purified. The His-tag 
of recombinant TDRl was cleaved off in this way (Figure 4.4). The absence of the His-tag 
results in a slight reduction in size of the protein, which corresponds to the loss of the 2 kD 
His-tag and can be visualised following SDS-PAGE. Successful cleavage was achieved 
after just two hours although subsequent reactions were performed for 18 hours as there 
was no protein degradation apparent and this incubation time would ensure complete His- 
tag removal. The loss of the His-tag did not affect the enzymatic characteristics of TDRl 
and it was useful for ensuring that findings regarding the native molecular mass were due 
to interacting protein subunits rather than an effect of the tag.
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Figure 4.4: Cleavage of His-tag from recombinant TDR1. Thrombin cleavages were carried out 
at room temperature with 2 U of thrombin for every mg of recombinant TDR1. At different time- 
points (indicated above the lanes, h -  hours) samples were taken to ensure there was no protein 
degradation and that successful cleavage (judged by slight band shift reflecting the loss of the His- 
tag). 2 pg of protein was loaded per lane onto a 12% acrylamide gel which was subsequently 
stained with Coomassie blue.
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4.1.4 Isolation of TDRl from Leishmania using S-hexyl-GSH 
Sepharose
In addition to producing recombinant TDRl it was found that the native protein could be 
separated from Leishmania lysates with S-hexyl-GSH, using a similar technique to that 
employed in chapter three in an attempt to isolate Leishmania GSTs. A protein of 50 kD 
could be detected as a distinct band following SDS-PAGE analysis of the eluate; 
confirmation of its identity as TDRl was achieved by western blotting (figure 4.5). This 
technique would prove useful as a means of effectively concentrating TDRl from large 
volumes.
y  y  y
Coomassie Western
Figure 4.5: Isolation of TDRl from Leishmania mq/or using S-hexyl-GSH. In the first panel, 
fractions from a S-hexyl-GSH isolation of TDR1 from L major (as indicated) were loaded onto a 
10% acrylamide gel and subjected to SDS-PAGE analysis. The eluate contains a clear band similar 
in size to the 50 kD recombinant TDRl. The panel labelled western' is a western blot of the eluate 
sample present on the coomassie-stained gel using rabbit anti-TDR1, confirming the identity of the 
50 kD band as TDRl
Joanne C. McGregor, 2006 Chapter 4 98
4.2 Biochemical characterisation of recombinant TDR1
Recombinant protein produced, purified and stored as described above was used for all 
investigations into the catalytic properties of TDRl of L  major. For studies on the native 
molecular mass of TDRl, protein that had had the His-tag removed was also used. The 
biochemical characterisation of recombinant TDRl is presented and discussed in Denton et 
al, 2004 and was carried out by Dr. Helen Denton of Glasgow University; accordingly it 
has not been summarised here.
4.3 Crystailsation of recombinant TDR1
In collaboration with Professor Bill Hunter and Dr. Karen McLuskey (both University of 
Dundee), TDRl crystalisation trials were attempted. This was in an effort to obtain TDRl 
crystals suitable for X-ray diffi-action, so that structural information could be gathered. The 
trials were set up with TDRl with and witliout GSH as well as with and without the His- 
tag but crystals were obtained with the His-tagged form only. The crystals formed were 
highly reproducible and measured approximately 0.15 mm x 0.15 mm x 0.05 mm in the 
absence of GSH, and 0.15 mm x 0.15 mm x 0.15 mm with GSH. Unfortunately, both sizes 
of crystals were not of particularly good quality, diffracting to just 8 Â. In order for 
structural information to be obtained, the crystals have to diffract to 3 Â and so this 
approach did not yield any information about regarding the native configuration of TDRl.
4.4 Temporal Expression of TDR1
Characterisation of when in the parasite life cycle TDRl was expressed would help clarify 
whether the enzyme contributed to the amastigote-specific toxicity of pentavalent 
antimonials. TDRl expression was analysed in several Leishmania species by western 
blotting using purified anti-TDRl anti-serum from rabbit and anti-TDRl anti serum from 
sheep. Both sera had been shown to recognise recombinant TDRl on dot-blots.
4.4.1 L  mex/cana Axenic Amastigote-like Forms Display a Similar 
Protease Expression Profile as Lesion Amastigotes
L. mexicana can be grown axenically as amastigote-like forms as well as promastigotes 
(Bates et al, 1992). However, before using them in experiments it was considered 
necessary to confirm the status of the forms as amastigotes by a means other than 
microscopic analysis. The protease expression between L. mexicana amastigotes and
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promastigotes differs substantially and is therefore a good indicator of life-cycle stage 
(Bates et al, 1992). Using gelatine SDS-PAGE, the protease activities of the putative L. 
mexicana axenic amastigotes were compared to those of L. mexicana promastigotes and 
amastigotes purified from animals (figure 4.6). It is clear that the protease activities of the 
axenic amastigotes resemble those of the animal amastigotes much more closely than those 
of the promastigotes. Together with the amastigote-like morphology of these cells, this 
result indicates these axenic parasites can be viewed as amastigotes with some degree of 
confidence.
1 2 3
Figure 4.6: Gelatin gel showing protease activities in different L. mexicana life-cycle stages.
Axenic amastigotes were grown in SDM pH 5.5 at 32 °C. Protein samples were separated on a 
12% acrylamide gel containing 0.2% gelatin by SDS-PAGE. The gel was incubated at 37X  for 1.5 
hours in sodium acetate pH 5.5 before staining with Coomassie blue. Lane 1, 12 pg axenic 
amastigote total protein; lane 2, 12 pg lesion amastigote total protein; lane 3, 60 pg promastigote 
total protein.
4.4.2 Detection of TDR1 in the Soluble Fraction of Leishmania
L. major, L  mexicana and L infantum promastigotes harvested in the stationary growth 
phase were all examined for TDRl expression. As described in chapter two, harvested 
parasites were separated into soluble and insoluble fi-actions following lysis by sonication. 
Western blotting revealed that the sheep anti-serum recognised a protein of approximately 
50 kD in L major and L mexicana (Figures 4.7A and 4.7B), which corresponds to the 
predicted size of TDRl. The protein was slightly smaller than recombinant TDRl, a 
difference in size that was attributed to the His-tag being absent in the native form of the
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iprotein, and was present in the soluble fractions only. Similar amounts of TDRl were {
present in L mexicana promastigotes and axenic amastigotes. j
]I
C p ' ^  C p ' \C fA
50 kD
30 kD
or a protein present in trace amounts in the original recombinant TDRl antigen sample. 
The possibility of it being a truncated or processed version of TDRl has also been 
considered.
4.4.3 TDR1 is uniformly expressed in L. major promastigotes
Although the L. major life-cycle has primarily two distinct stages, promastigote and 
amastigote, several different naturally occurring developmental forms of promastigotes are 
recognised that could potentially exhibit vaiying levels of protein expression. These can be 
broadly divided into early log (when the parasites are dividing but remain at a relatively 
low concentration of up to -4  x 10^  cells/ml), late log (when the parasites are dividing but 
are becoming more concentrated in the media at up to ~2 x 10^  cells/ml) and stationary 
phase (the parasites have ceased to divide and remain concentrated; metacyclic parasites 
appear). Western blotting of L. major lysates obtained during these different promastigote
Promastigotes Axenic amastigotes Promastigotes Promastigotes i
Figure 4.7: TDR1 expression in Leishmania. Westem blot analysis of TDR1 expression in ]
different Leishmania lysates following protein separation by SDS-PAGE. In each case at 10-20 pg j
of total protein was loaded per lane. (A) L mexicana soluble and insoluble extracts of both ]
promastigotes and axenic amastigotes alongside 100 ng of recombinant TDR1 protein. (B) L. major ;
soluble and insoluble promastigote extracts. (C) L. infantum soluble extract. j1
I
The anti-sera also recognised a protein of a similar size in L  infantum lysates (Figure j14.7C). Following SDS-PAGE, the L. infantum protein ran slightly smaller than that of L  j
major: this could be due to subtle differences between the protein amino acid sequences. j
The sheep anti-sera also recognised a protein of approximately 30 kD in the L. infantum i
lysates that was absent on the westem blots from the other Leishmania species. This \
unknown protein is probably recognised due to it having a similar epitope to either TDRl i
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life cycle stages revealed that TDRl expression appeared to remain at a similar level 
(Figures 4.8A). There was either no fluctuation in expression in promastigotes, or any 
changes were too minor to detect using this method.
1
Figure 4.8: Westem blot analysis off TDRl expression in difffferent L major iiffe-cycle stages.
(A) Different growth phases of L. major promastigotes. The densities of the parasites when they 
were harvested are indicated and after lysis and isolation of the soluble fraction approximately 10 
pg of total protein was loaded per lane. (B) Comparison of TDRl expression between L. major 
promastigotes and amastigotes. Lane 1, 200 ng of recombinant TDR1; lane 2,100 ng of 
recombinant TDR1; lane 3, 50 ng of recombinant TDRl; lane 4, S-hexyl-GSH binding fraction 
recovered from 0.23 mg of protein from the amastigote lysate; lane 5, S-hexyl-GSH binding fraction 
recovered from 0.23 mg of protein from the promastigote lysate.
4.4.4 Increased expression of TDR1 in L. mayor amastigotes
As stated, only leishmania amastigotes are susceptible to pentavalent antimonials and this 
phenomenon has been attributed to a life cycle-specific ability to reduce the drug to the 
more toxic trivalent form (Shaked-Mishan et al, 2001). L major amastigotes were 
extracted and purified fi’om animals and so TDRl expression could be compared between 
these and promastigotes grown in culture. The lysates were equalised for initial protein 
concentration before incubation with S-hexyl-GSH-agarose so the TDRl present in each 
sample could be isolated. The eluate from each was subjected to SDS-PAGE and westem 
blotting using the purified rabbit anti-serum revealed bands corresponding to the molecular 
mass of TDRl (Figure 4.8B), although interestingly it was apparent that more TDRl was 
present in the amastigote sample. It was estimated that approximately ten times more 
TDRl was recovered from the amastigote lysate than from the equivalent promastigote 
lysate.
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4.5 Spatial Expression of TDR1
Analysis of whether TDRl is secreted and the cellular distribution of the protein were of 
interest both to help identify a possible site of antimonial accumulation and reduction, and 
to further clarify the endogenous role of TDRl. In addition, it was of interest to ascertain 
whether the location of TDRl in the cell was similar to that of Tc52 or oGST, although 
investigation into the spatial expression of the latter has mainly focused on tissue-level 
rather than sub-cellular localisation. The sheep anti-TDRl serum was used for these 
investigations
4.5.1 Analysis of Secretion of TDRl from L. major
Investigations into whether a protein is released from a cell can be problematic due to the 
difficulty in detecting a given protein when it is dilute in large volumes. Here the fact that 
TDRl binds to S-hexyl-GSH was exploited so that spent culture media could be analysed 
for the presence of the protein. Westem blot analysis showed that TDRl could be detected 
in samples eluted from the S-hexyl-GSH, when it had been initially incubated with 10 ml 
of filtered, spent, L. major promastigote culture media (Figure 4.9). As a control, 10 ml of 
fresh culture media was ‘spiked’ with 160 ng of recombinant TDRl, and subjected to the 
same incubation with S-hexyl-GSH and elution conditions as the other sample. The 
amount of TDRl used in the control was approximately the total amount of TDRl present 
in 2 X 10^  T. major promastigotes harvested while in the stationary phase of growth, as 
determined by previous westem blot experiments. Several times more recombinant TDRl 
was detected in the control sample than from the spent media, suggesting that the amount 
of TDRl secreted by the cells is considerably less than that retained in the parasite. 
However, this may not be die case as secreted protein may be subjected to proteolysis or 
bound to other proteins, therefore hampering the recovery of the protein. The finding that 
TDRl is secreted could implicate the protein as being potentially involved in host-parasite 
interactions. As mentioned, Tc52 is also thought to be released from cells (Schoneck et ah, 
1994) and has been attributed such a role.
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Figure 4.9: Westem blot analysis of secretion of TDR1 from L. major. Seven-day old spent 
media and fresh, pH-adjusted media that had been ‘spiked’ with 160 ng of recombinant TDRl 
(necessary as a positive control) were filtered before incubating with S-hexyl-GSH (as previously 
described). The eluted fractions were subjected to SDS-PAGE and westem blot analysis using 
sheep anti-TDR1. A 50 kD was detected in both the L mayor spent media sample (labelled wild 
type) and the TDR1-spiked positive control sample (labelled rTDR1).
4.5.2 Immuno-localisation of TDR1 in L  major Promastigotes
Immuno-localisation studies were performed on wild-type L. major promastigotes, as well 
as on a TDRl KO L. major line that had been generated (see chapter five). The staining 
was not solely associated with the cell nucleus or kinetoplast but was dispersed throughout 
the cell (Figure 4.10 A). In some images there seemed to be some concentration of signal 
occurring, particularly around the kinetoplast and between the nucleus and kinetoplast, 
suggesting that the enzyme may be to some extent located in an as yet unidentified 
organelle. However, the fluorescence was observed throughout the parasites and was quite 
diffuse which is more indicative of TDRl being cytosolic. The vast reduction in intensity 
of a signal from the TDRl KO line under the same experimental conditions provided 
evidence that fluorescence visible in the wild-type line was largely TDRl-specific (Figure 
4.1 OB). Previous reports have shown that Tc52 is localised in reservomeres (Ouaissi et ai, 
1995b) but is also deemed to be a secreted protein (Ouaissi et al, 1995a). Meanwhile 
human oGST2 has been found to be both cytosolic and nuclear (Wang et al, 2005).
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Figure 4.10: Immunolocalisatlon of TDRl In L. ma/or promastigotes. (A) Distribution of TDR1 
within wild-type promastigotes. The blue staining shows DAPI, highlighting the nucleus and 
kinetoplast; the green stain shows the secondary antibody, Alexa-Fluor 488, and corresponds to 
TDR1 distribution. Merged images are shown alone and within the context of the DIG parasite 
image. (B) Comparison of TDR1 immunolocalisatlon signals between wild type (WT) and TDR1 
knock-out (KO) L major parasite lines. The Alexa-Fluor 488 secondary antibody signals (green 
staining) are comparable between panels, as experimental and image-processing conditions were 
equivalent. In all images the primary antibody (sheep anti-TDR1) was applied at a dilution of 1/100 
and the secondary antibody (as above) was applied at a dilution of 1/500. The white scale bar 
shown on each image represents a distance of 10 pM.
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4.6 Analysis of oxidation of trivalent antimonials by 
hydrogen peroxide
Although it is well established that pentavalent arsenicals and antimonials can be reduced, 
both enzymatically and directly upon reaction with thiols, little is known about whether the 
reverse reaction also persists. If oxidation of trivalent metalloids was possible in cells this 
could alter the perception of antimonial sensitivity: an increase in trivalent species 
oxidation rather than a decrease in pentavalent species reduction could result in drug 
resistance. Recently it was reported that trivalent arsenite could be oxidised to pentavalent 
arsenate by hydrogen peroxide (H2O2) (Aposhian et al, 2003). This was the first published 
account that alluded to the potential importance of this mechanism in the detoxification of 
trivalent metalloids in a biological system. However, there are accounts of bacteria and 
archaea that are capable of oxidising arsenite (and indeed antimonite (Lialikova, 1974)) 
and are deemed to possess arsenite oxidase enzyme activity. Several proteins have been 
implicated in oxidising arsenite and the best characterised are the aoxA and aoxB proteins 
originally found in Alcaligenes faecalis (Anderson et al, 1992). However, the L  major 
genome does not contain sequences with significant homology to either of these genes and 
accordingly, investigations into whether metalloid oxidation is possible in Leishmania 
have focused on the role of H2O2 . As described, the BPR assay was used to detect trivalent 
antimonial species present. For each experiment, a standard curve of potassium antimonial 
tartrate (KAT) versus the absorbance at 540 nm was constructed, and the amount of 
trivalent KAT remaining at each time point was calculated from that.
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4.6.1 Trivalent potassium antimony! tartrate is oxidised by H2O2
In the presence of H2O2, the amount of trivalent antimony present in the sample decreased 
over time (Figure 4.11). The elimination of the trivalent species was dependant on the 
amount of H2O2 present in the reaction and when there were equal concentrations of KAT 
and H2O2 present >90% of the KAT was removed after 130 minutes. However, the molar 
relationship between H2O2 present and KAT oxidised does not appear to be 1:1. For 
example, when the concentration of KAT is 1 mM and H2O2 is 0.5 mM, the percentage of 
KAT oxidised is -70%. The elimination of KAT was rapid and when higher concentrations 
of H2O2 were present much of the KAT had already been oxidised when the first time point 
was taken. The BPR assay can only be used to determine trivalent antimonials species 
present and so the identity of the product is unknown. However the analogous reaction 
with trivalent arsenite yields a pentavalent product (Aposhian et al, 2003).
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Figure 4.11: Trivalent KAT is depleted by H2O2 . 1 mM KAT was incubated at room temperature 
with 0, 0.1 mM, 0.5 mM, 1 mM or 2 mM H2O2 in 0.1 M Tris pH 8.0 in a final volume of 1 ml. Sb(lll) 
depletion was followed discontinuously by the BPR assay in which the samples were diluted 1/10. 
Points represent an average of two experiments.
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4.6.2 The effect of pH and recombinant TDR1 on oxidation of KAT 
by H2O2
In order to determine the optimal conditions for the oxidation of KAT by H2O2 the reaction 
was set up at a range of pH values. It was found that the oxidation did not occur when the 
pH was below 7.0 and as the pH was raised the reaction rate increased. It is worth noting 
that a basic environment was also required for the oxidation of trivalent antimonials by 
hydrogen peroxide in other studies (Quentel et al, 2004). In order to keep the experiments 
as physiologically relevant as possible, all subsequent investigations were carried out at pH 
8.0 .
It has been shown previously that some glutaredoxins can act as peroxidases in the cell by 
detoxifying H2O2 (Collinson et al, 2002). Due to the sequence similarities that exist 
between these proteins and TDRl, recombinant TDRl was added to the reactions at this 
stage so any affect its presence caused could be observed. If TDRl could detoxify H2O2 
then this may prevent any oxidation of trivalent antimony while it was also possible that 
TDRl could act as an oxidase and catalyse the antimonial oxidation. The effect of adding 
GSH and GSSG as well as TDRl was also monitored (see below). However, the addition 
of recombinant TDRl neither catalysed nor inhibited the oxidation of KAT (Figure 4.12); 
this was also the case at lower pH values.
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Figure 4.12: Recombinant TDRl has no effect on the oxidation of KAT by H2 O2 1 mM KAT 
was incubated at room temperature with 1 mM H2O2 , 4 pg TDRl or both, in 0.1 M Tris pH 8.0 in a 
final volume of 1 ml. Sb(lll) depletion was followed discontinuously by the BPR assay in which the 
samples were diluted 1/10. Points represent an average of two experiments.
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4.6.3 The trivalent product formed upon reaction of TDR1 with 
sodium stibogluconate is oxidised by H2O2
KAT is a trivalent antimonial compound that is not used as an antileishmanial drug and 
therefore it was desirable to establish whether H2O2 could oxidise additional trivalent 
antimonials that may be more relevant. As described, the product of the reaction between 
sodium stibogluconate and TDRl is a trivalent species and is likely to actually be 
encountered by the parasite. Therefore the product of TDRl activity on stibogluconate was 
quantified (using the BPR assay) and added to the reaction rather than KAT. H2 O2 was also 
found to be capable of oxidising this trivalent antimonial (Figure 4.13), indeed the rate of 
oxidation was faster than that achieved when KAT was the trivalent substrate. Again, 
without more in depth analysis it is impossible to be certain of the identity of the species 
formed but it is not unreasonable to speculate that it may have converted back to sodium 
stibogluconate. This is the first evidence that the parasitic metabolism of antimonial drugs 
does not necessarily consist of straightforward reduction from a pentavalent to a trivalent 
form. If it is possible for more toxic, trivalent antimonials, formed by reduction of the 
pentavalent drugs administered, to be converted back to the less toxic pentavalent form this 
has clear implications for the anti-parasitic activity of the drugs. Intracellular H2O2 
concentration could be a factor in antimonial toxicity, as is discussed in section 4.7.
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Figure 4.13: The trivalent antimonial formed upon reaction of TDRl and sodium 
stibogluconate is oxidised by H2O2 . Sodium stibogluconate was incubated overnight with TDRl 
and GSH and the trivalent product was quantified using the BPR assay. 1 mM of the product was 
incubated at room temperature with or without 1 mM H2O2 in 0.1 M Tris pH 9.0 in a final volume of 
340 pi. The resulting pH of the assay was pH -8.0. Sb(lll) depletion was followed discontinuously 
by the BPR assay in which the samples were diluted 1/10. Points represent an average of two 
experiments.
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4.6.4 GSH Inhibits Oxidation of KAT by H2 O2 while GSSG has no 
effect on the reaction
GSH is known to behave as a cellular anti-oxidant and react with H2O2 to form 2 H2O. 
Therefore its presence may prevent the oxidation of trivalent antimonials from proceeding, 
especially when it exists at a high level as reported by Ariyanayagam and Fairlamb 2001. 
GSH was added to the reactions and was found to decrease the amount of KAT oxidised 
(Figure 4.14). This is probably due to H2O2 reacting with the two molecules of GSH to 
form GSSG and H2O and therefore depleting the amount of H2O2 available to react with 
the antimonial. Curiously, the initial speed of the reaction appeared to be increased in the 
presence of GSH as in the first time point there is significantly less KAT remaining in the 
sample with GSH added than in that without (figure 4.14), although the overall level of 
oxidation was reduced. Due to the high intra-cellular concentrations of GSH, this result has 
significant implications for whether the feasibility of cellular oxidation of trivalent 
antimonials.
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Figure 4.14: GSH reduces the amount of oxidation of KAT by H2O2. 1 mM KAT was incubated 
at room temperature with 1 mM H2O2 , 1 mM GSH or both, in 0.1 M Tris pH 8.0 in a final volume of 
1 ml. Sb(lll) depletion was followed discontinuously by the BPR assay in which the samples were 
diluted 1/10. Points represent an average of two experiments.
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Due to the ability of the reduced from of glutathione -  GSH -  being capable of directly 
reducing pentavalent antimonials, the possibility that the oxidised form -  GSSG -  could be 
involved in oxidising trivalent antimonials was considered. It was also possible that GSSG 
could affect the oxidation by H2O2 . However, GSSG appeared to have no effect on the 
trivalent nature of KAT, or on the oxidation reaction (figure 4.15). However the rapid 
oxidation of KAT by H2O2 resulted in much of the KAT being eliminated before the initial 
rime point was taken, so any effect by GSSG on the reaction during this period cannot be 
monitored. As mentioned, the presence of TDRl in these reactions resulted in no 
significant further effect.
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Figure 4.15: GSSG has no effect on the oxidation of KAT by H2O2. 1 mM KAT was incubated at 
room temperature with 1 mM H2O2 , 1 mM GSSG or both, with or without 3 pg TDRl. The reaction 
was in 0.1 M Tris pH 8.0 in a final volume of 1 ml. Sb(lll) depletion was followed discontinuously by 
the BPR assay in which the samples were diluted 1/10. Points represent an average of two 
experiments.
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4.6.5 Analysis of KAT and Sodium Stibogiuconate upon 
incubation with Leishmania
It was decided to employ the BPR assay to monitor whether any changes in the state 
antimonials could be detected upon incubation with Leishmania. L. mexicana amastigote 
and L. major promastigote cultures were grown as standard, except that either KAT or 
sodium stibogluconate (or extra media as a negative control) were added to a final 
concentration of 200 pM. Every day for 10 days a sample was removed from each culture, 
the parasites were removed by centrifugation, and 50 pi of the spent media was subjected 
to analysis in a final volume of 200 pi using the BPR assay. The assay only detects 
trivalent species and so any decrease in trivalent antimonial level detected could be 
interpreted as either oxidation or as uptake by the parasites. However there was no detected 
decrease in the level of trivalent antimonial species when KAT was administered or 
formation of trivalent species when sodium stibogluconate was administered, when 
incubated with amastigotes or promastigotes. However, it is likely that the assay is too 
insensitive to detect any changes in the state of the drugs or uptake that was occurring.
Joanne c . McGregor, 2006 Chapter 4 112
4.7 Discussion
L. major TDRl was originally discovered -  and was of interest -  due to its similarity to 
omega GSTs, which was suggestive that the protein could be involved in reducing 
antileishmanial antimonials and therefore mediating drug-susceptibility. Upon analysis of 
the TDRl ORF it became clear that TDRl encoded a highly unusual protein containing 
two omega GST-like domains with different predicted active sites. Together with the 
observation that no other GSTs have been identified in Leishmania, these factors indicate 
the potentially fascinating activities of TDRl. Characterisation of recombinant TDRl and 
analysis of its cellular expression profile were intended to help elucidate which of the 
proteins many inferred functions were accurate.
Due to the nature of the two-domain structure of TDRl, it was desirable to obtain separate 
C- and N- terminal half-length proteins, as well as the full-length recombinant protein. It 
was hoped that this approach would provide an insight into whether the protein functioned 
as a whole or if each half was capable of acting independently. However, despite varying 
the expression-inducing XPTG concentrations and growth times of the E. coli expression 
cells, acquiring soluble and stable versions of these truncated proteins was problematic. At 
this point it was considered whether further attempts could have been made to obtain the 
half-length proteins. For example, re-cloning the gene fragments in expression vectors that 
add differently placed expression tags or alternative types of tag; or expressing the protein 
in a eukaryotic system. However, it was decided that these approaches could have been 
time-consuming and were without guarantee of a successful outcome; therefore they were 
discounted.
Meanwhile, satisfactory levels of active full-length TDRl were produced quite easily with 
approximately 20 mg of protein being recovered from one litre of bacterial culture. This 
relatively high yield was achieved despite the additional purification steps taken to 
eliminate any potentially contaminating proteins from the sample, specifically E. coli 
glutaredoxin 2. It is interesting to note that there is no published account of enzymatically 
active recombinant Tc52 - the most similar known protein to TDRl - being produced. In 
all reports native protein was characterised after purification from T. cruzi lysates with S- 
hexyl-GSH (Montiez et al, 1995) suggesting that production of recombinant Tc52 is not 
straightforward. Analysis of the recombinant protein revealed several enzymatic 
capabilities of TDRl, summarised in Denton et al, 2004.
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All the species analysed by western blot -  L  major, L. mexicana and L. infantum -  
expressed TDRl and the protein was detected in all life-cycle stages of L  major. This 
apparently ubiquitous expression, together with the highly conserved amino acid sequence 
between the proteins, could indicate that TDRl has a vital role in the parasite. Indeed Tc52 
has been reported to be essential (Allaoui et ah, 1999) with the authors being unable to 
obtain Tc52 knock out T. cruzi strains. However, as will be shown in chapter five this is 
not the case with TDRl, providing further evidence that TDRl and Tc52 have divergent 
roles.
Another area in which the two proteins differ is in their cellular localisation. Within T, 
cruzi epimastigotes, Tc52 is reported to reside in vesicles resembling the reservomere 
(Ouaissi et al, 1995b), large acidic organelles found towards the posterior end of the 
parasite. This contrasts with the distribution of TDRl in promastigotes, which was quite 
diffuse and may be cytosolic, and certainly was more concentrated at the anterior end of 
the parasite. However, the authors did not perform any co-localisation studies, using 
antibodies to characterised marker proteins to directly compare the distribution signals, and 
therefore the inferred localisation of Tc52 is not certain. This is also the case with the 
TDRl localisation study, although the comparative lack of staining detected in the TDRl 
knock out line at least indicates that the distribution pattern is specific to TDRl. Analysis 
of TDRl localisation in amastigotes -  either axenic or isolated from animals -  would also 
have been desirable as the protein may behave differently between life-cycle stages. For 
example the protein may be secreted from metacyclics and amastigotes but not procyclics. 
TDRl was detected by western blot in spent media from a stationary phase L. major 
promastigote culture. Although the media was filtered prior to analysis, the possibility that 
dead parasites may release TDRl upon degradation, rather than it being actively secreted, 
cannot be ruled out. Analysis of secretion from L mexicana axenic amastigotes -  spent 
media from L. major lesion amastigotes would be difficult to obtain -  would be potentially 
interesting. Tc52 is reportedly secreted (Schoneck et al, 1994) from epimastigotes, having 
an important role in aiding the parasite to modulate the mammalian host’s immune 
response to infection (Garzon et al, 2003). Whether TDRl has a similar role in 
Leishmania has not been investigated as part of this study, though if it is secreted by 
intracellular stages of the parasite this could help explain it’s involvement in parasite 
infectivity, discussed in chapter five.
The temporal expression pattern of TDRl is another area that potentially differs from that 
of Tc52. TDRl expression is uniform throughout the various growth phases of T. major 
promastigotes while an increase in expression was detected in lesion amastigotes relative
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to the promastigotes. In T. cruzi, Tc52 is most highly expressed in the epimastigote and
amastigote stages, and is less so in trypomastigotes (Ouaissi et al, 1995b). In L  mexicana
axenic amastigotes the same increase in TDRl expression was not observed: this could be
due to the axenic nature of the culture not entirely reflecting the natural environment
encountered by amastigotes and therefore affecting gene expression. However the lesion
amastigote-like protease expression profile of the axenic amastigotes suggested otherwise.
Equally, the differences in TDRl amastigote expression levels may be due to variations
between species. The implications of this apparent up-regulation may be significant.lt is
generally accepted that pentavalent antimonial drugs are toxic specifically to amastigotes
.yet it is not known if this is due to increased parasite susceptibility or stage-specific 
reduction -  and hence activation -  of the pentavalent compounds. Controversy also persists 
over whether activation occurs in the macrophage or the parasite (Ephros et al, 1999,
Sereno et al, 1998). It has been reported that only amastigotes and not promastigotes are ■fcapable of reducing pentavalent antimonials and that Pentostam-resistant L  donovani 
parasites were deficient in this activity (Shaked-Mishan et al, 2001). Although it has been 
demonstrated that some thiols are capable of directly reducing pentavalent antimonials 
(Frezard et al, 2001), the rate is very low. In chapter five, investigations on L. major 
lacking or expressing an increased amount of TDRl are presented, which help clarify 
whether TDRl is involved in mediating toxicity of pentavalent antimonial drugs.
Finally, the revelation that H2O2 can oxidise KAT and even more intriguingly, the trivalent 
product formed upon reaction between TDRl and sodium stibogluconate, shows that the 
metabolism of pentavalent antimonials may not be as straightforward as once thought. It is 
clearly possible for trivalent antimonials. Therefore reduction of the pentavalent drug 
administered could occur, but whether the product remains in the more toxic trivalent form 
or is oxidised back to a pentavalent species may be dependant upon the concentration of 
H2O2 present. Indeed it is possible that other reactive oxygen species found in Leishmania 
could also be capable of causing any trivalent antimonial species formed to be oxidised.
However, the observation that GSH inhibits the oxidation of KAT brings in to question the 
physiological relevance of the oxidation of trivalent antimonials. The concentration of 
GSH in L. donovani promastigotes is approximately 4 mM while T(SH)2 , which also reacts 
with H2O2  and is therefore likely to inhibit KAT oxidation in a similar way, is 
approximately 5.2 mM (Ariyanayagam and Fairlamb 2001). Although no accounts of H2O2  
concentration in Leishmania could be found, in T. brucei H2O2 is reportedly at a 
intracellular concentration of 70 pM (Meshnick et al, 1977). However H2O2 exists 
transiently in the cell: due to the reactive nature of the molecule it is constantly being 
synthesised and removed. Assuming that the concentration of H2O2 in Leishmania is
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of H2O2 in Leishmania is similar, the abundance of thiols means that newly produced 
molecules will be rapidly reduced and therefore not available to oxidise Sb(III). Moreover 
enzymes able to mediate the reduction of H2O2 have a similar effect: the oxidation of 
As(III) by H2O2 is inhibited when catalase is added to the reaction (Aposhian et at., 2004). 
Although Leishmania lack catalase, they do possess several peroxidases (Vickers et al, 
2004; Adak and Datta, 2005) which perform the same function as catalase and are 
therefore also likely to inhibit Sb(III) oxidation. However, this does not take into account 
the possibility that Sb(III) could be localised in an area of the parasite that contains higher 
levels of H2O2 . Indeed it has recently been shown that when X. donovani are treated with 
Sb(III), intracellular GSH and T(SH)2  are depleted due to efflux of the molecules and 
inhibition of trypanothione reductase, the enzyme responsible for maintaining the thiols in 
their reduced state (WylUe et al, 2004). Similar effects were observed when human 
macrophages were treated with Sb(III), as were increased level of reactive oxygen species 
(Wyllie and Fairlamb, 2006), creating conditions favouring the oxidation of Sb(III). The 
same effects also occurred in L. donovani amastigotes when treated with Sb(V). Although 
these observations certainly do not provide evidence of Sb(III) oxidation in Leishmania, it 
may be the case that conditions can arise within the parasites that enable some oxidation to 
occur. Therefore, in vitro evidence provided in this chapter that under the right conditions 
Sb(III) can be oxidised is potentially of great importance, although clearly in vivo studies 
are required to ascertain whether it is indeed a factor in antimonial metabolism.
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5 Functional study of L. ma/or TDR1
5.1 Introduction
In the previous chapter the expression of TDRl was described, although the analysis of the 
recombinant protein (rTDRl), which was carried out by Dr. Helen Denton, was not 
presented. The biochemical characterisation of rTDRl in vitro was an important step 
towards understanding the functions of TDRl, including whether the protein is capable of 
reducing pentavalent antimonials, and if, like the proteins it is similar to, it can catalyse 
thioltransferase reactions and hence may have a role in protection against oxidative stress. 
The properties of rTDRl are summarised below, while a full description is provided in 
Denton et al, 2004.
Recombinant TDRl, shown by gel filtration analysis to be trimeric, exhibited several 
interesting activities in vitro. In contrast to Tc52 which displays no GSH-conjugation 
activity (Montiez et aï., 1995), but like human oGSTl (Board et al, 2000), rTDRl 
exhibited low-rate conjugation of GSH with l-chloro-2,4-dinitrobenzene (CDNB), with a 
specific activity of 1.9 nmol/min/mg/protein. However, no reaction could be detected vdth 
the other conjugation substrates ethacrynic acid and l,2-epoxy-3(4-nitrophenoxy)propane. 
Like glutaredoxin (GRX), dehydroascorbate reductase (DHAR) and thioltransferase 
activities were evident, with TDRl capable of using GSH as an electron donor to reduce 
both dehydroascorbate and the synthetic disulphide 2-hydroxyethyldisulphide. The specific 
activities for these two substrates -  11.9 pmol/min/mg/protein and 11.2 
pmol/min/mg/protein -  were similar, and were significantly higher than those reported for 
the human oGST protein when assayed under similar conditions (Board et al, 2000).
Taken together, these results indicate that the enzymatic capabilities of TDRl are more 
similar to oGST and GRX than to other GSTs that typically have high GSH-conjugation 
activity. The result that TDRl acts more like GRXs, proteins that share predicted active 
site sequences with TDRl but are otherwise much smaller and rather dissimilar, than GSTs 
was also observed to be the case for human omega GST (Board et al, 2000).
In addition to these activities, TDRl was also found to be capable of reducing sodium 
stibogluconate and Glucantime, giving specific activities (pmol/min/mg/protein) of 6.3 and 
1.4, respectively. Significantly higher specific activities were recorded with the pentavalent 
arsenicals sodium arsenate and methylarsonate (MMA^). The BPR assay (Frezard et al, 
2001), which detects trivalent antimonial species, was employed to analyse the product(s) 
formed in the reactions with pentavalent antimonials. hi addition, using the BPR assay, it
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was shown that a trivalent antimonial compound was produced in the reaction between 
TDRl and the pentavalent antimonial drug, sodium stibogluconate. This was instrumental 
in determining the relevance of the findings reported above, as it is the reduction of sodium 
stibogluconate to a trivalent form that reportedly mediates toxicity (Shaked-Mishan et al., 
2001).
The fact that rTDRl is capable of reducing pentavalent antimonials to a trivalent form was 
clearly of great interest. It is generally accepted tliat pentavalent antimonial drugs are toxic 
specifically to amastigotes, yet it is not known if this is due to increased parasite 
susceptibility or stage-specific reduction -  and hence activation -  of the pentavalent 
compounds. Controversy also persists over whether activation occurs in the macrophage or 
the parasite (Ephros et at., 1999, Sereno et al., 1998). It has been reported that only 
amastigotes and not promastigotes are capable of reducing pentavalent antimonials and 
that Pentostam-resistant L. donovani parasites were deficient in this activity Shaked- 
Mishan et al, 2001. Although it has been demonstrated that some thiols are capable of 
directly reducing pentavalent antimonials (Frezard et al, 2001), the rate is very low and 
accordingly is unlikely to be as physiologic^ly relevant as the faster, enzyme-mediated 
reaction reported here. As TDRl is the first Leishmania protein reported to be able of 
reducing antimonials enzymatically, together with its increased abundance in amastigotes 
demonstrated in the previous chapter, it is tempting to speculate that TDRl could play a 
key role in antimonial susceptibility. However, further analysis is required. These studies 
have not provided any in vivo evidence of the antimonial-reducing capability of TDRl, and 
the affect this has on the parasite. For example, although reduction is thought to mediate 
toxicity, it may be possible that upon reduction by TDRl antimonials are more easily 
cleared by die cell, making them more quickly detoxified and therefore effectively less 
toxic. In this chapter, investigations on L. major lacking or expressing an increased amount 
of TDRl are presented, in an attempt to address whether TDRl has a bearing on 
antimonial susceptibility in vivo.
There are implications of TDRl potentially behaving as a GRX in the parasite. 
Glutaredoxins help maintain the redox balance of the cell by reducing protein and GSH 
disulphides and have a role in stress-response in the cell (Potamitou et al, 2002). This may 
point towards the natural role of TDRl in Leishmania'. after all, the protein is unlikely to 
have evolved to improve the efficacy of antileishmanial chemotherapy; that aspect of the 
protein’s function is more likely to be an unhappy coincidence for the parasite. In this 
chapter, the production and analysis of TDRl knockout and over-expressing L. major 
parasites is described. One of the important purposes of this was to investigate the cellular
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role of TDRl, to elucidate what the protein does regardless of its potential as an antimonial 
reductase.
5.2 Over-expression of TDR1 in Leishmania
It was hoped that manipulating the normal expression levels of TDRl in L major would 
result in alterations in the parasites that could be detected. This would enable the 
importance of TDRl in vivo to be assessed and help establish the protein’s functions. The 
first approach was to increase the expression of TDRl, achieved by over-expressing the 
protein from an episomal vector.
5.2.1 Creation of TDRl over-expressing L. mayor promastigotes
The sequence encoding TDRl was amplified from L major genomic DNA, sub-cloned 
into the pGEM T-easy and then cloned into the pGL102 plasmid. The plasmid with the 
TDRl gene was named pGL102TDRl ; maps of this and the empty vector are shown in 
figure 5.1. The pGL102 plasmid is a Leishmania episomal expression vector and contains 
the neomycin resistance gene as a selectable marker. Uncut pGL102 and pGL102TDRl 
were transfected into L. major promastigotes which were subsequently incubated in culture 
with neomycin so that only successful transformed parasites would grow. The transformed 
parasite lines will be herein referred to by the names of the vectors they were transformed 
with (pGL102 and pGL102TDRl).
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Figure 5.1: Plasmids for the over-expression of TDRl in L. major promastigotes. Schematic 
representation of the pGL102 plasmid for the over-expresslon of TDRl In Leishmania. A -  pGL102 
+ TDRl (pGL102TDR1) for the over-expresslon of TDRl. amp, amplclllln resistance gene; neo, 
neomycin resistance gene. The restriction sites used to clone TDRl Into the vector are shown In 
dark red. B -  empty pGL102 vector, for use as a negative control.
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5.2.2 Analysis of over-expression
Whether pGL102TDRl parasites that grew in the presence of the selective drug had been 
successfully transformed, resulting in increased levels of TDRl, was assessed by western 
blot analysis. pGL102 and pGL102TDRl parasites grown with neomycin and in the 
stationary phase of growth were harvested and lysed and the soluble fractions were 
retained. The protein concentration of each sample was determined, and equal quantities 
were separated by SDS-PAGE before western blotting. The sheep ani-TDRl antibody was 
used to detect TDRl expression. To ensure equal loading of the samples, cysteine synthase 
(CS) expression was examined in parallel with TDRl, using a rabbit anti-CS antibody 
donated by Dr R. Williams of the University of Glasgow. While the expression of CS 
remained constant, TDRl was significantly more highly expressed in pGL102TDRl than 
in pGL102 L  major promastigotes (figure 5.2); at least a four-fold increase in TDRl 
expression was observed.
TDRl
CS
Figure 5.2: Western blot analysis of TDRl expression In pGL102 and pGL102TDR1 L. major 
promastigotes. 20 pg of soluble parasite lysate was loaded per lane. CS, cysteine synthase 
protein, used as a control to ensure equal loading. The relative positions of the proteins are 
indicated to the left of the image.
5.2.3 Phenotypic analysis of TDRl over-expressing L. major
Western blot analysis confirmed that pGL102TDRl parasites were over-expressing TDRl 
as compared to pGL102 parasites, and therefore phenotypic tests could be conducted with 
confidence that TDRl was at increased levels. In some experiments the TDRl over­
expressing parasites were compared to WT as well as pGL102 parasites to help corroborate 
any differences between data sets.
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5.2.3.1 Morphology and growth
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Parasites over-expressing TDRl were examined microscopically and no morphological 
differences could be seen between them and the parasites containing the empty pGL102 
vector or WT parasites. After several passages with neomycin present in the culture media, 
the pGL102 and pGL102TDRl lines were counted and diluted to the same concentration. 
Thereafter their growth was monitored by daily counting (figure 5.3). The parasite lines 
were found to grow at similar rates.
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Figure 5.3: Growth curve of pGL102 and pGL102TDR1 L. major promastigotes. Cultures were 
seeded at a concentration of 2 x 10® parasites/ml and were counted daily. Both lines were grown 
with 50 pg/ml neomycin.
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5.2.3 2 In vitro infectivity to macrophages
C hapters 121
The ability of WT, pGL102 and pGL102TDRl stationary phase promastigote parasite lines 
to infect peritoneal macrophages was assessed (figure 5.4). pGL102TDRl infected a 
higher percentage of macrophages than either the pGL102 or WT lines: approximately 4 
times and twice as many, respectively. This suggests that the over-expression of TDRl in 
parasites aids infection. However, the differences were not significant which reflects the 
low number of replicates of this experiment that were performed: further analysis is 
required to conclude whether over-expression of TDRl impacts upon the infectivity of the 
parasites to macrophages. The variation between the infection rates between the WT and 
pGL102 lines was also of concern as they would be expected to infect at a similar rate. It is 
possible that the pGL102 line have been adversely affected by the transformation 
procedure, causing them to be less infective in vitro.
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Figure 5.4: Infectivity of WT, pGL102 and pGL102TDR1 L. mayor promastigotes to 
macrophages. Stationary phase promastigotes were used to infect peritoneal macrophages at a 
rate of 2:1 and the slides were incubated for 5 days post-infection. Results are the means ± SE 
from at least two experiments. The infection rates of the different parasite lines were not 
significantly different (p > 0.05)
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5.2.3 3 In vivo infectivity to mice
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To assess the in vivo infectivity, metacyclic pGL102 and pGL102TDRl parasites were 
purified from stationary phase cultures and inoculated into mouse footpads, the thicknesses 
of which were then measured over time (figure 5.5). pGL102TDRl parasites were 
responsible for significantly more rapid footpad growths than those that were induced by 
pGL102. However, footpad infectivity experiments described elsewhere in this chapter 
suggest that the infectivity of pGL102 parasites may be compromised: footpads infected 
with WT parasites reach an average of 4 mm after 6 weeks (figure 5.16), while here 
footpads infected with pGL102 parasites are an average of just 3.5 mm after 10 weeks. 
However, although the experimental conditions are the same between these two 
experiments, some parameters may be subject to change e.g. the amount of time between 
metacyclic promastigote purification and inoculation. Therefore the differences observed 
between the two experiments may not be due to the pGL102 line being defective. 
Regardless of whether pGL102 parasites are infectious as WT, the footpad infections 
caused by pGL102TDRl are particularly virulent as after just five weeks the footpads had 
reached an average width of 4.9 mm. The difference between the footpad infections caused 
by the pGL102TDRl parasites in this experiment and the WT parasites in the experiment 
described in section 5.3.3.4 and demonstrated in figure 5.16 is significant (p < 0.02). As 
described in the previous section, pGL102TDRl parasites were also more infective to 
macrophages than both WT and pGL102 parasites.
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Figure 5.5: Infectivity of pGL102 and pGL102TDR1, L. mayor metacyclic promastigotes to 
mice. 1x10® metacyclic promastigotes were resuspended in 20 pi PBS and inoculated into one 
footpad of each BALB/C mouse. The footpad thicknesses were subsequently measured weekly, 
and the results are the means ± SD from five mice. The footpad thicknesses of mice infected with 
pGL102TDR1 parasites were significantly greater than those of mice infected with pGL102 five 
weeks post-infection (p < 0.0006).
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5.2.3 4 Effect of Sb(V) on macrophage infections
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The effect of sodium stibogluconate (Sb(V)) on macrophages infected with pGL102 and 
pGL102TDRl parasites was assessed (figure 5.6). The parasites and macrophages were 
incubated overnight, the excess parasites were washed off and dilutions of Sb(V) in media, 
or drug-free media, were applied. The parasites were incubated with the drug for a total of 
five days, with the drug being refreshed once during that time. At the highest drug 
concentration (250 pg/ml) the percentage of macrophages infected by the pGL102 and 
pGL102TDRl parasites had fallen to around 30% of the percentage of cells infected when 
no drug was applied. There was no significant difference in the effect of Sb(V) between the 
different parasite lines.
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Figure 5.6: Effect of sodium stibogiuconate on the infectivity of pGL102 and pGL102TDR1 L. major promastigotes to macrophages. Stationary phase promastigotes were used to infect 
peritoneal macrophages at a rate of 3:1 at 37 °C. After the parasites and macrophages had been 
incubated together overnight, the parasites were washed off and doubling dilutions of sodium 
stitx)gluconate (Sb(V)) were applied. Results are the means ± SE from at least two experiments. 
There is no significant difference between the effect of Sb(V) on the infectivity of pGL102 and 
pGL102TDR1 promastigotes to macrophages (p > 0.5). The results are expressed as the 
percentage of cells infected when no drug was present in order to normalize varying levels of 
infection.
5.2.3 5 ICso values when incubated with agents that induce oxidative stress
IC50 values -  the concentration of a substance that causes half of the maximum inhibitory 
effect it exerts to occur -  were obtained for H2O2 and paraquat, against WT and 
pGL102TDRl parasites, and are presented in table 5.1. These were obtained by incubating 
parasites with doubling dilutions of the compounds in 96-well plates, and adding Alamar 
Blue to indicate living parasites. H2O2 itself is a reactive oxygen species (ROS) while
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paraquat can diffuse across cell membranes and react with dioxygen, resulting in the 
intracellular production of superoxide (O2 ) (Hassan and Fridovich, 1978). As described in 
the introduction to this chapter, TDRl displays glutaredoxin-like activities in vitro, 
functioning as a thioltransferase and dehydroascorbate reductase. Therefore increasing the 
abundance of TDRl in vivo may be expected to protect the parasites against oxidative 
stress, and increase their tolerance to agents that induce it. However, the IC50 values 
obtained for H2O2 and paraquat were similar for both WT and pGL102TDRl parasites.
The pGL102TDRl parasites are slightly more tolerant to H2O2 than WT, although 
paradoxically they are slightly more sensitive to paraquat.
WT PGL102TDR1
H2 0 2 253.3 ±2.9 301.7 ±7.6
paraquat 5500 ±1004 2200 ±130
Table 5.1:10» values of paraquat and H2O2 against WT and pGL102TDR1 L. major 
promastigotes. All values were obtained using the Alamar Blue test; parasites were incubated 
with doubling dilutions of the compounds for a total of four days. The values and standard 
deviations were calculated using the Graft software I C 5 0  programme. All values are in pM.
5.2.3 6 Growth of promastigotes with paraquat
To further assess the effect of paraquat on pGL102TDRl parasites compared to L. major 
promastigotes with normal TDRl levels, parasite cultures were grown with the compound 
(figure 5.7). WT, pGL102 and pGL102TDRl promastigotes were seeded at 1 x 10^  and in 
standard media containing 5 mM paraquat. Over the course of seven days, the parasite 
lines grew at similar rates, although between day 3 and day 6 the pGL102TDRl were at a 
slightly lower concentration than the WT and pGL102 parasites.
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Figure 5.7: Effect of paraquat on the growth of WT. pGL102 and pGL102TDR1 L. major 
promastigotes. The parasites were seeded at 1 x 10 /ml with 50 pg/ml neomycin and 5 mM 
paraquat and were counted daily.
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5.3 Knocking-out of TDR1 in L. major
It was anticipated that removing the TDRl gene from L. major by two rounds of 
homologous recombination would affect the parasites and result in a phenotype that would 
clarify the role of TDRl in vivo. Analysis of the knockout parasites’ susceptibility to Sb(V) 
would also elucidate the role, if any, of TDRl in pentavalent antimonial activation.
5.3.1 Creation of L  major TDRl knock-out parasite lines
The 3’ and 5’ flanking regions of TDRl were amplified from L. major genomic DNA, sub­
cloned into pET28a(+) and cloned into vectors pGL345, pGL1033 and pGL842 which 
contain hygromycin, bleomycin and blasticidin resistance genes, respectively (figure 5.8). 
The constructs containing the flanking regions and drug resistance markers were cut out 
and purified and the linear DNA was used to transform L  major promastigotes. Following 
the two independent second-round transfections and overnight recovery period, the 
appropriate selective drugs were added and the cultures were divided: 1 ml of each was 
used to set up serial dilutions in an attempt to derive clonal lines. Two independent lines, 
KOTDRl 1 and KOTDR18, were generated, both having undergone transformation with 
two constructs sequentially and grown up in the presence of the selection drugs.
KOTDRl 1 was transformed with DNA obtained from the pGL345 (hygromycin) and 
pGL1033 (bleomycin) plasmids, while KOTDRl 8 was generated with DNA from the 
pGL345 and pGL842 (blasticidin) plasmids. In addition, a clonal line was derived from the 
initial serial dilutions of the KOTDRl population; it was named KOTDRl 1 A. After 
several passages in the selective drugs, three further clonal lines were derived by setting up 
KOTDRl 1 and KOTDRl 8 in 96-well plates at a concentration of approximately 0.1 
parasites per well. One clone, KOTDRl IB, was isolated from KOTDRl 1 and two clones 
were isolated from KOTDRl 8: KOTDRl 8A and KOTDRl 8B. The clones were derived in 
the presence of selective drugs, but these were omitted from the media following the 
isolation of the clones.
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Figure 5.8: Construct for the gene knock-out of TDRl in L. major promastigotes. Schematic 
representation of the pGL345 plasmid containing the TDRl 3’ and 5’ flanking regions. The second 
plasmids used for the construction of the TDRl knock-out lines were pGL842 and pGLIOSS, which 
are exactly the same as pGL345 except that they contain blasticidin and bleomycin resistance 
genes respectively, rather than hygromycin resistance gene. Hyg, hygromycin resistance gene; 
amp, ampicillin resistance gene; DHFR flanks, flanking regions of the dihydrofolate reductase 
gene. The restriction sites used to clone the TDRl flanks and hygromycin resistance gene into the 
vector are shown in dark red. Hindlll and Bglll were used to cut out the flank-containing linear 
construct for transfection into L major.
5.3.2 Analysis of knock-out lines
Whether the TDRl gene had successfully been knocked out of KOTDRl lA, KOTDRl IB, 
KOTDRl 8 A and KOTDRl 8B, resulting in the absence of TDRl, was assessed by western 
blot analysis. WT and TDRl knockout parasites in the stationary phase of growth were 
harvested and lysed and the soluble fractions were retained. The protein concentration of 
each sample was determined, and equal quantities were separated by SDS-PAGE before 
western blotting. The sheep ani-TDRl antibody was used to detect TDRl expression. To 
ensure equal loading of the samples and as a positive control, CS expression was examined 
in parallel with TDRl, using the rabbit anti-CS antibody as before. While CS expression 
was apparent in all lines tested, TDRl was solely expressed in WT parasites (figure 5.9). 
Therefore KOTDRl lA, KOTDRl IB, KOTDRl 8A and KOTDRl 8B were judged as being 
successful TDRl knockouts.
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Figure 5.9: Western blot analysis of TDR1 expression in WT, KOTDR18A, KOTDR18B, 
KOTDR11A and KOTDRl IB L. ma/or promastigotes. 15 pg of soluble parasite lysate was 
loaded per lane. CS, cysteine synthase protein, was used as a control to ensure equal loading. The 
relative positions of the proteins are indicated to the left of the image.
5.3.3 Phenotypic analysis of TDR1 knock-out lines 
5.3.3.1 Morphology and growth
TDRl knockout parasites were examined microscopically and no morphological 
differences could be seen between them and WT. The KOTDRl 1 A, KOTDRl IB,
KOTDRl 8A and KOTDRl 8B clonal lines were counted and diluted to the same 
concentration. Thereafter their growth was monitored by counting at regular intervals 
(figure 5.10). The KOTDRl8A and KOTDRl IB lines took slightly longer to reach 
stationary phase than the other lines. KOTDRl 8A did not reach a density greater than 1.2 x 
10^  parasites/ml, while all other lines reached 2x10^ parasites/ml. Moreover, after 30 days 
in culture, the KOTDRl 8A parasites began to die while the other lines did not. After the 
KOTDRl lA, KOTDRl IB and KOTDRl8B lines had been passed through mice, the 
growth curves were repeated and all three grew at similar rates to, and reached similar 
densities in the stationary growth phase as WT parasites.
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Figure 5.10: Growth curve of WT, KOTDR11A, KOTDRl IB, KOTDR18A and KOTDRl8B L  
ma/or promastigotes. Cultures were seeded at a concentration of 1 x 10® parasites/ml and were 
counted at regular intervals. All parasite lines were grown without any selective drugs added.
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5.3.3 2 Differentiation to metacyclic promastigotes
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The percentage of WT, KOTDRl 1 A, KOTDRl IB, KOTDRl 8 A and KOTDRl 8B 
promastigotes that differentiated to metacyclic forms was monitored over time (figure 
5.11). Parasite cultures were seeded at equal concentrations and, after they had reached the 
stationary phase of growth, aliquots were removed and the percentage of metacyclic forms 
in each sample was assessed. The percentage of metacyclic forms in each of the parasite 
lines tested increased over time. The percentage of metacyclic forms in each culture was 
similar at each time interval, although the highest percentage was consistently in the 
KOTDRl 1A line. At 16 days after the cultures were initiated, a lower percentage of 
metacyclogenesis was observed in the KOTDRl 8A sample, as compared to the other lines.
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Figure 5.11: Metacyciic formation in WT, KOTDRl 1 A, KOTDRl IB, KOTDRl 8A and 
KOTDRl8B L  major promastigotes over time. Parasite cultures were seeded at 1 x 10®/ml and 
metacyclogenesis was assessed after they had reached the stationary phase of growth. The 
parasites in each culture were counted, incubated with peanut agglutinin and re-counted. 
Metacyclogenesis was also assessed by analysis of parasite morphology. Number of days refers to 
the time since the cultures were initiated.
5.3.3 3 In vitro infectivity to macrophages
The ability of WT, KOTDRl 8B, KOTDRl 1A and KOTDRl 1B stationary phase 
promastigote parasite lines to infect peritoneal macrophages was assessed (figure 5.12). 
The KOTDRl 8A line was not used here, or in any other macrophage infectivity 
experiments because, as discussed in section 5.3.3.4, this line was not infective to mice. 
While the KOTDRl8B, KOTDRl lA and KOTDRl IB parasite infected macrophages at 
similar levels, the WT parasites infected a significantly lower number of cells. This 
suggests that the loss of TDRl enhances the macrophage infectivity of L major. This was
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an unexpected result, as the over-expression o f TDRl in L. major promastigotes had a 
similar effect (section 5.2.3.2).
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Figure 5.12: Infectivity of WT, KOTDRl 1 A, KOTDRl IB, KOTDRl8A and KOTDRl8B L. major 
promastigotes to macrophages. Stationary phase promastigotes were used to infect peritoneal 
macrophages at a rate of 2:1 and the slides were incubated for 6 days at 37 “C post-infection. 
Results are the means ± SE from at least two experiments. All three TDRl knockout lines are 
significantly more infectious to macrophages than WT parasites (p < 0.05).
In the previous experiment the macrophages were incubated at 37 °C. Whether the 
incubation temperature affected the infectivity of WT, KOTDRl 8B, KOTDRl lA and 
KOTDRl IB promastigotes was assessed (figure 5.13A). At both 35 °C and 35 °C, the WT 
parasites infected a lower percentage of macrophages than the TDRl knockout lines. 
However, this effect was much more pronounced at 37 °C: while the percentage of infected 
macrophages for the three TDRl knockout lines remained constant between the two 
temperatures, the WT parasites infected less than half the percentage of macrophages at 37 
°C than they did at 35 °C. The effect of the different temperatures on the average number 
of parasites in each infected cell was also determined (figure 5.13B). When incubated at 35 
°C the average number of parasites in each infected cell varied between the KOTDRl 8B, 
KOTDRl lA and KOTDRl IB lines (approximately 11, 14 and 17, respectively). However 
these were all higher than the average of 8 parasites per cell observed in macrophages 
infected with WT parasites. At 37 °C there was a decrease in the average number of 
parasites per cell in all the lines tested. At the higher temperature the average number of 
parasites was similar in cells infected by the three TDRl knockout lines, and once again 
the number of WT parasites per cell was considerably less.
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Figure 5.13: Infectivity of WT, KOTDRl 1 A, KOTDRl IB, KOTDRl 8A and KOTDRl 8B L. major 
promastigotes to macrophages and the number of parasites per infected cell, when 
incubated at different temperatures. Stationary phase promastigotes were used to infect 
peritoneal macrophages at a rate of 3:1 and the slides were incubated for 6 days post-infection. A -  
the percentage of macrophages infected after 6 days. B -  the average number of parasites present 
in each in infected cell. The number of parasites present in at least 20 infected cells was counted, 
and the average number calculated.
A second experiment was conducted to analyse the affect of temperature, but also the 
infection ratio of parasites to cells, on the infectivity of WT, KOTDRl 1 A, KOTDRl IB, 
KOTDRl 8A and KOTDRl 8B to macrophages (figure 5.14). A second L. major WT line 
with a higher passage number was also used, to corroborate the observation in the previous 
experiments that the WT parasites were less infective to macrophages than the TDRl 
knockout lines. Parasites with a higher passage number were used as these had not been so 
recently harvested from animals and had had longer to adjust to growing in vitro. The 
percentage of infected macrophages by the WT lines were highly similar when infection 
ratios of 2:1 and 3:1 parasites to macrophages were used, and at both 35 °C and 37 °C. 
Both WT lines infected a lower percentage of macrophages than the three TDRl knockout 
lines, which infected similar levels of cells. In all the parasite lines used in these 
experiments and at both temperatures, a significantly higher percentage of macrophages
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were infected when the infection ratio of parasites to cells was 3:1 as opposed to 2:1. Once 
again, the percentage of macrophages infected by WT parasites was significantly lower at 
37 °C than 35 °C; this effect was apparent with both WT lines used, and was regardless of 
the infection ratio used. The percentages of macrophages infected with the three TDRl 
knockout lines at each of the infection ratios used were not significantly different between 
the two temperatures.
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Figure 5.14: infectivity of two independent WT lines and KOTDRl 1 A, KOTDRl IB,
KOTDRl 8A and KOTDRl8B L. ma/or promastigotes to macrophages using different 
infection ratios and when incubated at different temperatures. Stationary phase promastigotes 
were used to infect peritoneal macrophages at a rate of 2:1 or 3:1 as indicated, and the slides were 
incubated for 6 days post-infection. A -  incubated at 35 °C. B -  incubated at 37 “C. Results are the 
means ± SE from at least two experiments. For both WT and TDRl knockout parasites and at both 
temperatures, the percentage of cells infected when an infection ratio of 3:1 was used was 
significantly higher than when an infection ratio of 2:1 was used (p < 0.05). For each infection ratio 
the percentage of macrophages infected with WT parasites when the cells were incubated at 35 °C 
was significantly higher than when incubated at 37 °C (p < 0.05). This was not the case for the 
TDRl knockout parasites (p > 0.1).
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Finally, the effect of time on macrophage infections by both WT lines and the three TDRl 
knockout lines was examined. The parasites were removed after being incubated with the 
macrophages overnight, and the cells were incubated for a further one, three or five days 
before the percentage of infected cells was assessed (figure 5.15). After one day, all the 
parasite lines resulted in a similar percentage of infected macrophages. However, by the 
fifth day both the WT lines infected significantly less cells than the three TDRl knockout 
lines, which again infected very similar levels of macrophages.
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Figure 5.15: infectivity of two independent WT iines and KOTDRl 1 A, KOTDRl IB,
KOTDRl BA and KOTDRl 8B L. mayor promastigotes to macrophages over time. Stationary 
phase promastigotes were used to infect peritoneal macrophages at a rate or 3:1 and the slides 
were incubated for 1, 3 or 5 days post-infection as indicated. Results are the means ± SD from at 
least three experiments. After five days the percentage of macrophages infected by the WT 
parasites was significantly less than the percentage infected by the TDRl knockout lines (p < 
0.05).
Taken together, these experiments show that all three TDRl knockout lines consistently 
infect a significantly higher percentage of macrophages than WT parasites do, and also 
produce infections with a higher number of parasites per infected cell than WT. The WT 
cell lines infected a lower percentage of cells when incubated at 37 °C as compared to 35 
°C; this effect was not apparent in infections by the TDRl knockout lines. A similar 
phenomenon was observed when the macrophages were incubated for varying amounts of 
time post-infection: while all lines produced similar levels of infected macrophages after 
one day, after five days the percentage of macrophages infected with the WT parasites was 
significantly less than the percentage infected with the TDRl knockout lines. The three 
TDRl knockout lines behaved similarly, causing comparable levels of cells to be infected 
under all the conditions tested here. The two WT lines used also produced similar results.
Joanne C. McGregor, 2006 Chapter 5 133
For all the lines tested and at both 35 °C and 37 °C, a 3:1 infection ratio resulted in a 
higher percentage of infected macrophages that when a 2:1 infection ratio was used.
5.3 3.4 In vivo infectivity to mice
To assess the in vivo infectivity of the TDRl knockout parasites, metacyclic promastigotes 
were purified from stationary phase cultures and inoculated into mouse footpads, the 
thicknesses of which were then measured over time. Initially only the KOTDRl 1A and 
K0TDR18A lines were used, together with WT parasites (figure 5.16). Both the WT and 
KOTDRl 1A parasites infected the mice footpads, with the KOTDRl 1A parasites causing 
slightly more rapid footpad growths to occur than the WT parasites. However, the 
KOTDRl 8A line was found to be completely non-infective to the mice; the footpad widths 
did not increase in any of the mice. The same result was obtained in a second experiment 
using this line. This was an unexpected result given the infectivity of the KOTDRl 1A line. 
However, previous experiments described in section 5.3.3.1 show that KOTDRl 8A 
promastigotes did not grow to as high densities as WT and the other TDRl knockout lines, 
and expired before them. Metacyclogenesis was also reduced in the KOTDRl 8A line, 
albeit only at the latest time point (section 5.3.3.2). Therefore the KOTDRl 8A line was 
judged to have been damaged in some way -  possibly during the transformation procedure 
-  and was therefore not used for subsequent phenotypic analysis.
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Figure 5.16: Infectivity of WT, KOTDRl8A and KOTDR11A L. mayor metacyciic 
promastigotes to mice. 1x10^ metacyclic promastigotes were resuspended in 20 pi PBS and 
inoculated into one footpad of each BALB/C mouse. The footpad thicknesses were subsequently 
measured weekly, and the results are the means ± SO from three mice. The footpad thicknesses of 
mice infected with KOTDRl 1A parasites were significantly greater than those of mice infected with 
WT parasites five weeks post-infection (p < 0.025).
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The infectivity of WT parasites and the remaining TDRl knockout lines KOTDRl 1 A, 
KOTDRl IB and KOTDRl83 to mice footpads was investigated (figure 5.17). All the 
lines infected the mice, although the three TDRl knockout lines caused significantly more 
rapid footpad width increases to occur than the WT parasites did. This reflects the in vitro 
data, with the TDRl knockout lines being consistently being more infective to 
macrophages than the WT parasites. Following the experiment, parasites were recovered 
from the footpads and cultured as normal for use in further investigations.
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Figure 5.17: infectivity of WT, KOTDR18B, KOTDRl 1A and KOTDRl IB L. mayor metacyclic 
promastigotes to mice. 1x10^ metacyclic promastigotes were resuspended in 20 pi PBS and 
inoculated into one footpad of each BALB/C mouse. The footpad thicknesses were subsequently 
measured weekly, and the results are the means ± SD from five mice. The footpad thicknesses of 
mice infected with all three TDRl knockout lines were significantly greater than those of mice 
infected with WT parasites five weeks post-infection (p < 0.05).
5.3.3 5 Effect of Sb(V) on infectivity to macrophages
The effect of Sb(V) on macrophages infected with WT, KOTDRl 1 A, KOTDRl IB and 
KOTDRl 8B parasites was assessed, as before. Initially only the WT and KOTDRl 1A 
lines were used (figure 5.18). The results are presented as both the percentage of infected 
macrophages at the varying drug concentrations, and as of the percentage of the level of 
infection achieved when no drug was applied; this is to normalise the data for the 
anomalies in the infection levels between the lines. At the second-highest drug 
concentration (250 pg/ml) the percentage of macrophages infected with WT parasites had 
fallen to around 50% of the percentage of cells infected when no drug was applied, while 
the infection level of macrophages infected with the KOTDRl 1A line remained 
unchanged. This was the only drug concentration at which a significant difference was 
observed and suggests that macrophage infections of KOTDRl 1A may be less susceptible
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to Sb(V) than WT infections. This is in accordance with the hypothesis that TDRl is able 
to reduce pentavalent antimonials to a more harmful trivalent form in vivo, effectively 
mediating toxicity of the drug. However, the large standard errors obtained from the data, 
caused by inconsistency between duplicate experiments, meant that further analysis was 
required.
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Figure 5.18: Effect of sodium stibogluconate on the infectivity of WT and KOTDRl 1A L. major promastigotes to macrophages. Stationary phase promastigotes were used to Infect 
peritoneal macrophages at a ratio of 3:1. Doubling dilutions of sodium stibogluconate (Sb(V)) were 
applied as before and cells were Incubated for 5 days with the drug. A - % Infected macrophages. 
B -  results expressed as the percentage of cells Infected when no drug was present In order to 
normalize varying levels of Infection. Results are the means ± SE from two experiments. When the 
drug concentration was 250 pg/ml, the percentage of macrophages Infected with WT parasites 
relative to the no drug control was significantly less than the percentage Infected with KOTDRl 1A 
parasites (p < 0.04). At all other drug concentrations there was no significant difference (p > 0.05).
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In a second experiment the effect of Sb(V) on macrophages infected with WT,
KOTDRl 1 A, KOTDRl IB and KOTDRl 8 was investigated (figure 5.19). Again, the raw 
data together with the normalised results are presented. In this experiment, the percentage 
of macrophages infected with WT parasites was very low: only around 15% of cells were 
infected when no drug was present. Meanwhile the infection levels achieved with the 
TDRl knockout lines was consistently around 50%. At the highest drug concentration (1 
mg/ml) the percentage of macrophages infected with WT and KOTDRl 8B parasites had 
fallen to around 50% and 55%, respectively, of the percentage of cells infected when no 
drug was applied, while the level of macrophages infected with KOTDRl 1A and 
KOTDRl IB were approximately 80%. However, there was no consistent significant 
differences between the effect of Sb(V) on WT infections compared to TDRl knockout 
infections. The low infection rate observed for the WT line when no drug was present is 
problematic when analysing the data: the effect of Sb(V) on WT infection levels may be 
far more dramatic if the initial infection rates were higher.
The effect of the incubation temperature on macrophages infected with WT, KOTDRl 1 A, 
KOTDRl IB and KOTDRl 8 parasites, and treated with Sb(V) was assessed. Both the 
percentage of infected macrophages (figure 5.20) and the average number of parasites per 
cell (figure 5.21) were analysed. Only the normalised data is presented here (the 
percentage of the infection levels and parasites/cell observed with no drug present); the 
results correlate with the data presented in figure 5.13 as they are part of the same 
experiment. Only two concentrations of Sb(V) were used in these experiments: 0.5 mg/ml 
and 2.5 mg/ml and at the latter Sb(V) may also be slightly toxic to the macrophages. This 
high concentration was used to assess whether improved toxicity to L. major could be 
achieved. With all the parasite lines tested, Sb(V) was much more effective at reducing the 
percentage of infected macrophages at 37 °C than at 35 °C, However, the effect of the drug 
on the number of parasites per cell did not differ between the two temperatures (although, 
as described in section 5.3.3.3, the average number of parasites per cell is less at 37 °C 
than at 35 °C for all the lines tested). No macrophages infected with WT parasites could be 
detected when the cells had been incubated at 37 °C, although cells were infected with all 
three TDRl knockout lines at this temperature. With the exception of this observation, 
there were no noticeable differences in the effect of Sb(V) on the infections between the 
cell lines; this applies to both the percentage of infected macrophages and to the average 
number of parasites per cell. As before, much higher levels of infection were achieved with 
the TDRl knockout lines than the WT parasites and this may have affected this inference.
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Figure 5.19: Effect of sodium stibogluconate on the infectivity of WT, KOTDR18B,
KOTDRl 1A and KOTDRl IB  L. mayor promastigotes to macrophages. Stationary phase 
promastigotes were used to infect peritoneal macrophages at a rate of 2:1. Doubling dilutions of 
sodium stibogluconate (Sb(V)) were applied as before and cells were Incubated for 7 days at 37 “0 
with the drug. Results are the means ± SE from two experiments. A - % Infected macrophages B - 
results expressed as the percentage of cells infected when no drug was present in order to 
normalize varying levels of Infection. At all drug concentrations used, there were no significant 
differences In the effect of Sb(V) on the percentage of macrophages Infected with the WT and 
TDRl knockout lines relative to the no drug control (p > 0.05).
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Figure 5.20: Effect of sodium stibogluconate on the infectivity of WT, KOTDR18B, 
K0TDR11A and KOTDR11B L. mayor promastigotes to macrophages at varying 
temperatures. Stationary phase promastigotes were used to infect peritoneal macrophages at a 
rate of 3:1. Sodium stibogluconate (Sb(V)) at one of two concentrations, or no drug, was applied 
and cells were incubated for 5 days. The results are expressed as the percentage of cells infected 
when no drug was present In order to normalize varying levels of Infection. A -  Incubated at 35 ®C. 
B -  Incubated at 37 “C.
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Figure 5.21: Effect of sodium stibogluconate on the average number of parasites per 
infected macrophage of infections with WT, KOTDRl SB, KOTDRl 1A and KOTDRl IB L. major promastigotes at varying temperatures. Stationary phase promastigotes were used to 
Infect peritoneal macrophages at a rate of 3:1. Sodium stibogluconate (Sb(V)) at one of two 
concentrations, or no drug was applied and cells were Incubated for 5 days. The number of 
parasites present In at least 20 Infected cells was counted, and the average number calculated. 
The results are expressed as the percentage parasites per cell that were present when no drug 
was applied. In order to normalize the data. A -  Incubated at 35 ®C. B -  Incubated at 37 °C.
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5.3 3.6 IC50 values when incubated with toxic substances
■■iIUsing both the acid phosphatase and Alamar Blue assays, IC50 values were obtained for 
various substances against WT and TDRl knockout parasites. Three different 
hydroperoxides -  H2 O2, cumene hydroperoxide and tert-butyl hydroperoxide -  were tested
against the KOTDRl 1 and KOTDRl 8 parasite populations (table 5.2). Because of the 
glutaredoxin-like in vitro activities of rTDRl, it was hypothesised that parasites lacking 
TDRl may be more sensitive to these oxidising agents. However, the IC50 values obtained 
were broadly similar for each substance between the WT and TDRl knockout parasites.
ÏC50 values were also calculated for several compounds against WT, KOTDRl 1 A,
KOTDRl IB and KOTDRl8B parasites (table 5.3). The substances tested were the 
trivalent antimonial compound potassium antimonial tartrate (Sb(III)), which is toxic to 
Leishmania and affects the redox balance of the parasites (Wyllie et al, 2004); juglone, 
which is toxic to trypanosomes (Akerman and Muller 2005) and produces intracellular 
ROS (Kampkotter et al, 2003); N-methylphenazinium methyl sulphate, which is toxic to 
trypanosomes (Akerman and Muller 2005) and generates intracellular O2’ (Maridonneau et 
al, 1983) and p-mercaptoethanol, a chemical that reduces disulphide bonds and affects the 
expression levels of& coli glutaredoxins (Potamitou et al, 2002). Both the KOTDRl 1A 
and KOTDRl IB lines were considerably more sensitive to paraquat (IC50 values of 1.2 and *
1.4 mM, respectively) than WT parasites (IC50 value of 5.5 mM). Therefore the effect of 
paraquat on the different parasite lines was investigated further.
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WT KOTDRl 1 KOTDRl 8
H2 0 2 234.5 ±10.7 328.7 ±29.9 227.8 ±13.8
Cumene hydroperoxide 9.4 ±1.2 9.4 ±1.3 9.0 ±0.6
Tert-butyl hydroperoxide 27.3 ±1.7 14.4 ±6.5 27.2 ±2.6
Table 5.2: IC50 values of H2O2, cumene hydroperoxide and tert-butyl hydroperoxide against 
WT, KOTDR11 and KOTDR18 L. mayor promastigotes. All values were obtained using the acid 
phosphatase assay. The values and standard deviations were calculated using the Grafit software 
IC5 0 programme. All values are in pM.
WT KOTDRl 1A KOTDRl IB KOTDRl 8B
Sb(III) 23.2 ±2.7 16.7 ±3.0 N/D N/D
P-me 330.8 ±21.9 301.4 ±36.3 N/D N/D
juglone 2.3 ±0.7 2.4 ±0.3 N/D N/D
H2O2 253.3 ±2.9 264.4 ±6.8 266.6 ±7.6 290.6 ±8.1
paraquat 5500 ±1004 1200 ±100 1400 ±500 N/D
NMPMS 10.1 ±0.4 7.8 ±0.54 N/D N/D
Table 5.3: IC50 values of different com pounds against WT, KOTDRl 1 and KOTDR18 L. major 
promastigotes. All values were obtained using the Alamar Blue assay. The values and standard 
deviations were calculated using the Grafit software I C 5 0  programme. All values are In pM. Sb(lll), 
potassium antimonial tartrate; |3-me, p-mercaptoethanol; NMPMS, N-methylphenazinium methyl 
sulphate; N/D, not determined.
5 3.3.7 Effect of agents that induce oxidative stress on TDR1 expression in 
L  major promastigotes
In chapter four the varying expression of TDRl between different life-cycle stages was 
demonstrated. Given that TDRl displays thioltransferase and DHAR activities in vitro, it 
may have a role in protecting the parasite from oxidative stress and therefore TDRl 
expression may be modulated by fluctuations in the intracellular redox environment of the 
parasite. In order to determine whether exposure to oxidative stress could stimulate TDRl 
expression in WT L, major promastigotes, parasites were incubated for varying times with 
different concentrations of H2O2 or paraquat and western blots were performed on the 
resultant parasite lysates (figure 5.22). The protein concentrations of the samples were 
determined and normalised, but to ensure equal loading of the samples CS and/or 
transketolase (TK) expression was examined in parallel with TDRl, using the rabbit anti- 
CS and anti-TK antibodies. TDRl expression did not change in L  major parasites 
incubated with 125 pM H2O2 at any of the time-points tested, nor in parasites incubated 
with 500 pM H2O2 after 4 hours (at later time-points the parasites were mostly dead so the 
TDRl expression could not be determined) (figure 5.22A), It is possible any changes in 
expression would take place before the initial four hour time-point when the parasites were
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harvested. Accordingly, L major parasites were incubated with paraquat for less time, with 
the parasites being harvested at three time-points within 24 hours of initial exposure to the 
oxidant. However, no variations in TDRl expression were visible at any of these time- 
points with the different paraquat concentrations (figure 5.22B). TDRl may have a role in 
protecting the parasite against oxidative stress; however, its expression is not affected by 
exposure to these oxidants under the conditions tested.
A H A  (pM) 125 500
TDRl
Time (h) 4 24 72
B Paraquat (mM) 0 0.1 1 0.1 1 0.1
TK
TDRl mm 
CS «—
Time (h) 0 1 4 24
Figure 5.22: Western blot analysis of the effect of H2O2 and paraquat on TDRl expression in 
L. major promastigotes. A -  parasites inbubated with H2O2 . 12 pg of soluble parasite lysate 
loaded per lane. B -  parasites incubated with paraquat. 16 pg of soluble parasite lysate loaded per 
lane. The concentrations of the reagents are shown above each figure and the length of exposure 
time is shown below In h (hours). TK (transketolase) and CS (cysteine synthase) were used as 
loading control proteins. The Identities of the different proteins are Indicated to the left of the Image. 
There was no noticeable change In TDRl expression under the conditions tested.
5.3 3.8 Growth of promastigotes with paraquat
The IC50 data presented in section 5.3.3.6 showed that the TDRl knockout lines 
KOTDRl 1A and KOTDRl IB are approximately four times more sensitive to paraquat 
than WT parasites. To further investigate the effect of paraquat on these lines, WT, 
KOTDRl 1 A, KOTDRl IB and KOTDRl8 parasite cultures were seeded at 1 x lOVml and 
grown with 5 mM paraquat, and the growth of the parasites’ was monitored by counting 
(figure 5.23). While the parasite density of the WT culture increased to approximately 2 x 
10^  after six days, over the same time period the parasite density of the three TDRl 
knockout lines fell to 1.4-2.6 x 10^ . This result reflects the IC50 data presented previously
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and demonstrates a clear difference in the sensitivity of the TDRl knockout lines to 
paraquat as compared to WT parasites.
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Figure 5.23: Effect of paraquat on the growth of WT, KOTDR18B, KOTDRl 1A and 
KOTDR11B L. major promastigotes. The parasites were seeded at 1 xIO* with 5 mM paraquat 
and were counted daily.
5.4 Re-expressing TDR1 In TDRl knock-out parasite lines
In order to clarify whether any phenotype observed in the TDRl knockout lines was due to 
the loss of TDRl as opposed to any secondary mutation or damage the parasites may have 
accumulated, TDRl was re-expressed in the knockout lines. This was achieved by 
transforming the KOTDRl lA, KOTDRl IB and KOTDRl8 parasites with the 
pGL102TDRl plasmid used to over-express TDRl in WT L major, as described in section
5.2.1. In addition the same lines were transformed with the pGL102 plasmid so they could 
be used as negative control samples. These plasmids were previously presented in figure
5.1. Using the names of the original lines and plasmids used to transform them, the new 
lines were named KOTDRl 1A + pGL102, KOTDRl 1A + pGL102TDRl, KOTDRl IB + 
pGL102, KOTDRl IB + pGL102TDRl, KOTDRl8B + pGL102 and KOTDRl8B + 
pGL102TDRl.
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5.4.1 Analysis of re-expression
Whether the TDRl knockout parasites transformed with pGL102TDRl that grew in the 
presence of the selective drug had been successfully transformed, resulting in TDRl being 
re-expressed, was assessed by western blot analysis. WT, KOTDRl 1A + pGL102TDRl, 
KOTDRl IB + pGL102TDRl and KOTDRl8B + pGL102TDRl promastigotes grown 
with neomycin were harvested and lysed, and the soluble fractions were separated by SDS- 
PAGE before western blotting. The sheep ani-TDRl antibody was used to detect TDRl 
expression. As a positive control, CS expression was examined in parallel with TDRl, 
using the rabbit anti-CS antibody as before. TDRl was expressed in all three re-expressing 
lines (figure 5.24)
TDRl
CS
Figure 5.24: Western blot analysis of TDRl expression In pGL102 L  mayor promastigotes 
and KOTDRl L. mayor promastigotes transformed with pGL102TDR1.10-20 pg of soluble 
parasite lysate was loaded per lane. CS, cysteine synthase protein, was used as a positive control. 
The identities of the different proteins are indicated to the left of the image. TDRl was re­
expressed in each of the lines tested.
5.4.2 Growth of parasites re-expressing TDRl, with paraquat
The IC50 data presented in section 5.3.3.6, together with the growth curves presented in 
section 5.3.3.8, show that the TDRl knockout lines KOTDRl 1A and KOTDRl IB are 
more sensitive to paraquat than WT parasites. To investigate whether the loss of TDRl 
was responsible for this phenotype, the parasite lines re-expressing TDRl were grown with 
paraquat. WT, KOTDRl 1 A, KOTDRl IB, KOTDRl 1A + pGL102, KOTDRl 1A + 
pGL102TDRl, KOTDRl IB + pGL102, KOTDRl IB + pGL102TDRl parasite cultures 
were seeded at 1 x lOVml and grown with 5 mM paraquat, and growth was monitored by
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counting (figure 5.25). While the parasite density of the WT culture increased as before, 
the density of all the other lines decreased in a similar rate to the TDRl knockout parasites. 
Clearly, the re-expression of TDRl, which was confirmed by western blot analysis, does 
not complement the paraquat-sensitive phenotype of the TDRl knockout cultures. Whether 
this is due to the original phenotype being caused by a factor other than the loss of TDRl, 
or whether TDRl re-expression does not reinstate the parasites’ relative insensitivity to 
paraquat for some other reason, is currently unknown.
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Figure 5.25: Effect of paraquat on the growth of WT L. major promastigotes and KOTDR1 L. major promastigotes transformed with pGL102 or pGL102TDR1. The parasites were seeded at 
1 X 10®/ml with 5 mM paraquat and were counted daily. With the exception of WT, KOTDR11A and 
KOTDR11B, the parasites were also grown with 50 pg/ml neomycin.
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5.5 Discussion
The in vitro characteristics of rTDRl described in the introduction to this chapter are 
consistent with the observed activities of oGST. rTDRl exhibited GSH-CDNB conjugating 
activity which is characteristic of other types of GSTs, but as for human oGST, it was at a 
very low level. However, this activity should not be ignored as although an elongation IB 
complex displaying trypanothione S-transferase activities was recently identified in L. 
major (Vickers et al, 2004), no known GSTs have ever been found in Leishmania. 
Therefore TDRl is the first protein with GST activity to be identified in the parasite.
However, the more notable functions displayed by rTDRl were DHAR and 
thioltransferase activities. Whether the DHAR activity displayed by TDRl is of relevance 
is an interesting question. Although ascorbate has been detected in T. cruzi (Clark et al, 
1994), it has never been detected in Leishmania although an ascorbate-dependant 
peroxidase has also been identified (Adak and Datta, 2005). However, trypanothione is 
able to reduce dehydroascorbate (Krauth-Siegel and Ludemann, 1996) and may be 
sufficient to maintain ascorbate levels without the need for an enzymatic reductase. The 
issue of ascorbate being necessary in Leishmania, and therefore whether TDRl may have a 
role in maintaining it in the reduced from, is addressed in chapter six. The high 
thioltransferase activity exhibited by TDRl is the only in vitro enzymatic capability that 
was also displayed by the most closely related protein to TDRl, Tc52. CDNB-GSH 
conjugating activity was not detected in tlie T. cruzi protein (Montiez et al, 1995) and it 
was not assessed for DHAR (or indeed metal-reducing) activities. It is possible that the 
active site differences between TDRl and Tc52 described in chapter three account for 
these differences. As mentioned, DHAR and thioltransferase activities are commonly 
exhibited by glutaredoxins, a class of proteins that share predicted active site sequences 
with TDRl but are otherwise much smaller and rather dissimilar. As described in chapter 
three, L. major contains several proteins that are annotated as, and share sequence 
similarity to, glutaredoxins. Organisms often possess several GRXs that may display 
redundancy towards each other due to their overlapping functions (Draculic et al, 2000). 
Therefore the possibility of redundancy between TDRl and other Leishmania proteins 
must be taken into account when considering the glutaredoxin-like role of TDRl in vivo.
To investigate the role of TDRl in vivo, parasites over-expressing TDRl (figure 5.2) and 
clonal TDRl knockout lines (figure 5.9) were created. The growth rates of all these lines 
were assessed and were found to be similar to that of WT promastigotes (figures 5.3 and 
5.10) with the exception of one of knockout lines, KOTDRl 8A, The grovyth rate of this
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line, together with the parasite density in stationary-phase cultures, was slightly impaired 
and analysis of the line was discontinued. The metacyclogenesis of the TDRl knockout 
lines was assessed and was shown to be broadly similar to that of WT parasites in all the 
lines tested. These findings contrast with the observations of T. cruzi parasites that had 
reduced levels of Tc52: epimastigotes did not grow well in culture and were impaired in 
their ability to differentiate into metacyclic forms (Allaoui et ah, 1999). Moreover, only a 
mono-allelic Tc52 knockout line was obtained; knocking out both copies of Tc52 is 
thought to be lethal.
The IC50 values of several compounds against WT TDRl knockout, and TDRl over­
expressing lines were calculated in order to determine if the level of TDRl affected the 
sensitivity of parasites to different types of stress (tables 5.1, 5.2 and 5.3). There was no 
consistent significant difference in the IC50 values of most of the compounds tested 
between the different lines, including the hydroperoxides, potassium antimonial tartrate 
and p-mercaptoethanol. However, several agents that induce the production of intracellular 
ROS were tested and a significant difference in the IC50 value of one of these -  paraquat -  
was apparent between WT parasites and those lacking TDRl. This finding was reinforced 
by the observation that WT cells were much more tolerant to paraquat than TDRl 
knockout parasites were, when the lines were grown in the presence of the chemical (figure 
5.23).
Glutaredoxins (GRXs) have been previously linked with protecting cells against paraquat- 
induced oxidative stress. Knocking out the WT and expressing a mutated version of GRX5 
in Schizosaccharomyces pombe resulted in increased sensitivity to paraquat (Chung et ah, 
2005) and a similar phenotype was observed in S. pombe GRX2 null mutants (Chung et al, 
2004). These reports reflect the increased sensitivity of TDRl knockout parasites to 
paraquat that are described in this chapter, and support the hypothesis based on the in vitro 
activities of the protein that TDRl functions as a glutaredoxin in Leishmania.
A possible reason for the increase in paraquat sensitivity of the GRX mutants could be that 
they have depleted ascorbate levels (due to a lack of DHAR activity). Ascorbate is a low- 
molecular weight antioxidant which can react directly with ROS, and is the essential co­
factor for ascorbate-dependant peroxidases, proteins that enzymatically reduce H2O2 . 
Paraquat treatment caused dehydroascorbate reductase activity to increase in Conyza 
bonariensis plants (Ye and Gressel, 2000) and TRXl levels to increase in mouse liver and 
lung tissues (Jurado et al, 2003). Although the expression of TDRl in L. major was not 
affected by exposure to sub-lethal concentrations of paraquat (figure 5.22), this was also
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found to be the case elsewhere; although exposure to the chemical did not result in 
increased GRX2 levels in S. pombe (Chung et al, 2004), or GRXl or GRX2 levels in 
mouse liver or lung tissues (Jurado et al, 2003). Meanwhile, the expression of a human 
DHAR gene in tobacco plants caused them to be less susceptible to paraquat-induced 
damage (Kwon et al, 2003). Over-expression of TDRl did not cause the parasites to 
become more tolerant to the compound (table 5.1 and figure 5.7). This would be the 
expected result if ascorbate recycling is not the rate-limiting step in ROS detoxification in 
Leishmania.
If the loss of TDRl is responsible for the increased sensitivity to paraquat of the TDRl 
knockout lines, re-expressing TDRl in these lines should restore resistance to the chemical 
as displayed by WT parasites. Despite confirmation that TDRl was being re-expressed by 
parasites transformed with pGL102TDRl, the susceptibility of these lines to paraquat did 
not decrease (figure 5.25). There are several possible reasons for this. It may be the case 
that some other mutation or damage to the TDRl knockout lines is responsible for their 
increased sensitivity to paraquat. However, this seems unlikely given that all three 
independently derived knockout lines exhibit the same phenotype. Another possibility is 
that an aspect of the TDRl re-expression does not comply with WT expression and that 
this effectively inactivates the protein. For example, the expression level or the localisation 
of TDRl may differ in the re-expressing lines. Further analysis is required to determine 
which of these scenarios is correct. Re-expressing TDRl from the original gene locus or 
fi*om another chromosomal location may also be a helpful approach.
L. major parasites over-expressing TDRl were more infective to macrophages than WT 
and pGL102 control parasites (figure 5.4), and were also more infective to mice than the 
control line (figure 5.5). Paradoxically, the TDRl knockout lines were also more infective 
to macrophages (section 5.3.3.3) and, to a lesser extent, mice, than WT parasites (section 
5.3.3.4). It was also notable that the percentage of macrophages with WT parasites 
appeared to be more susceptible to a prolonged incubation time and an increase in 
incubation temperature than the TDRl knockout parasites (figures 5.13-5.15). The reasons 
for the apparent contradictions between the TDRl over-expressing and knockout infection 
data are unclear. The pGL102 line which acted as a control for the TDRl over-expressing 
line appears to be in some way damaged: the parasites were less infective than WT 
parasites to both macrophages and mice. However, misinterpretation of the TDRl over­
expressing line infection data due to it being compared to a faulty control is not to blame, 
as the TDRl over-expressing line was also more infective than WT. Whether the WT line 
itself could also be impaired was considered. However, the utilisation of a second WT line
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which was of a different passage number gave very similar macrophage infection data to 
the original WT line (figures 5.14 and 5.15), suggesting that this was not the case. One 
possibility is that when TDRl is knocked out, the levels of other proteins -  possibly the 
glutaredoxin-like proteins described in chapter three -  are modulated to compensate for the 
loss. This in turn could have a positive effect on the TDRl knockout parasites, improving 
their viability in vivo. Meanwhile, given the glutaredoxin-like properties of TDRl, over­
expression of the protein could have a more straightforward beneficial effect on L. major, 
the increased infectivity may be due to them being better equipped to cope with the 
oxidative stress encountered upon invasion of a cell.
Once again, the results do not correspond with the Tc52 knockout and over-expresser data. 
Although there was no difference between the infectivity of WT T. cruzi and parasites 
over-expressing Tc52, parasites with decreased Tc52 levels were significantly less 
infective to both macrophages and mice than WT parasites (Allaoui et al, 1999). Moreover 
Tc52 knockout parasites that do infect animals result in an attenuated form of Chagas’ 
disease with reduced parasitemia compared to WT infections (Garzon et al, 2003). Tc52 is 
secreted and is thought to have a role in modulating the immune response of the host 
(Fernandez-Gomez et al, 1998; Borges et al, 2001; Ouaissi et al, 2002; Garzon et al, 
2003), which is hypothesised to be the reason behind the reduced infectivity displayed by 
parasites with decreased levels of Tc52 (Garzon et al, 2003). It was shown in chapter four 
that TDRl is also released from promastigote parasites but the increased infectivity of 
parasites lacking TDRl suggests that the protein does not perform the same function as 
Tc52.
As described in the introduction to this chapter, rTDRl was able to reduce pentavalent 
antimonials to the more toxic trivalent forms in vitro. This was in keeping with the ability 
of mammalian oGST to reduce pentavalent arsenicals (Zakharyan et al, 2001), and 
supported the hypothesis that TDRl may be involved in mediating antimonial 
susceptibility in Leishmania. To resolve whether TDRl did indeed perform this fimction in 
vivo, macrophages infected with WT, TDRl over-expressing and TDRl knockout L. major 
parasites were incubated with sodium stibogluconate (Sb(V)) and the impact of the drug on 
the infections was assessed. The effect of Sb(V) on L. major promastigotes could not be 
tested as they are not sensitive to the trivalent drug. However, it proved to be extremely 
difficult to assess the impact of Sb(V) on L. major macrophage infections for two main 
reasons: the difference in the basal macrophage infection rates of the various lines, and the 
insensitivity of all the lines tested to the drug.
Joanne C. McGregor, 2006 Chapter 5 150
There appeared to be no significant difference between the susceptibility of TDRl over- 
expressing and control parasites to the drug (figure 5.6). When considering the raw data on 
the effect of Sb(V) on the macrophage infections of the WT and TDRl knockout, it looks 
like the knockout parasites are highly insensitive to the drug, consistent with the idea that 
TDRl mediates antimonial toxicity. Even at tlie highest concentrations of Sb(V), 
approximately 30-40% of macrophages were infected with the TDRl knockout parasites, 
compared to only 5% infected with WT parasites (figure 5.19). Similar results were 
achieved in other experiments (section 5.3.3.5). However, due to the different infectivity of 
WT and TDRl knockout parasites to macrophages when no drug was present, in order to 
directly compare the effect of Sb(V) between the lines, it was necessary to consider the 
effect of the drug on the reduction of the initial infection level. Therefore, the data for the 
infection levels achieved with the varying drug concentrations was converted to the 
percentage of the infection levels achieved with no drug was present. This makes the data 
look very different and shows that despite the impressive infection levels of the knockout 
lines achieved with high concentrations of the drugs, the reduction in the infection level is 
similar to that of the WT parasites. However, manipulating the data in this way is not an 
ideal solution; similar basal infection levels between the lines would allow a proper 
comparison of the effect of Sb(V). A useful approach may be to analyse the effect of Sb(V) 
on in vivo infections of the different lines, as these were at a more similar basal level than 
the macrophage infections. This would also circumvent the problem of the apparent 
insensitivity of L. major parasites in macrophages to Sb(V).
While this study was in progress, another arsenate reductase-like protein that could reduce 
pentavalent metalloids in vitro was identified, LmACR2 (Zhou et al, 2004). Although 
LmACR2 knockout parasites were not constructed, the protein was over-expressed in L. 
infantum and this resulted in an increase in sensitivity to Sb(V). The effect of Sb(V) was 
assessed using a similar macrophage infection assay to the one used in this investigation. 
The approximate Sb(V) IC50 value, as calculated from their findings, was 120 pg/ml 
against parasites over-expressing LmACR2, and 180 pg/ml against WT parasites. Clearly 
this is a much lower value than in the experiments detailed in this chapter. Although there 
was variation between experiments and the incubation temperature affected the Sb(V) 
efficacy, the IC50 was approximately 500-1000 pg/ml, a concentration that also appeared 
to be toxic to tlie macrophages. Therefore, manipulating the expression of TDRl in a 
Leishmania strain that is more susceptible to Sb(V) may help to ascertain whether the 
protein does indeed mediated antimonial sensitivity in vivo.
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The TDRl over-expressing and knockout L. major lines generated were useful tools in 
analysing the role of TDRl in vivo. The unexpected ease in constructing null mutants -  
which could not be achieved for Tc52 in T. cruzi -  together with the observations that the 
resultant parasites proliferated well in vitro and were infectious to aimais and cells showed 
that TDRl was non-essential in L. major. The protein is likely to function similar to a 
glutaredoxin and may protect parasites from oxidative stress. The fact that L. major 
contains several glutaredoxin-like sequences and that redundancy is known to occui- 
between glutaredoxins may explain why the parasites were able to lose TDRl so easily. 
Another reason could be that the protein is only essential when the parasites are residing in 
the sandfly vector. Whether TDRl affects the Leishmania susceptibility to antimonials 
remains unresolved. A recent study has shown that the expression of TDRl was not 
modulated in antimonial resistant field-isolates (Decuypere et al, 2005), suggesting that 
the protein is not responsible for drug-resistance. However, in this study protein expression 
was interpreted from the RNA transcript levels; because DNA transcription in Leishmania 
is polycistronic the relevance of this observation is unclear. However, in order to determine 
whether the protein is able to reduce the pentavalent dugs in vivo, further experimentation 
is required. Analysis of the effect of Sb(V) on animals infected with the different lines 
generated here may help to clarify the impact of the protein.
152
6 Functional study of L-gulono lactone oxidase in 
L. major
6.1 Introduction
6.1.1 The role of ascorbate in the cell
Like GSH, ascorbate -  commonly known as vitamin C -  is a low-molecular weight 
antioxidant which can react directly with ROS, donating an electron which stabilises the 
free radical (Rose and Bode, 1993). In turn the ascorbate is oxidised and forms 
monodehydroascorbate which can then be recycled back to the reduced form -  directly or 
via dehydroascorbate by enzymes that display dehydroascorbate reductase activity -  as 
discussed in section 6.1.4. The highly reactive hydroxyl radical, which is not thought to be 
detoxified enzymatically, can be neutralised in this way. Ascorbate is present in high 
concentrations in many types of both mammal (Rose and Bode, 1993) and plant (Agius et 
al, 2003; Chen et al, 2003) tissues and is therefore an important antioxidant. As well as 
participating in reactions with free radicals directly, ascorbate has a further role in 
counteracting oxidative stress by acting as the electron donor in reactions mediated by 
ascorbate-dependant peroxidases (APXs) which are involved in the detoxification of H2O2 . 
While the antioxidant enzyme catalase, which has a high turnover rate, is important in 
removing H2O2 , it has a low affinity for the compound and is not suitable for managing 
low concentrations of it. On the contrary, peroxidases -  including APXs -  have a high 
affinity for H2O2 and can scavenge it even at low concentrations. The control of H2O2 
levels is of the utmost importance, given its emerging role in the control of signal 
transduction and gene expression (Noctor et al, 2000). Many APX isoenzymes with 
differing sub-cellular localisations are known to exist (reviewed in Shigeoka et al, 2002) 
and have been especially well characterised in plants. However APX has also been found 
in bovine eye tissue (Wada et al, 1998) and several types of eukaryotic algae including 
Euglena gracilis (Ishikawa et al, 1996) which, like the trypanosomatids, lacks catalase. 
The absence of catalase m these organisms is interesting as it may be indicative of 
peroxidases having even greater importance in the elimination of oxidative stress. As 
discussed in section 6.1.5, APX has also been found in both T. cruzi and L  major.
Ascorbate has a clear role in protecting cells from oxidative stress and this is demonstrated 
by the phenotypes of various mutants of different organisms that have abnormal levels of 
ascorbate. The lack of reports of plant lines that are completely deficient in ascorbate
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suggests that it is an essential compound in plants. However, various A. thaliana lines 
which have low levels of ascorbate -  deemed vtc mutants -  are hypersensitive to ozone 
(Conklin et al, 2000) and salt stress (Huang et al, 2005), and have growth deficiencies 
(Pavet et al, 2005). Plants engineered to over-express an ascorbate peroxidase were less 
sensitive to various types of oxidative stress (Murgia et al, 2004). Meanwhile S. cerevisiae 
engineered to lack D-arabinono-1,4-lactone oxidase (ALO) -  one of the proteins required 
for ascorbate biosynthesis in yeast -  exhibited increased sensitivity to both H2O2 and 
menadione, while yeast over-expressing the protein were less sensitive to these oxidants 
(Huh et al, 1998). Ascorbate synthesis was enhanced in rat cells treated with oxidative- 
stress-inducing agents; when this was prevented by simultaneous treatment with sorbinil 
(which inhibits ascorbate synthesis) greater levels of ROS were found in the cells (Chan et 
al, 2005).
Although ascorbate has an unequivocal role as an antioxidant, it is also involved in many 
other cellular processes (reviewed in Arrigoni and De Tullio, 2002; De Tullio and 
Arrigoni, 2004). These include synthesis of various cell compounds and cell-wall synthesis 
(Smirnoff, 2000), cell division (Liso et al, 1984) and elongation (Smirnoff and Wheeler, 
2000). The part ascorbate plays in many of these processes is explained by its role in 
reactions mediated by dioxygenases, a large group of enzymes that catalyse the 
incorporation of O2 into an organic substrate and are themselves responsible for a wide 
range of reactions. Ascorbate-dependant dioxygenases (AADs) are a sub-group of these 
proteins which can use ascorbate as a co-substrate: indeed some specifically require it 
(Dong et al, 1992). An important reaction catalysed by an AAD called P4H is the 
hydroxylation at carbon 4 of proline residues to be incorporated into polypeptide chains 
such as collagen and the transcription factor HIFa (Myllyharju, 2003). Depletion of 
ascorbate affects proline hydroxylation in guinea pigs and results in reduced collagen 
synthesis, in turn leading to scurvy-like symptoms (Peterkofsky, 1991). In tobacco plants, 
inhibition of P4H alters cell-wall synthesis and cell division (Cooper et al, 1994). Other 
AADs include N-trimethyl-L-lysine hydroxylase and gamma-buytro-betaine hydroxylase 
which together are essential for the synthesis of carnitine, an amino acid derivative 
involved in fatty acid metabolism. Carnitine synthesis is affected by ascorbate levels (Ha et 
al, 1991) and its depletion is responsible for several phenotypes including muscle 
weakness in humans (http://www.emedicine.com/PED/topic321.htm). AADs are also 
implicated in hormone and fiavonoid synthesis in plants (Arrigoni and De Tullio, 2002) 
and in the control of the cell cycle (De Tullio and Arrigoni, 2004). Although this account 
of the processes ascorbate is involved in is not exhaustive, the diverse range of activities 
dependant on ascorbate and its resultant significance in the cell is clear.
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6.1.2 Ascorbate synthesis
Ascorbate or the similar compound erythroascorbate are produced in a wide variety of 
eukaryotic organisms albeit by several different biosynthetic pathways (see figure 6.1). In 
most mammals ascorbate is synthesised from glucose via the uronic acid pathway, first 
proposed in the 1950s (Isherwood et al, 1954). Interestingly humans (along with other 
primates and guinea pigs) lack the L-gulonolactone oxidase enzyme required for the final 
step in ascorbate synthesis (Sato and Udenfriend, 1978). Instead, they obtain ascorbate 
from plants, which contain high levels of ascorbate. Indeed plants employ several different 
biosynthetic pathways to convert D-glucose-6-Phosphate, D-fructose-6-phosphate or D- 
marmose-6-phosphate to ascorbate (Wheeler et al, 1998; Valpuesta and Botella, 2004). 
Meanwhile, some fungi and yeast species synthesise D-erythroascorbate rather than 
ascorbate (Smirnoff, 2001). These two compounds are very similar and are tliought to have 
similar functions within the cell; indeed the characterised enzymes that mediate D- 
erythroascorbate synthesis are similar to enzymes involved in ascorbate synthesis from 
other organisms. The various known ascorbate (and D-erythroascorbate) synthesis 
pathways are diagrammatically shown in figure 6.1, and characterised enzymes known to 
be involved in ascorbate synthesis are discussed below and summarised in table 6.1.
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Figure 6.1: The biosynthesis of ascorbate in mammals, plants and fungi. The proposed 
mammalian synthesis pathway is shown in red, the proposed plant pathways are shown in green 
and the proposed fungi pathway is shown in blue. The steps in the pathways are numbered where 
an enzyme able to catalyse the reaction has been identified and the numbers correspond with 
those in tables 6.1 and 6.2. 1, D-arabinose dehydrogenase; 2, D-arabinono-1,4-lactone oxidase 
(ALO); 3, Aldono-lactonase; 4. L-gulonolactone oxidase (GLO); 5, GDP-mannose 
pyrophosphorylase; 6, GDP-mannose-3’,5’-epimerase; 7, L-galactose-1-phosphate phosphatase; 
8, L-galactose dehydrogenase; 9, L-galactono-1,4-lactone dehydrogenase (GALDH); 10, Inositol 
oxygenase; 11, D-galacturonic reductase.
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6.1.2.1 Biosynthesis in mammals
Although the mammalian ascorbate synthesis pathway is well established, only two of the 
enzymes involved have been purified and characterised to date: a very recently identified 
aldono-lactonase, thought to catalyse the formation of L-gulono-1,4-lactone fi*om L- 
gulonic acid, and L-gulonolactone oxidase (GLO), which catalyses the formation of 
ascorbate from L-gulono-1,4-lactone. These are the penultimate and final reactions in 
ascorbate biosynthesis, respectively. It has been suggested that the recently identified 
mouse aldono-lactonase is responsible for L-gulono-1,4-lactone formation (Kondo et al, 
2006). However only the reverse reaction -  hydrolysis of L-gulono-1,4-lactone -  has been 
detected and characterised. However, mice lacking this enzyme and fed an ascorbate-fiee 
diet developed symptoms of scurvy and had greatly reduced ascorbate levels compared to 
wild-type mice, showing that the protein is critical for normal ascorbate production. GLO, 
which is absent in humans (the reason for susceptibility to scurvy), is expressed primarily 
in liver and kidneys and is localised to the microsomes of cells (Kiuchi et al, 1982; Puskas 
et al, 1998). Naturally occurring disruptions of the gene that encodes GLO in both pigs 
and mouse cause ascorbate deficiency (Hasan et al, 2004; Mohan et al, 2005). 
Surprisingly few reports have been recently published on this protein: there is no account 
of a gene encoding mammalian L-gulonolactone oxidase being cloned.
6.1.2.2 Biosynthesis in plants
The production of ascorbate in plants is complicated by the apparent existence of several 
different biosynthesis pathways (Valpuesta and Botella, 2004) that have not yet been 
firmly established. Currently three different pathways are proposed to exist (see figure 
6.1): the first, with L-galactose as an intermediate; the second, where ascorbate is 
synthesised fi'om mj^o-inositol; and thirdly with galacturonic acid as a precursor.
The L-galactose pathway is the most extensively characterised pathway of the three and 
most steps have been experimentally confirmed (Wheeler et al, 1998). Arabidopsis 
thaliana leaves were shown to synthesise ascorbate from both glucose and mannose 
(Wheeler et al, 1998), although a higher percentage of mannose is converted to ascorbate 
as it participates in fewer additional cellular reactions. It is well established that GDP-D- 
mannose and GDP-L-galactose are synthesised from D-glucose-6-phosphate via several 
intermediates for participation in polysaccharide synthesis (Smirnoff, 2000). L-galactose is 
thought to be formed by a two-step hydrolysis of GDP-L-galactose, the second step of 
which has been recently found to be catalysed in kiwifruit and A. thaliana by L-galactose-
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1-phosphate phosphatase (Laing et al, 2004). Thereafter L-galactose is converted to L- 
galactono-1,4-lactone by L-galactose dehydrogenase (Gatzek et al, 2002) before ascorbate 
is finally produced after catalysis by the mitochondrial L-galactono-1,4-lactone 
dehydrogenase (GALDH) (Ostergaard et al, 1997). GALDH performs an analogous 
function to, and shares amino acid sequence similarity with, mammalian GLO: cauliflower 
GALDH shares 27% amino acid identity with GLO from rat, although GALDH has a large 
N-terminal extension relative to GLO. Meanwhile L-galactose dehydrogenase is not 
particularly similar to mouse aldono-lactonase, the enzyme thought to catalyse the 
penultimate step in ascorbate production in mammals: they share just 10% identity at the 
amino acid level. The L-galactose pathway has been further complicated by the finding 
that GDP-mannose-3 ’,5 ’-epimerase can catalyse the formation of GDP-L-gulose as well as 
GDP-L-galactose (Wolucka and Van Montagu, 2003). It has also been proposed that L- 
gulonic acid could be formed fi'om GDP-L-gulose, and that this is converted to ascorbate 
via the same pathway that occurs in mammals (Valpuesta and Botella, 2004). This will be 
discussed in more detail in relation to the wjo-inositol pathway below.
The conversion of GDP-L-galactose to L-galactose is considered to be the first reaction in 
the pathway specific to ascorbate synthesis (Wheeler et al, 1998). However, both GDP- 
mannose pyrophosphorylase and GDP-mannose-3’,5’-epimerase, which catalyse the 
previous two steps in the pathway, have been postulated to have an important role in 
ascorbate synthesis as they are inhibited and down-regulated, respectively, upon addition 
of exogenous ascorbate in vivo (Tabata et al, 2002; Wolucka and Van Montagu, 2003). 
Furthermore, mutations in.^ 4. thaliana lines defective in ascorbate synthesis mapped to the 
GDP-mannose pyrophosphorylase gene (Conklin et al, 1999). Evidence also exists for 
both L-galactose dehydrogenase and GALDH directly affecting in vivo ascorbate levels: 
ascorbate levels decrease when antisense L-galactose dehydrogenase (Gatzek et al, 2002) 
or GALDH (Tabata et al, 2001) RNA transcripts are expressed in A. thaliana.
The formation of ascorbate firom myo-inositol is a less well-characterised route of 
biosynthesis. It was previously known that plants can derive mj/o-inositol from glucose-6- 
phosphate (Naccarato et al, 1974) and that /Mj/o-inosftol could be in turn converted to D- 
glucuronic acid by inositol oxygenase (Reddy et al, 1981). Recently this enzyme was 
found in A. thaliana and when over-expressed was shown to significantly increase the 
amount of ascorbate in the plant (Lorence et al, 2004). Because D-glucuronic acid is an 
intermediate in the ascorbate biosynthesis pathway found in mammals (see figure 6.1), 
there has been speculation that the mammalian pathway may be operating in plants, albeit 
mediated by different enzymes. Indeed, over-expression of rat GLO in A. thaliana plants
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deficient in ascorbate synthesis complemented the mutant phenotype (Radzio et al, 2003). 
This is in accordance with the hypothesis that L-gulose, formed from GDP-D-mannose due 
to GDP-mannose-3 % 5 ' -epimerase activity (see above), can be converted to L-gulonic acid 
and then to ascorbate via the mammalian pathway. There is evidence to support the idea 
that the mammalian ascorbate biosynthetic pathway is operating in plants: when L-gulose 
and D-glucuronic acid were administered to A. thaliana cell culture, the rate of ascorbate 
synthesis increased (Davey et al, 1999). In addition, L-gulonic acid has been detected in 
plants (Wagner et al, 2003), and GLO activity has been detected in A thaliana (Wolucka 
and Van Montagu, 2003). Clearly additional investigation is required to clarify whether 
part or the entire ascorbate biosynthetic pathway is also present in plants.
The third putative pathway of ascorbate synthesis in plants is from D-galacturonic acid, 
which is released in plants upon hydrolysis of cell wall breakdown products. It had been 
previously shown that pea extracts could catalyse the formation of ascorbate firom methyl- 
D-galacuronate and galacturonic acid (Mapson and Isherwood, 1954) and more recently 
ascorbate synthesis was shown to be increased when these compounds were added to A. 
thaliana cell culture (Davey et al, 1999). Enzymatic confirmation of this third pathway 
was provided when a D-galacturonic reductase cloned fi'om strawberry was shown to 
convert D-galacturonic to L-galactonic acid, which is spontaneously converted to L- 
galactono-1,4-lactone, the substrate for GALDH (which is also synthesised in the L- 
galactose pathway) (Agius etal, 2003). Moreover, over-expression of the ^ 4. thaliana 
version of the gene resulted in a significant increase in ascorbate levels within the plants. 
The authors of this paper have also suggested that the various pathways responsible for 
ascorbate synthesis within the cell may be developmentally regulated (Agius et al, 2003), 
perhaps providing in part an explanation for the presence of more than one ascorbate 
biosynthetic pathway in the organism: perhaps different pathways operate at different 
points in the plant life-cycle or in different tissue-specific localisations.
6.1.2.3 Biosynthesis in yeast
As mentioned, yeast and other lower eukaryotes have been shown to synthesise the 
ascorbate analogue D-erythroascorbate from D-arabinose (see figure 6.1). However, when 
given the alternative substrates L-galactono-1,4-lactone and L-gulono-1,4-lactone 
(intermediate compounds from the plant and mammalian ascorbate biosynthetic pathways 
respectively), S. cerevisiae could also produce ascorbate, although L-gulono-1,4-lactone 
was a poor substrate (Spickett et al, 2000). These observations show that the enzymes that 
mediate the pathway can use various substrates, either because they have evolved from a
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common ancestor to similar proteins in plants and mammals, or because ascorbate or 
erythroascorbate are synthesised from whatever substrates are available,
D-arabinose is first converted to D-arabinono-1,4-lactone, possibly via D-arabinono-1,5- 
lactone, by D-arabinose dehydrogenase (ARAl), which has been purified and characterised 
from several organisms: Candida albicans (Kim et al, 1996), Neurospora crassa 
(Carrasco et al, 1981) and S. cerevisiae (Kim et al, 1998). The C albicans and S. 
cerevisiae enzymes can also use L-galactose as substrates, showing that this step in the 
biosynthetic pathway is similar to that in plants. However, when compared to the 
analogous A. thaliana L-galactose dehydrogenase enzyme, the amino acid sequences were 
just 17% identical. Moreover, S. cerevisiae ARAl shares just 11% identity with the 
recently identified mouse aldono-lactonase. S. cerevisiae ARAl is more similar to glycerol 
dehydrogenases and is 38% identical to glycerol dehydrogenase from Aspergillus nidulans. 
Whether plant L-galactose dehydrogenase displays similar substrate specificities as the 
fungal enzymes and can convert D-arabinose has not yet been investigated.
The final step in D-erythroascorbate synthesis is the conversion of D-arabinono-1,4- 
lactone, a reaction catalysed by D-arabinono-1,4-lactone oxidase (ALO). This has been 
purified and characterised from S. cerevisiae (Huh et al, 1998) and C. albicans (Huh et al, 
1994). Both reported ALO proteins can catalyse the production of ascorbate from L- 
gulono-1,4-lactone and L-galactono-1,4-lactone (the penultimate compounds in the 
mammalian and plant ascorbate biosynthesis pathways, respectively), as well as D- 
erythroascorbate from D-arabmono-1,4-lactone. Indeed, ALO is similar to GLO and 
GALDH: the amino acid sequence of S. cerevisiae ALO shares 32% and 21% identity with 
those of rat GLO and cauliflower GALDH, respectively (Huh et al, 1998). Therefore, at 
least at the amino acid level, ALO is significantly more similar to mammalian GLO than to 
plant GALDH. This is perhaps surprising given that yeast ARAl is more similar to A. 
thaliana L-galactose dehydrogenase than to the mouse aldono-lactonase thought to 
catalyse the penultimate reaction in ascorbate biosynthesis. Elucidation of which substrates 
these plant and mammalian enzymes are capable of acting on will clarify which pathway 
D-erythroascorbate synthesis resembles more.
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Enzyme Name Organisms found in Reaction catalysed
1. D-arabinose 
dehydrogenase (ARAl )
Yeast and fungi: N. crassa, 
C. albicans, S. cerevisiae
D-arabinose to D-arabinono- 
1,4-lactone
2. D-arabinono-1,4- 
lactone oxidase (ALO)
Yeast and fungi:
C. albicans, S. cerevisiae
D-arabinono-1,4-lactone to 
erythroascorbate
3. Aldono-lactonase Mammals: mouse, human, 
rat
L-gulonic acid to L-gulono- 
1,4-lactone
4. L-gulonolactone 
oxidase (GLO)
Mammals: pig, mouse, rat. 
Also chicken.
L-gulono-1,4-lactone to 
ascorbate
5. GDP-mannose 
pyrophosphorylase
Plants: A. thaliana. 
Tobacco
D-mannose-1 -Phosphate to 
GDP-D-mannose
6. GDP-mannose-3%5'- 
epimerase
Plants: A. thaliana GDP-D-mannose to GDP-L- 
gulose OR GDP-L-galactose
7. L-galactose-1- 
phosphate phosphatase
Plants: A. thaliana, 
kiwi fruit
L-galactose-1-phosphate to 
L-galactose
8. L-galactose 
dehydrogenase
Plants: A. thaliana, pea L-galactose to L-galactono- 
1,4-lactone
9. L-galactono-1,4- 
lactone dehydrogenase 
(GALDH)
Plants: Cauliflower, sweet 
potato, tobacco
L-galactono-1,4-lactone to 
ascorbate
10. Inositol oxygenase Plants: A. thaliana wyo-inositol to D-glucuronic 
acid
11. D-galacturonic 
reductase
Plants: A. thaliana, 
strawberry
D-galacturonic to L- 
galactonic acid
Table 6.1: Enzymes involved in ascorbate biosynthesis. Enzymes identified from fungi are 
coloured in blue, from mammals are coloured in red, and from plants are coloured in green.
6.1.3 Uptake of ascorbate
Cellular uptake of ascorbate is clearly of importance in humans and other species which 
cannot synthesise ascorbate de novo. However, a wide variety of organisms, including 
plants and mammals able to produce their own ascorbate, can also obtain ascorbate from 
their surroundings. Specific transporters able to mediate uptake in plants are yet to be 
identified (Horemans et al, 2000). In addition to the mammalian ascorbate transporters 
described below, a bacterial operon that encodes several proteins that regulate ascorbate 
uptake and metabolism in E. coli has recently been identified (Yew and Gerlt, 2002; Zhang 
et al., 2003). Although sgaT (UlaA), sgaA (UlaC) and sgaB (UlaB) are all required for 
ascorbate uptake (Zhang et al., 2003), sgaT is thought be the actual transporter, which is 
predicted to include 12 transmembrane regions. In mammalian cells, two known routes of 
transport have been characterised: facilitated diffusion of dehydroascorbate primarily via 
glucose transporters (followed by reduction to ascorbate upon entry to the cell), and active 
transport of ascorbate itself, mediated by sodium-dependant transporters. These two 
mechanisms have been reviewed in detail elsewhere (Wilson, 2005).
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Three separate glucose transporters have been shown to mediate dehydroascorbate uptake: 
GLUTl and GLUT3 (Rumsey et al, 1997) (from rat and human respectively, characterised 
in hamster and xenopus cells) and rat GLUT4 (characterised in rat and xenopus cells) 
(Rumsey et al, 2000). Dehydroascorbate was completely reduced to ascorbate following 
uptake by GLUTl and GLUT3 (Rumsey etal, 1997). Intracellular ascorbate levels 
increased when either of these transporters was over-expressed and transport was inhibited 
by glucose. However, it should be noted that glucose does not completely inhibit 
dehydroascorbate uptake in all cell types (Himmelreich et al, 1998; Daskalopoulos et al, 
2002), leading to speculation that other, as yet unidentified, transporters can also transport 
oxidised ascorbate (Wilson, 2005).
The second route of ascorbate uptake by mammalian cells is mediated by the sodium- 
dependant transporters SVCTl and SVCT2, which exhibit high affinity transport of 
ascorbate (Daruwala et al, 1999; Tsukaguclii et al, 1999). The amino acid sequences of 
the two transporters, as well as the activities, are very similar, although the mammalian 
expression profiles differ. Both transporters are highly specific for ascorbate and were 
found not to significantly mediate the uptake of several compounds including 
dehydroascorbate and L-gulono-1,4-lactone (Tsukaguchi et al, 1999). When SVCT2 
expression was decreased by antisense RNA expression, ascorbate uptake decreased (Seno 
et al, 2004). These sodium-dependant channels are thought to be more important than the 
GLUT channels for ascorbate uptake in vivo, as extracellular ascorbate is primarily in the 
reduced from, and because uptake by GLUT transporters is inhibited by glucose 
(Tsukaguchi et al, 1999; Liang et al, 2001).
6,1.4 Ascorbate recycling
As discussed, ascorbate molecules participate in a wide variety of cellular reactions, many 
of which involve counteracting oxidative stress. When ascorbate is oxidised -  for example 
as a result of ascorbate peroxidase or oxidase activity -  monodehydroascorbate (MDHA) is 
formed. MDHA is an unstable free radical which can be enzymatically reduced by MDHA 
reductase (MDHAR) to form ascorbate, or disproportionates to ascorbate and 
dehydroascorbate (DHA). In turn DHA can be reduced by DHA reductase (DHAR) 
enzymatically to ascorbate. These mechanisms, described in more detail below, have been 
previously summarised (Arrigoni and De Tullio, 2002) and are represented 
diagrammatically in figure 6.2. The reactions are often referred to as the ascorbate- 
glutathione cycle as DHARs use GSH. If DHA is not reduced it is degraded, although the 
exact degradation pathway and products are not yet clear.
Joanne C. McGregor, 2006 Chapter 6 162
NADP NADPH + H'
GR
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Figure 6.2: Ascorbate recycling via the ascorbate-glutathione cycle. Enzymes are shown in 
red: GR, glutathione reductase; DHAR, dehydroascorbate reductase; MDHAR, 
monodehydroascorbate reductase; APX, ascorbate peroxidase. Not all reactions are depicted 
stoichiometrically. Figure redrawn from Noctor and Foyer 1998.
MDHAR is a relatively uncharacterised enzyme despite its important role in maintaining 
reduced ascorbate in the cell. NADH/NADPH-dependant MDHAR activity was first 
detected in plant chloroplast extracts (Marre and Arrigoni 1958) and has since been found 
in a wide range of organisms. The enzyme responsible for the activity has been purified 
from several species including soybean (Dalton et al, 1992) and cucumber (Hossain and 
Asada 1985) and is a FAD-binding protein. More recently the gene encoding MDHAR has 
been cloned (Murthy and Zilinskas 1994, Sano et ai, 2005) and analysed: the amino acid 
sequences, especially those of plant MDHARs, share similarity with some prokaryotic 
flavoenzymes (Murthy and Zilinskas 1994). Both N- and C- terminal targeting regions 
have been found in the various sequences which explain the diverse range of sub-cellular 
localisation attributed to the protein (Lisenbee et al, 2005; Sano et al, 2005). Treatment 
with various different sources of oxidative stress (including paraquat) was shown to up- 
regulate the expression of cabbage MDHAR protein (Yoon et al, 2004), suggesting that 
the protein may be important for maintaining optimal ascorbate levels.
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DHAR activity has been attributed to several different categories of proteins, including 
glutaredoxins and omega GSTs, as described in chapter one. In addition to these, the 
activity has been reported in protein disulphide isomerase (Wells et al, 1990), thioredoxin 
(Tromper et al, 1994), 3 alpha-hydroxysteroid dehydrogenase (Del Bello et al, 1994), 
GSH-peroxidase (Washbum and Wells, 1999), and a trypsin-inhibitor (Trumper et al, 
1994). Interestingly, the CXXC motif found in dithiol glutaredoxins is present in the 
majority of these proteins; however, their amino acid sequences are otherwise diverse. 
Studies have shown that DHAR activity impacts intracellular ascorbate levels: when 
DHAR (an omega-GST like enzyme) was over-expressed in tobacco and maize, ascorbate 
levels rose accordingly (Chen et al, 2003). A similar result was obtained in a study in 
which human omega GST was over-expressed in tobacco, and the plants also displayed 
increased tolerance to H2O2 and paraquat-induced oxidative stress (Kwon et al, 2003).
6.1.5 Ascorbate in the trypanosomatids
The presence of both ascorbate and dehydroascorbate has been previously reported in T. 
cruzi epimastigotes. Furthermore, in both trypanosomes and L. major^ ascorbate 
peroxidases have been previously identified and characterised (Wilkinson et al, 2002a; 
Adak and Datta, 2005), the presence of which may be suggestive of ascorbate having an 
important role in the parasite. Indeed it was shown that the T. cruzi protein used ascorbate 
as an electron donor and reacted with H2O2 but not t-butyl hydroperoxide or cumene 
hydroperoxide in vitro. Wliether the recombinant protein could also use the ascorbate 
analogue erythroascorbate, which is found in fungi, was not investigated. When the T. 
cruzi ascorbate peroxidase was over-expressed in the parasite, resistance was conferred to 
exogenous H2O2 with the parasites displaying a two-fold increase in resistance. Despite 
their exposure to high levels of oxidative stress due to the oxidative burst during invasion, 
trypanosomatids do not possess catalase (Boveris et al, 1980), an important enzyme for 
the detoxification of H2O2 in many organisms. Thus an important role in protection against 
exogenous oxidative stress has been postulated for peroxidases, including this ascorbate- 
dependant protein (Adak and Datta, 2005). However, the localisation of the T. cruzi 
ascorbate peroxidase - and possibly the similar Leishmania enzyme due to the presence of 
a targeting sequence and transmembrane domain in the protein - to the endoplasmic 
reticulum (ER), may also implicate the protein in protection against endogenous H2O2 . In 
r. cruzU a second peroxidase has been localised to the ER (Wilkinson et al, 2002b) and it 
has been postulated that it could protect the cell against reactive oxidant species generated 
here.
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As mentioned, the dehydroascorbate reductase activity of TDRl was one reason for 
investigating ascorbate in Leishmania. Over-expressing or knocking out TDRl may have a 
knock-on affect on cellular ascorbate levels therefore ascorbate-dependant processes. 
Moreover if TDRl was necessary for ascorbate recycling in Leishmania then loss of TDRl 
could result in ascorbate biosynthesis being up-regulated to compensate for the lack of 
recycled material. However, it has previously been reported that the recycling of ascorbate 
from dehydroascorbate in T. cruzi is not mediated enzymatically and instead occurs 
spontaneously upon interaction of the oxidised compound with trypanothione (Krauth- 
Siegel and Ludemann, 1996). The authors were imable to detect any increase in ascorbate 
formation in vitro upon addition of crude parasite extract to the reaction mix which 
contained glutathione and dehydroascorbate. Regardless of whether TDRl has a role in 
ascorbate recycling, the relative lack of published research on this interesting molecule in 
parasites was intriguing. Investigation into whether the parasites contained the machinery 
for, and were capable of, synthesising ascorbate would be the first step in elucidating the 
role of ascorbate in Leishmania, and is detailed in this chapter.
A very reeently published report details an investigation into ascorbate synthesis in T. 
brucei (Wilkinson et ah, 2005). A sequence similar to L-gulonolactone oxidase, L- 
galactono-1,4-lactone dehydrogenase and D-arabinono-1,4-lactone oxidase, the final 
enzymes in the ascorbate biosynthetic pathways of mammals, plants and fimgi 
respectively, was found in the parasite and designated TbALO. Recombinant TbALO was 
produced which was able to synthesise ascorbate from both L-galactono-1,4-lactone and 
D-arabinono-1,4-lactone, the plant and fungi substrates respectively. T. brucei bloodstream 
form parasites engineered to lack TbALO were viable and able to differentiate and infect 
mice, although they displayed a slight growth defect when cultured which was enhanced 
when ascorbate was depleted from the serum.
6.1.6 Aims of this study
In chapters three, four and five the discovery and characterisation of L  major TDRl was 
described. Like oGST and glutaredoxins, with which TDRl shares sequence similarity and 
active site motifs respectively, recombinant TDRl displayed dehydroascorbate reductase 
activity in vitro. L. major TDRl knockout parasites were hyper-sensitive to paraquat; a 
possible reason for this could be depleted ascorbate levels due to inefficient recycling of 
the oxidised form, caused by the absence of TDRl. As described, the maintenance of 
reduced ascorbate in trypanosomatids has been previously attributed to non-enzymatic
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reduction by trypanothione; however, the possibility that TDRl was capable of ascorbate 
recycling in vivo was intriguing.
Unlike many organisms, humans cannot synthesise ascorbate and instead scavenge it from 
their diet. Whether Leishmania also scavenge ascorbate, or whether they contain one of the 
several ascorbate biosynthetic pathways known to function in other life forms, was 
unknown. In order to clarify the situation we aimed to determine whether proteins similar 
to known ascorbate synthesis enzymes were present in L. major. In all ascorbate 
production pathways reported, a similar enzyme catalyses the final step; GLO in mammals, 
ALO in yeast and GALDH in plants. Therefore this protein in particular was of interest and 
it was our aim to ascertain whether Leishmania possessed such a protein and if so, to help 
determine its role in the parasite by altering its expression levels by genetic manipulation 
and analysing any resultant phenotype of the resultant mutants.
6.2 Results
6.2.1 Analysis of ascorbate biosynthesis homologues in L. major
As discussed in section 6.1.2 and illustrated in figure 6.1, several ascorbate and 
erythroascorbate biosynthetic pathways have been identified and various enzymes able to 
mediate reactions in the synthesis of ascorbate have been characterised; these are 
summarised in table 6.1. In order to determine whether Leishmania may possess such 
pathways, the amino acid sequences of these enzymes were used as enquiry sequences to 
search the L. major predicted protein database for putative ascorbate biosynthesis enzymes. 
As in chapter three, searches for L. major sequences were conducted using the omniblast 
feature at www.genedb.org and identified proteins were used as enquiry sequences to 
search known proteins of the original organism using the blastp facility found at 
http://www.ncbi.nlm.nih.gov/BLAST/. For each search the most significantly similar 
predicted protein to that of the enquiry sequence is described; less similar sequences are 
not described unless they displayed particularly high similarity. Alignments were 
performed using the alignX feature of vector NTI. The results of these blast searches and 
the ensuing analysis of the sequences identified are presented in this section and 
summarised in tables 6.2, 6.3 and 6.4.
6.2.1.1 GDP-mannose pyrophosphorylase
In the plant L-galactose pathway, the first enzyme known to be involved in ascorbate 
synthesis is GDP-mannose pyrophosphorylase which is responsible for the production of
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GDP-D-mannose. As well as being involved in ascorbate synthesis (Conklin et al, 1999; 
Keller et al, 1999; Tabata et al, 2002), the protein has an important role in the 
glycosyiation of proteins and lipids and polysaccharide synthesis as GDP-D-mannose is 
required for these reactions. The L. major predicted protein database was searched for 
similar proteins using the 361 amino acid .4. thaliana GDP-mannose pyrophosphorylase as 
an enquiry sequence. The most similar protein (p/n value = 1.2e’^ '^ ) was the 379 amino acid 
LmjF23.0110, a previously characterised GDP-mannose pyrophosphorylase (Garami and 
Ilg 2001; Davis et al, 2004). The protein sequence shares 50% identity and 70% 
conservation with that of the A. thaliana GDP-mannose pyrophosphorylase which was also 
the most alike A. thaliana protein to LmjF23.0110. Despite clear evidence that 
LmjF23.0110 is a GDP-mannose pyrophosphorylase, this is not implicit with it being 
involved in ascorbate synthesis due to its other known functions and published reports of 
LmjF23.0110 do not link it to ascorbate synthesis.
6.2.1.2 GDP-mannose-3%5-epimerase
The plant enzyme which catalyses the subsequent reaction in ascorbate biosynthesis in this 
pathway -  the conversion of GDP-D-mannose to GDP-L-galactose (or GDP-L-gulose) -  is 
GDP-mannose-3’,5’-epimerase. Again the activity of this protein may not be restricted to 
catalysing ascorbate synthesis (Wolucka et al, 2001): GDP-L-galactose is a component of 
N-glycans and xyloglucans in plants and polysaccharides in invertebrates. The A, thaliana 
GDP-mannose-3 ’,5 ’-epimerase 337 amino acid sequence was used as the enquiry sequence 
in the blast search. The most similar L. major protein (p/n value = 9.9e’^ ) was 
LmjF26.2230, an uncharacterised predicted protein 446 amino acids in length which is 
more than 100 amino acids longer than the A. thaliana protein. When the two sequences 
were aligned LmjF26.2230 had an N-terminal extension and several small N-terminal 
insertions as compared to the other protein. The protein sequence shares just 22% identity 
and 40% conservation with that of A thaliana GDP-mannose-3 ’ ,5 ’ -epimerase. Moreover 
when LmjF26.2230 was used as an inquiry sequence for a blastp search of A. thaliana 
proteins, 41 sequences were more similar than the GDP-mannose-3’,5’-epimerase with the 
most similar protein to LmjF26.2230 being annotated as a NADPH-dependant epimerase. 
Considering the low identity and conservation scores together with the results of the blastp 
search, it seems likely that LmjF26.2230 encodes a protein other than the GDP-mannose- 
3’,5’-epimerase involved in ascorbate synthesis.
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6.2.1.3 L-galactoôe-1-phosphate phosphatase
In this same plant pathway, the enzyme that converts GDP-L-galactose to L-galactose-1- 
phosphate has not yet been elucidated. However, the recently identified L-galactose-1- 
phosphate phosphatase catalyses the subsequent step: the dephosphorylation of L- 
galactose-1-phosphate to L-galactose (Laing et al, 2004). As the authors allude to, this 
step is thought to be specific to ascorbate synthesis as L-galactose is not known to 
participate in any other cellular processes. The 279 amino acid A. thaliana sequence was 
used to search the L. major predicted protein database. Two sequences were highly similar 
to the enquiry protein: the 288 amino acid LmjF17.1390 (p/n value = 1.8e‘^ )^ and the 466 
amino acid LmjF15.0880 (p/n value = 2.1e’^ )^. LmjF17.1390 shares 35% identity and 55% 
conservation withv4. thaliana L-galactose-1-phosphate phosphatase while Lmj F15.0880 
shares 32% identity and 49% conservation. Alignments between the amino acid sequences 
and that of the A thaliana protein showed that while LmjF17.1390 was similar to the plant 
protein, LmjF15.0880 displayed both N- and C-terminal extensions as well as several large 
insertions, explaining the differences in amino acid lengths. Like the A, thaliana (and 
kiwifruit) enzyme, the L. major sequences are both annotated as being putative myo­
inositol-1-phosphate phosphatases although the plant enzymes have now been shown to 
have much higher activity to L-galactose-1-phosphate than to myo-inositol-1-phosphate 
(Laing et al, 2004). Given the high similarity between LmjF17.1390 and the A. thaliana 
protein, together with the fact that the L. major protein is more similar to it than any other 
A. thaliana protein, it is likely that LmjF17.1390 protein is a L-galactose-1-phosphate 
phosphatase. Due to the differences in size between the plant protein and LmjF 15.0880 and 
the large insertions that appear to be present in the L. major protein based on the alignment 
with the A. thaliana sequence, it is unclear whether LmjF15.0880 may also act as a L- 
galactose-1-phosphate phosphatase. Interestingly, a blast search of the mouse protein 
database revealed there to be a very similar protein to the A. thaliana L-galactose-1- 
phosphate phosphatase (identification number NP061352) and this will be discussed in 
section 6.3 of this chapter. An alignment of this mouse sequence, together with A thaliana 
L-galactose-1-phosphate phosphatase and LmjF17.1390 is shown in figure 6.3.
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Figure 6,3: Alignment of A. thaliana L-galactose-1-phosphate phosphatase with the most 
similar L. major sequence, LmjF17.1390, and a putative mouse L-galactose-1-phosphate 
phosphatase. A. thal LG1PP and mouse LG1PP-A. thaliana and putative Mus musculus L- 
galactose-l-phosphate phosphatase (identification number NP061352)i respectively. Dashes 
indicate gaps in the alignment. Identical residues are printed in white on a black background, 
conserved residues are printed in white on a grey background and similar residues are printed in 
black on a grey background.
2 5 0  ■VIlfpE l E f P S  E^M#':T DVS
6.2.1.4 L-galactose dehydrogenase and D-arabinose dehydrogenase
The plant enzyme that catalyses the next step in ascorbate synthesis via the L-galactose 
pathway is L-galactose dehydrogenase, which is similar in both sequence and function to 
the yeast erythroascorbate synthesis protein D-arabinose dehydrogenase. These enzymes 
catalyse the conversion of L-galactose to L-galactono-1,4-lactone and of D-arabinose to D- 
arabinono-1,4-lactone, respectively, although the yeast enzyme can use also L-galactose as 
a substrate. The amino acid sequences of A thaliana L-galactose dehydrogenase and the S. 
cerevisiae D-arabinose dehydrogenase were used as enquiry sequences in blastp searches: 
the two most similar proteins to the plant sequence were the 286 amino acid LmjFB 1.2880 
(p/n value -  1.5e'^ )^ and the 279 amino acid LmjF32.0460 (p/n value = 3.1e‘^ )^ and the two 
most similar to the yeast sequence were LmjF32.0460 (p/n value = 1.2e"^ )^ together with 
the 285 amino acid LmjF31,2150 (p/n value -  1.5e"^ )^. LmjF31.2880 and LmjF32.0460
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share 20% and 23% identity, respectively, and 40% and 41% conservation, respectively, 
with A. thaliana L-galactose dehydrogenase. Reflecting these relatively low scores, when 
the L. major sequences were used as enquiry sequences to search the A. thaliana protein 
database, there were 35 more similar proteins to LmjF32.0460 and 28 more similar 
proteins to LmjF31.2150 than the L-galactose dehydrogenase. Meanwhile LmjF32.0460 
and LmjF31,2150 share 37% and 35% identity, respectively, and both share 54% 
conservation with S. cerevisiae D-arabinose dehydrogenase. However, again the single 
organism blast searches show that these predicted proteins are more similar to S. cerevisiae 
proteins other than D-arabinose dehydrogenase: 4 other proteins were more similar to 
LmjF32.0460 and 3 were more alike LmjF31.2150. LmjF32.0460 is similar to both the 
yeast and plant sequences; this was expected due to the similarity between the two proteins 
although the p/n scores together with the identity and conservation percentages clearly 
show that LmjF32,0460 is most similar to the yeast enzyme. LmjF31.2150 is also much 
more like D-arabinose dehydrogenase than LmjF31.2880 is to L-galactose dehydrogenase. 
However, the results of the single organism blast searches suggest that none of these four 
L  major sequences actually encode proteins involved in ascorbate biosynthesis as they are 
all more similar to proteins with different fimctions.
6.2,1.5 D-galacturonic acid reductase
Interestingly, a blast search using strawberry D-galacturonic acid reductase as the enquiry 
sequence identified the same L. major proteins as the searches using the A thaliana L- 
galactose dehydrogenase and S. cerevisiae D-arabinose dehydrogenase sequences. D- 
galacturonic reductase operates in a separate plant ascorbate synthesis pathway catalysing 
the conversion of D-galacturonic to L-galactonic acid, which is then converted to L- 
galactono-1,4-lactone, and has not previously been shown to be similar to these other 
ascorbate synthesis proteins. The most similar proteins to the 319 amino acid strawberry 
D-galacturonic reductase were LmjF31.2150 (p/n value = 2.0e'^^) and LmjF32.0460 (p/n 
value = 9.5e'^^). LmjF31.2150 shares 37% identity and 56% conservation with strawberry 
D-galacturonic reductase while LmjF32.0460 shares 38% identity and 59% conservation. 
Alignments between the amino acid sequences and that of the strawberry protein showed 
that the L. major sequences both contained small deletions as compared to the other 
sequence, reflecting the 35/40 residue size difference. When the sequences were used to 
blast search the A. thaliana protein database there were two proteins more similar to the L. 
major sequences than the D-galacturonic reductase with the most alike protein in each case 
being annotated as a putative oxidoreductase. Therefore, despite the fact that LmjF31.2150 
and LmjF32.0460 are both more similar to D-galacturonic reductase than to L-galactose
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dehydrogenase or D-arabinose dehydrogenase, they may encode proteins that are not 
involved in ascorbate biosynthesis. This seems even more likely for LmF31.2150, which 
has been experimentally shown to possess prostaglandin f2-alpha synthase activity 
(Kabututu et al, 2003).
6.2.1.6 Aldono-lactonase
The enzyme that catalyses the penultimate step in ascorbate synthesis in mouse -  and 
presumably therefore in other mammals that synthesise ascorbate via the uronic acid 
pathway -  was recently identified as an aldono-lactonase which is not similar to the 
proteins performing this step in other organisms described in the previous two paragraphs. 
Accordingly, the L major sequence most similar to the 299 amino acid mouse sequence 
was the 413 amino acid LmjF28.1230 (p/n value = 1.4e'^ )^, not a protein identified in a 
previous blast search. LmjF28.1230 shares 24% identity and 43% conservation with the 
amino acid sequence of the mouse aldono-lactonase; an alignment of the two sequences is 
shown in figure 6.4. Alignment of the two proteins showed that the L major sequence had 
several small insertions, together with a small C-terminal extension in comparison to the 
mouse sequence. However when LmjF28.1230 was used as an inquiry sequence in a blastp 
search of mouse proteins, the most similar was the aldono-lactonase. This is intriguing, as 
despite the relatively low identity and conservation scores, and the discrepancies between 
the alignments of the two sequences, LmjF28.1230 is not more similar to any other mouse 
protein. It is also annotated as a sequence orphan in the L, major database. Therefore it 
remains possible that LmjF28.1230 does encode an aldono-lactonase involved in ascorbate 
biosynthesis.
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Figure 6.4: Alignment of mouse aldono lactonase with the most similar L. major sequence, 
LmjF28.1230. Mouse A-lac -  Mus musculus aldono lactonase. Dashes Indicate gaps In the 
alignment Identical residues are printed In white on a black background and similar residues are 
printed In black on a grey background.
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6.2.1.7 GLO, ALO and GALDH
The final step in ascorbate production in the mammalian, yeast and the plant L-galactose 
and D-galacturonic acid pathways is catalysed by a similar enzyme: GLO in mammals, 
ALO in yeast and GALDH in plants. Representative sequences of all three proteins -  the 
440 amino acid pig GLO, the 526 amino acid S. cerevisiae ALO and the 610 amino acid A. 
thaliana GALDH - were used in blast searches of L. major predicted proteins and the same 
sequence was identified in each: Lmj*F17.1360 (p/n values = 9.6e‘^ ,^ 3.2e"^  ^and 6.7e"^ ,^ 
respectively). LmjF17.1360, which is 502 amino acids in length, shares 28% identity and 
54% conservation with pig GLO, 19% identity and 38% conservation with S. cerevisiae 
ALO, and 20% identity and 42% conservation with A thaliana GALDH. Alignments 
between the sequences, shown in figure 6.5, reveal that LmjF 17.1360 has a small C-
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terminal extension and a 55 amino acid insertion in comparison to the pig GLO, is lacking 
a 100 amino acid N-terminal extension when compared to the A. thaliana GALDH and 
aligns poorly with 6". cerevisiae ALO in the middle of the sequences. When LmjF 17.1360 
was used as an enquiry sequence to search the protein databases of pig, A. thaliana and S. 
cerevisiae, the L. major sequence was most like the GLO, GALDH and ALO respectively. 
This suggests that LmjF17.1360 is likely to encode a protein capable of mediating the final 
step in ascorbate biosynthesis in Leishmania, Given the much higher p/n value and identity 
and conservation scores between it and the pig sequence rather than those of plant or yeast, 
it appears that LmjF17.1360 is most closely related to GLO and will be herein referred to 
as LmGLO. This sequence shares 45% identity and 64% conservation with the recently 
identified T. brucei enzyme TbALO (Wilkinson et al, 2005) described in section 6.1.5 of 
this chapter. However, based on substrate preference, the authors concluded that the 
enzyme is most similar to ALO or GALDH rather than GLO, which contrasts with which 
enzyme it is most closely related to based on amino acid sequence similarity alone.
6.2.1.8 Inositol oxygenase
Inositol oxygenase is the only other protein involved in ascorbate synthesis to have been 
identified and characterised to date. The protein is thought to participate in an alternative 
pathway in plants, converting myo-inositol to D-glucuronic acid. The L, major predicted 
protein database was searched with the 317 amino acid sequence ofW. thaliana inositol 
oxygenase and the most similar protein (p/n value 0.51) was the 378 amino acid 
LmjF18.1380. LmjF18.1380 shares just 14% identity and 32% conservation with the A, 
thaliana protein, poorly aligns with the sequence and has N- and C- terminal extensions 
compared to it. When the L, major sequence was used to search the A, thaliana protein 
database there were 38 more similar proteins to it than the inositol oxygenase; the most 
alike was a pyruvate dehydrogenase which was also what Lmj F18.1380 was annotated as 
in the L. major database. Taking all this information together, it is highly unlikely that 
LmjF 18.1380 encodes an inositol oxygenase involved in ascorbate synthesis.
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Figure 6.6: Alignment of A. thaliana GALDH, S. cerevisiae ALO and pig GLO with the most 
similar L. mayor sequence, LmjF17.1360, and the similar trypanosome enzyme, T. brucei 
ALO. A. thal GALDH -  A. thaliana GALDH, S. cev ALO -  S. cerevisiae ALO, pig GLO -  Sus scrofa 
GLO. The putative T. brucei ALO C-terminal SHL signalling tag which Is absent In the L major 
sequence is underlined In red. Dashes Indicate gaps In the alignment. Identical residues are printed 
In white on a black background, conserved residues are printed in white on a grey background and 
similar residues are printed in black on a grey background.
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This analysis does not provide any definitive proof of which ascorbate pathways, if any, 
are present in L. major. However, it seems reasonable to conclude that some of the 
sequences identified may have a role. LmjF 17.1390 is very like the A. thaliana L- 
galactose-1-phosphate phosphatase. Meanwhile LmjF28.1320 and LmjF 17.1360 are 
similar to the only known enzymes that mediate the mammalian ascorbate biosynthesis 
pathway: the recently identified mouse aldono-lactonase and pig GLO. Crucially, these L  
major sequences were more similar to ascorbate biosynthesis enzymes, which have no 
other known function, than any other proteins in the species the original enquiry sequences 
were derived from. Thus, they were judged to be the most likely to be involved in 
ascorbate synthesis in Leishmania. The importance of GLO in ascorbate synthesis in 
mammals is paramount: humans lack this enzyme and therefore have to derive ascorbate 
from their diet. Whether LmGLO has a similar role in the parasite was investigated, and is 
discussed herein.
Enquiry sequence: 
organism, enzyme 
name, and amino acid 
length
Leishmania 
homologues, p/n 
scores and 
number of 
amino acids
% identity, % 
conservation and 
observations on 
alignments
Single organism 
back BLAST 
results
1. S. cerevisiae D- 
arabinonose 
dehydrogenase 
(NP009707), 344 
amino acids
a. LmjF32.0460
1.2e"^  , 279 amino 
acids
b. LmjF31.2150
1.5e"^ ,^ 285 amino 
acids
a. 37%, 53%. N- 
term more alike.
b. 35%, 54%. L. 
maj seq 30 amino 
acid gap 137-167.
a. 5“* hit to enq seq. 
Best is glycerol 
dehydrogenase.
b. 4* hit to enq seq. 
Best is as above.
2. S. cerevisiae D- 
arabinono-1,4-lactone 
oxidase (NPO13624), 
526 amino acids
LmjF17.1360
3.2e'^ ,^ 502 amino 
acids
19%, 38%.
Middle of 
sequences display 
poor similarity.
Best hit to enq seq.
Table 6.2: L. major sequences similar to ascorbate biosynthesis enzymes in fungi.
Abbreviations used are L. maj -  L major, seq -  sequence, ext -  extension, N-term -  N-terminal, C- 
term -  C terminal, enq -  enquiry. Numbers in first column correlate with those in figure 6.1.
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Enquiry sequence: 
organism, enzyme 
name, and amino acid 
length
Leishmania 
homologues, p/n 
scores and 
number of 
amino acids
% identity, % 
conservation and 
observations on 
alignments
Single organism 
back BLAST 
results
3. Mouse aldono 
lactonase (NP033086), 
299 amino acids
LmjF28.1230
1.4e'*^ , 413 amino 
acids
24%, 43%. Six 
small gaps in 
mouse seq. L. maj 
seq also has small 
C-term ext.
Best hit to enq seq.
4. Pig L-gulonolactone 
oxidase (Q8HXW0), 
440 amino acids
LmjF17.1360
9.6e'^ ,^ 502 amino 
acids
28%, 54%. Pig 
seq. contains a 55 
amino acid gap. 
235-290. L. maj 
seq has small C- 
term ext.
Best hit to enq seq.
Table 6.3: L. mayor sequences similar to ascorbate biosynthesis enzymes in animals.
Abbreviations used are L. maj -  L major, seq -  sequence, ext -  extension, N-term -  N-terminal, 0- 
term -  C terminal, enq -  enquiry. Numbers in first column correlate with those in figure 6.1.
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Enquiry sequence: 
organism, enzyme 
name, and amino acid 
length
Leishmania 
homologues, p/n 
scores and 
number of 
amino acids
% identity, % 
conservation and 
observations on 
alignments
Single organism 
back BLAST 
results
5. A. thaliana GDP-6- 
mannose
pyrophosphorylase 
(AAC78474), 361 
amino acids
LmjF23.0110
1.2e'^ ' ,^ 379 amino 
acids
50%, 70%. 
Region between 
250-270 displays 
poor similarity.
Best hit to enq seq.
6. A. thaliana GDP- 
mannose-3’,5’- 
epimerase 
(CAD70055), 377 
amino acids
Lmj26.2230
9.9e'*, 446 amino 
acids
22%, 40%. L. maj 
seq has N-term 
ext. Also, gaps in 
A. thaliana N- 
term
42"  ^hit to enq seq. 
Best is NADPH- 
dependant 
epimerase/dehydro 
genase.
7. A. thaliana L- 
galactose-1 -phosphate 
phosphatase 
(NPOO1030626), 269 
amino acids
a. LmiF17.1390
1.8e"^  , 288 amino 
acids
b. LnijF15.0880
2.1e'^ , 466 amino 
acids
a. 35%, 55%. 
Good similarity.
b. 32%, 49%. 
Large gaps in A. 
thaliana seq. N- 
and C- term ext. 
in L. maj seq.
a. Best hit to enq 
seq.
b. Best hit to enq 
seq.
8. A. thaliana L- 
galactose 
dehydrogenase 
(CAD10386),319 
amino acids
a. LmiF31.2880
1.5e*’ , 286 amino 
acids
b. LmjF32.0460
3.1e‘‘^  279 amino 
acids
a. 20%, 40%. 
Better similarity 
in N-term.
b. 23%, 41%. 
Quite poor 
overall.
a. 36^ hit to enq 
seq. Best is 
oxidoreductase.
b. 29^ hit to enq 
seq. Best is as 
above.
9. A. thaliana L- 
galactono-1,4-lactone 
dehydrogenase 
(NP190376),610 
amino acids
LmjF17.1360
6.7e’^ ,^ 502 amino 
acids
20%, 42%. L. maj 
seq lacks first 100 
amino acids.
Best hit to enq seq.
10. A. thaliana inositol 
oxygenase 
(AAP59548), 317 
amino acids
LmjF18.1380
0.51, 378 amino 
acids
14%, 32%. L. maj 
seq N- and C- 
term ext. Also 
small gaps in A. 
thaliana seq.
39“* hit to enq. seq. 
Best is pyruvate 
dehydrogenase.
11. Strawberry D- 
galacturonic reductase 
(AAT76306), 319 
amino acids
a. LnnF31.2150
2.0e'^ , 284 amino 
acids
b. LmjF32.0460
9.5e'^ ,^ 279 amino 
acids
a. 37%, 56%. 
Small gaps in L. 
maj seq.
b. 38%, 59%. 
Small gaps in L. 
maj seq.
a. 3*^  ^hit to enq seq. 
Best is
oxidoreductase
b. 3*^“ hit to enq seq. 
Best is
oxidoreductase.
Table 6.4: L. mayor sequences similar to ascorbate biosynthesis enzymes in plants.
Abbreviations used are L. maj -  L major, seq -  sequence, ext -  extension, N-term -  N-terminal, C- 
term -  C terminal, enq -  enquiry. Numbers in first column correlate with those in figure 6.1.
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6.2.2 LmGLO expression in Leishmania
In order to clarify whether LmGLO expression could be detected, western blots were 
performed on various Leishmania species promastigote lysates, using rat anti-sera that had 
been raised to recombinant LmGLO (figure 6.6). As well as L. major, L. infantum and L 
mexicana lysates were also used as sequences with 94% and 81% identity to LmGLO are 
present in the L. infantum and L. braziliensis protein databases, respectively. Both the first 
and final bleed batches of antisera were used for western blotting (figure 6.6A and 6.6B, 
respectively) but unfortunately both antibodies detected several different proteins. The first 
bleed antiserum detected the 57 kD 6-His LmGLO recombinant protein and in the L. major 
promastigote lysate a slightly smaller band that may be LmGLO (untagged LmGLO is 
predicted to be 56 kD). Unfortunately this could not be further investigated as all of the 
antiserum obtained from the first bleed was used in this experiment and when re-used did 
not detect either the recombinant protein or any proteins from Leishmania lysates. In 
addition to the ~56 kD band the first bleed antibody detected several larger proteins, which 
were presumed to be due to non-specific cross-reactivity of the anti-sera. The final bleed 
antiserum detected many proteins, both in the recombinant protein fraction and in the 
parasite lysates. One of the proteins detected appeared to be of around the expected size of 
LmGLO, however, despite repeated attempts to optimise the conditions of the western blot 
when using the antiserum, it was impossible to distinguish the band and discern any useful 
information regarding endogenous LmGLO expression.
B
LmGLO
CS
1-bleed 2"" bleed
Figure 6.6: Western blot analysis of LmGLO expression in the soluble fraction of Leishmania. A -  first bleed antiserum. A protein of a slightly smaller size than the annotated 
LmGLO recombinant protein is visible in the L  mayor lysates. B -  second bleed antiserum. 10 pg- 
30 pg of parasite lysate was loaded per lane. CS, cysteine synthase, (control).
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6.2.3 Creation of LmGLO over-expressing L. major promastigotes
The sequence encoding LmGLO was amplified from L major genomic DNA, sub-cloned 
into the pGEM T-easy and then cloned into the pGL102 plasmid. The plasmid with the 
LmGLO gene was named pGL102LmGLO; maps of this and the empty vector are shown in 
figure 6.7. The pGL102 plasmid is a Leishmania episomal expression vector and contains 
the neomycin resistance gene as a selectable marker. Uncut pGL102 and pGL102LmGLO 
were transfected into L. major promastigotes which were subsequently incubated in culture 
with neomycin so that only successful transformed parasites would grow. The transformed 
parasite lines will be herein referred to by the names of the vectors they were transformed 
with.
pGL102
6794 bp3’13K
amp
5'DST Sma \ (1366)
3*13K
pGL102LmGLO
8303 bp LmGLO
amp
Figure 6.7: Plasmids for the over-expression of LmGLO in L. major promastigotes.
Schematic representation of the pGL102 plasmid for the over-expresslon of LmGLO In Leishmania. 
A -  empty pGL102 vector, for use as a negative control. B -  pGL102 + LmGLO (pGL102LmGLO) 
for the over-expresslon of LmGLO. amp, amplclllln resistance gene; neo, neomycin resistance 
gene. The restriction sites used to clone LmGLO Into the vector are shown In dark red.
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6.2.4 Phenotype analysis of L. major putative LmGLO over­
expressing lines
Due to the failure of the anti-LmGLO antiserum to detect LmGLO specifically, it was not 
possible to confirm the over-expression of LmGLO in the parasites and the phenotypic 
analysis presented in this section must be regarded in this context.
6.2.4.1 Morphology and growth of promastigotes
Parasites putatively over-expressing LmGLO were examined microscopically and no 
morphological differences could be seen between them and the parasites containing the 
empty pGL102 vector. After several passages with neomycin present in the culture media, 
the pGL102 and pGL102LmGLO lines were counted and diluted to the same 
concentration. Thereafter their growth was monitored by daily counting (figure 6.8). The 
parasite lines were found to grow at similar rates.
1.00E+08
E 1.00E+07.1
2 & 1.00E+06
1.00E+05 1
PGL102
pGL102LmGLO
0 2 4 6 8
Number of days
Figure 6.8: Growth curves of pGL102 and pGL102LmGLO L. mayor promastigotes. Cultures 
were seeded at a concentration of 2 x 10® parasites/ml and were counted daily. Both lines were 
grown with 50 pg/ml neomycin.
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6.2 4.2 In vitro infectivity to macrophages
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The ability of the different stationary phase promastigote parasite lines to infect peritoneal 
macrophages was assessed (figure 6.9). pGL102LmGLO infected a higher percentage of 
macrophages than either the pGL102 or WT lines: approximately 4 times and twice as 
many, respectively. This suggests that if pGL102LmGLO parasites are indeed over­
expressing LmGLO then this aids infection. However, the differences observed were not 
found to be significant, likely to be due to the lack of repetitions of this experiment: further 
investigation is required. The variation between the infection rates between the WT and 
pGL102 lines was also of concern as they would be expected to infect at a similar rate. It is 
possible that the pGL102 line have been adversely affected by the transformation 
procedure, causing them to be less infective in vitro.
60
I  40I 30
"So 20 0)
10
WT pGL102 pGL102LmGLO
Figure 6.9: Infectivity of WT, pGL102 and pGL102LmGLO L. mayor promastigotes to 
macrophages. Stationary phase promastigotes were used to infect peritoneal macrophages at a 
rate of 2:1 and the slides were incubated for 5 days post-infection. Results are the means ± SE 
from two experiments. The WT and pGL102LmGLO lines did not infect the macrophages at 
significantly different rates (p > 0.05).
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6.2.4 3 In vivo infectivity to mice
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To assess in vivo infectivity, pGL102LmGLO, pGL102 and WT stationary growth-phase 
promastigotes were inoculated into mouse footpads, the thicknesses of which were then 
measured over time (figure 6.10). The results broadly reflected those of the in vitro 
infectivity experiments: pGL102LmGLO parasites were responsible for the most rapid 
footpad growths which were slightly, but not significantly, faster than those infected with 
the WT parasites, while footpads infected with pGL102 parasites took approximately 2 
weeks longer to reach similar thicknesses. Over-expression of LmGLO is from an 
episomal expression vector, the presence of which is assured by keeping the parasites 
under neomycin pressure. This is not possible during in vivo work and the number of 
episomes, and therefore the level of LmGLO expression, is likely decrease over time. This 
may explain why the increased infectivity of pGL102LmGLO parasites as compared to the 
WT and pGL102 lines is not as marked as in the macrophage infectivity experiment, where 
infections are monitored over days as opposed to weeks. Once more the pGL102 parasites 
caused less virulent infections than the WT parasites, which again may be indicative of 
them being compromised in some way by the transformation procedure. This will be 
discussed in more detail in section 1.3.
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Figure 6.10: Infectivity of WT, pGL102 and pGL102LmGLO, L. mayor promastigotes to mice.
5x10® stationary-phase promastigotes were resuspended in 20 pi PBS and inoculated into one 
footpad of each BALB/C mouse. The footpad thicknesses were subsequently measured weekly, 
and the results are the means ± from five mice. The WT and pGL102LmGLO infections were not 
significantly different (p > 0.05).
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6.2.5 Creation of L. major LmGLO knock-out parasite lines
The 3’ and 5’ flanking regions of LmGLO were amplified from L major genomic DNA, 
sub-cloned into pET28a(+) and cloned into vectors pGL345 and pGL842 which contain 
hygromycin and blasticidin resistance genes, respectively (figure 6.11). The constructs 
containing the flanking regions and drug resistance markers were cut out and purified and 
the linear DNA was used to transform L  major promastigotes. Two independent lines, 
K0LmGL03 and K0LmGL08, were generated, both having undergone transformation 
with each of the constructs sequentially and grown up in the presence of the selection 
drugs. In addition, following the second transfection and overnight recovery period, the 
two independent cultures were divided and ascorbate was added to one of each to a final 
concentration of 10 mM. This was to ensure that it would be available if the loss of 
LmGLO resulted in the parasites having to exogenously source their ascorbate. 
K0LmGL08 grew up to stationary phase regardless of whether ascorbate had been added 
to the media, while only the K0LmGL03 culture that contained ascorbate grew up 
quickly. After several passages in the selective drugs, K0LmGL03 and K0LmGL08 
clones were derived by setting up the cultures with ascorbate in 96-well plates at a 
concentration of approximately 0.1 parasites/well. Two clones were isolated from 
K0LmGL03 -  deemed KOLmGLOAl and KOLmGLOA2 -  and one clone was derived 
from K0LmGL08: KOLmGLOB. All three clones took several weeks to grow up.
LmGLO 5 'flank Sail {I)
HindWl (6808) DHFR flank
I (944)
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amp pGL345 LmGLO 3' and S' flanks7301 bp fiomHI(l997)
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gg/H (4005) Sma\(3367)
LmGLO 3' flank
Figure 6.11 : Construct for the gene knock-out of LmGLO in L  major promastigotes.
Schematic representation of the pGL345 plasmid containing the LmGLO 3' and 5" flanking regions. 
The second plasmid used for the construction of the LmGLO knock-out was the pGL842 plasmid, 
which is exactly the same except that it contains a blasticidin rather than hygromycin resistance 
gene. Hyg, hygromycin resistance gene; amp, ampicillin resistance gene; DHFR flanks, flanking 
regions of the dihydrofolate reductase gene. The restriction sites used to clone the LmGLO flanks 
and hygromycin resistance gene into the vector are shown in dark red. Hindlll and Bglll were used 
to cut out the flank-containing linear construct for transfection into L. major.
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Because it was not possible to ascertain whether LmGLO had been successfully knocked 
out by western blotting, a southern blot was performed on genomic DNA derived from 
KOLmGLOAl and KOLmGLOA2 and KOLmGLOB, together with WT parasites. The 
DNA was digested with restriction enzymes that, depending on whether the WT or 
replacement allele was present, would yield fragments of different lengths containing the 
LmGLO 3’ flanking region (figure 6.12A). The 3’ flanking region was used as a probe and 
would hybridise to a fragment of approximately 1.4 kb if the WT allele was present, 2.4 kb 
if the blasticidin resistance gene was present and 3.7 kb if the hygromycin resistance gene 
was present. Unfortunately no fragments were detected in the WT and KOLmGLOAl and 
KOLmGLOA2 digested DNA samples. However, fragments of approximately 2.4 kb and
3.7 kb were detected in the KOLmGLOB sample (figure 6.12B), corresponding to both 
resistance markers that would be present in a bona fide LmGLO knockout. Therefore it 
was concluded that KOLmGLOB lacks LmGLO. The absence of fragments detected in 
KOLmGLOAl and KOLmGLOA2 suggest it is unlikely that they are genuine LmGLO 
knockouts although the experiment was inconclusive.
6.2.6 Phenotype analysis of L  major LmGLO knock-out parasite 
lines
The parent lines of the clones, K0LmGL03 (which KOLmGLOAl and K0LmGL0A2 
were derived from) and KOLmGLOB (which KOLmGLOB was derived from) were 
analysed in some experiments as the clones took a long time to obtain. As well as 
examining the phenotype of KOLmGLOB -  deemed to be a genuine LmGLO knockout -  
KOLmGLOAl and KOLmGLOA2 and their parent lines were also included in 
experiments. This was because, although unlikely to lack LmGLO, they would act as 
useful controls due to them having undergone the same transformation procedure and 
exposure to drugs as KOLmGLOB.
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Figure 6.12: Southern blot analysis of the LmGLO locus of L  major KOLmGLO lines. A -
Southern blot analysis of genomic DNA extracted from the different parasite lines as indicated 
above the gel image. The 2.4 kb and 3.7 kb bands visible in the lane containing DNA from the 
KOLmGLOB clone are indicated with red arrows. The blot was exposed to the film for 7 days. The 
positions and sizes of the molecular size markers are indicated to the left of the gel image; kb, kilo 
base pairs. B -  schematic representation of the LmGLO locus on chromosome 17 (LmGLO shown 
in blue), and the altered locus following successful gene replacement with either the hyg 
(hygromycin) or bsd (blasticidin) resistance markers (shown in red). The expected sizes of the 
fragments following digestion of the genomic DNA with Xhol and Sa//, to be detected by southern 
blot using the 3’ flanking region as a probe, are indicated below each diagram and represented with 
a black line. The restriction sites and their relative positions are also shown.
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6.2.6.1 Growth of promastigotes grown with and without exogenous 
ascorbate
As described, K0LmGL03 and KOLmGLOS were originally divided and grown with and 
without ascorbate (+asc and -asc) added to the culture media although only KOLmGLOS 
with exogenous ascorbate thrived. After several passages, the growth rates of the 
remaining three cultures — K0LmGL03+asc, K0LmGL08-asc and K0LmGL08+asc -  
were monitored as before (figure 6.13). The three parasite lines grew at similar rates 
although K0LmGL03+asc grew slightly faster than K0LmGL08+asc which grew faster 
than K0LmGL08-asc. However the most marked difference between the cultures was in 
the concentrations the parasites reached when in the stationary phase of growth. After 
several days K0LmGL03+asc grew to and remained at a density of ~2 x 10^  parasites/ml, 
as WT parasites do under similar conditions. Meanwhile K0LmGL08-asc and 
K0LmGL08+asc reached concentrations of just -0.7 x lOVml and 0.9 x 10^ /ml 
respectively, even after 10 days in culture. KOLmGLOB, derived from K0LmGL08+asc, 
was the only clone found to lack the LmGLO gene while the clones derived from 
K0LmGL03+asc were shown to be unlikely to lack the gene. Therefore it is possible that 
the loss of LmGLO causes a growth defect in L. major promastigotes, causing the parasites 
to grow more slowly than usual and to fail to reach high densities. This is in accordance 
with the growth defect observed in bloodstream form T. brucei lacking the homologous 
gene to LmGLO (Wilkinson et ai, 2005). Also, the observation that K0LmGL08-asc 
grows at a slightly slower rate and reaches lower parasite densities in culture than 
K0LmGL08+asc suggests that the presence of exogenous ascorbate may have had a 
beneficial effect in the early stages of transformation.
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Figure 6.13: Growth curve of WT, K0LmGL03+asc, KOLmGLOB+asc and KOLmGLOS-asc L. 
major promastigotes. Cultures were seeded at a concentration of 2 x 10  ^parasites/ml and were 
counted daily. All lines except WT parasites were grown with 15 pg/ml blasticidin and 100 pg/ml 
hygromycin. K0LmGL03+asc and K0LmGL08+asc were also grown with 1 mM ascorbate 
present.
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The three cultures were also grown with and without added ascorbate to ascertain if its 
inclusion in the culture media affected the growth rates of the parasites after they had been 
in culture for several passages (figure 6.14). Exogenous ascorbate had no affect on the 
growth of any of the cultures at this stage and was subsequently omitted from the culture 
media.
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Figure 6.14: Growth curves showing K0LmGL03+asc, KOLmGLOB+asc and KOLmGLOS- 
asc with and without exogenous ascorbate. Cultures were seeded at a concentration of 2 x 10  ^
parasites/ml and were counted daily. All lines were lines were grown with 15 pg/ml blasticidin and 
100 pg/ml hygromycin. Ascorbate was added to cultures as indicated to a final concentration of 10 
mM. Exogenous ascorbate had no effect on the growth rates of these L  mayor lines.
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6.2.6 2 In vitro infectivity to macrophages
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The ability of KOLmGLOS and KOLmGLOS stationary phase promastigote parasite lines 
to infect peritoneal macrophages was assessed (figure 6.15). Both these lines had 
previously been grown with ascorbate, as described. KOLmGLOS infected a similar 
percentage of macrophages as WT parasites: approximately 20%. However KOLmGLOS 
parasites infected a lower number of cells: approximately just 5%. Once again, the 
difference in phenotype is observed in the parent line of the clone found to be genuine 
LmGLO knockouts. Therefore the loss of LmGLO may also cause reduced infectivity in L. 
major in vitro. However, despite the variation in infection levels observed between the WT 
and KOLmGLOS lines, the difference was not found to be significant. This is likely to be 
due to the high standard errors and the low number of replicates performed and further 
investigation is required to show conclusively that the LmGLO knockout parasites are 
defective in their ability to infect macrophages.
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Figure 6.15: Infectivity of WT, KOLmGLOS and KOLmGLOB L. ma/or promastigotes to 
macrophages. Stationary phase promastigotes were used to infect peritoneal macrophages at a 
rate of 2:1 and the slides were incubated for 5 days post-infection Results are the means ± SE 
from at least two experiments. The WT and KOLmGLOB lines did not infect the macrophages at 
significantly different rates (p > 0.05).
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6.2.6 3 In vivo infectivity to mice
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In vivo infectivity of the clones KOLmGLOAl and KOLmGLOB were assessed. Parasites 
in the stationary phase of growth were inoculated into mouse footpads, the thicknesses of 
which were then measured over time (figure 6.16). Relative to the infections caused by WT 
parasites, infections caused by KOLmGLOB were significantly much less rapid in growth, 
as determined by the increase in footpad thicknesses. After five weeks the footpads 
infected with WT parasites had increased from an average of 1.8 mm to 4.3 mm while 
those infected with KOLmGLOB parasites had reached an average of just 2.1 mm. Similar 
results were obtained with KOLmGLOAl parasites. After 10 weeks the KOLmGLOB 
infected footpads were on average 4 mm thick while those infected with KOLmGLOAl 
were on average just 2.5 mm although did continue to increase thereafter. So both clones 
caused attenuated infections to occur as compared to WT parasites. Given that 
KOLmGLOB was shown to lack LmGLO while KOLmGLOAl is unlikely to, this was an 
unexpected result. In order to grow in the presence of the selective drugs, the 
KOLmGLOAl parasites must either be supporting one or more extra-chromosomal 
plasmids or have one or more constructs, intended for integration at the LmGLO locus, 
integrated elsewhere in their genome. It is reasonable to consider that either of these 
scenarios could be detrimental to the parasites, explaining their decreased infectivity to 
mice, but that the reduced infectivity of the KOLmGLOB parasites may be due to the loss 
of the LmGLO gene. However, it is also possible that both clones were damaged during 
the transformation procedure, hence the similar phenotype observed.
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Figure 6.16: Infectivity of WT, KOLmGLOAl and KOLmGLOB L. mayor promastigotes to 
mice. 5x10^ stationary-phase promastigotes were resuspended in 20 pi PBS and inoculated into 
one footpad of each BALB/C mouse. The footpad thicknesses were subsequently measured 
weekly, and the results are the means ± SD from five mice. The footpad thicknesses of mice 
infected with WT parasites were significantly greater than those of mice infected with KOLmGLOB 
five weeks post-infection (p < 0.0004).
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6.3 Discussion ;:’ï
Ascorbate synthesis was originally of interest due to the ability of TDRl to reduce oxidised 
ascorbate in vitro. Whether TDRl also functions as a dehydroascorbate reductase in I
Leishmania remains controversial. As detailed in the introduction to this chapter, reduction 
of dehydroascorbate is thought to occur non-enzymatically by trypanothione (Krauth- 
Siegel and Ludemann, 1996) as parasite lysates failed to increase ascorbate being formed 
in in vitro experiments. However, in order to minimise spontaneous reaction the assay was 
performed at pH 6.5 although the optimal pH for DEAR activity in vitro has previously 
been reported to be -8.0 (Maellaro et al, 1997; Girardini et al, 2002). Therefore the pH 
may have prevented GSH-dependant DEAR activity being detected in the assay; the 
absence of a positive control being performed means this cannot be ruled out.
Trypanosomatids do not possess glutathione reductase, which, as detailed in section 6.1.4, 
is important for dehydroascorbate reduction by glutathione-dependant enzymes, as it in 
turn recycles glutathione. As trypanosomatids instead possess trypanothione reductase, it 
may be the case that trypanothione-dependant proteins would be responsible for any 
enzymatically mediated recycling of ascorbate. This would be analogous to Leishmania 
containing trypanothione S-transferases rather than glutathione S-transferases, as has 
recently been shown (Vickers et al, 2004). However, glutathione can be reduced by 
trypanothione and glutathione-dependant enzymes do prevail in trypanosomatids 
(Wilkinson et al, 2002b). Whether any enzymatic DEAR present in T. cruzi could have 
been dependant on trypanothione rather than glutathione has not been investigated.
The recently published account of TbALO (Wilkinson et al, 2005), an ALO-like T. brucei 
enzyme capable of converting L-galactono-1,4-lactone to ascorbate and D-arabinono-1,4- 
lactone to erythroascorbate, to an extent addresses the initial questions postulated here of 
whether trypanosomatids were capable of synthesising ascorbate and whether it was 
important for viability. LmGLO shares 45% identity with TbALO although the region 
between amino acid 235 and amino acid 320 poorly aligns and is of very low similarity. It 
may be significant that LmGLO lacks the C-terminal SHL motif thought to target the T. 
brucei protein to the glycosome as differences in localisation of ascorbate synthesis 
between the parasite species could be indicative of diverse roles for ascorbate.
TbALO is so called because it is most like yeast ALO in terms of substrate specificity 
although investigation into the TbALO amino acid sequence revealed that, like LmGLO, it 
is most similar to mammalian GLOs. However TbALO was unable to utilise the 
mammalian substrate L-gulono-1,4-lactone, therefore diminishing the likelihood of the
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mammalian synthesis pathway operating in trypanosomatids. Indeed the authors of the 
TbALO paper propose that it is the plant L-galactose pathway that is most likely to be 
responsible for ascorbate synthesis in T. brucei, based on unnamed sequences that they 
have identified in the genome. Several sequences similar to those of plant ascorbate 
synthesis enzymes were identified in Leishmania (section 6.2.1). Due to the role of GDP-6- 
mannose pyrophosphorylase in a range of cellular processes, the presence in Leishmania of 
the similar sequence LmjF23.0110 may not be relevant to ascorbate synthesis and as such 
has not been considered here.
Conversely, the activity of the plant L-galactose-1-phosphate phosphatase protein is 
thought to be exclusive to the ascorbate synthesis pathway and therefore the discovery of 
the similar Leishmania sequence LmjF17.1390 was intriguing. However, analysis of the 
mouse -  and indeed human- protein databases revealed that they too possess similar 
sequences to L-galactose-1-phosphate phosphatase which were not more similar to any 
other A, thaliana protein. Clearly experimental characterisation is required to ascertain 
whether these mammalian proteins are involved in a different cellular process or whether 
they too have a role in ascorbate synthesis. For example it is feasible that they could 
dephosphorylate D-glucuronic acid-1 -phosphate (figure 6.1). The existence of the 
mammalian sequences certainly cast doubt on whether LmjF17.1390 is indeed a dedicated 
ascorbate synthesis protein exclusive to the plant L-galactose pathway. A set of proteins 
similar to yeast and plant enzymes that mediate the penultimate ascorbate synthesis steps - 
arabinose dehydrogenase, L-galactose dehydrogenase and galacturonic reductase were - 
also identified in Leishmania. However, these were all more similar to other yeast and 
plant proteins and one of them -  LmjF31.2150 -  has been experimentally characterised as 
a prostaglandin f2 alpha synthase (Kabututu et al, 2003). Meanwhile LmjF28.1230, which 
is similar to the mammalian aldono-lactonase which mediates the penultimate step in 
ascorbate synthesis in mouse, is more similar to the aldono-lactonase than any other mouse 
protein. Therefore the substrate specificity of TbALO is the only evidence of the plant 
pathway being operational in trypanosomatids. Controversy already exists over whether 
plant GALDH can utilise L-gulono-1,4-lactone as a substrate; A. thaliana cells used it as a 
precursor for ascorbate synthesis (Wolucka and Van Montagu, 2003) while purified sweet 
potato GALDH could only metabolise L-galactono-1,4-lactone (Oba et al, 1995). It is 
possible that activity with L-gulono-1,4-lactone is difficult to reproduce in vitro. It is clear 
that experimental characterisations of several enzymes - including LmGLO and the 
putative ascorbate synthesis proteins identified and described in this chapter - are required 
before any conclusions regarding which pathway(s) is responsible for ascorbate
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biosynthesis in the trypanosomatids. In addition the potential for Leishmania to scavenge 
different intermediates in the synthesis pathways should be addressed.
Indeed, the ability to scavenge ascorbate is the reason postulated to explain the exacerbated 
growth defect of T. brucei TbALO null mutants in ascorbate-Ifee media compared to 
normal media (Wilkinson et al, 2005). Serum is reported as having an ascorbate 
concentration of 40 pM but it is not stated what percentage of the final media is comprised 
by serum. Standard media is often 10% (v/v) serum, which would give a final 
concentration of 4 pM ascorbate, much lower than the reported Kms for known ascorbate 
and dehydroascorbate transporters (Rumsey et al, 1997; Daruwala et al, 1999; Rumsey et 
al, 2000). Although not described in detail here, searches of the L. major genome for 
possible transporters were conducted using enquiry sequences of known ascorbate 
transporters (as detailed in section 6.1.3). There were no significantly similar proteins to 
the sodium-dependant transporters SVCTl and SVCT2, or to the E. coli sgaT transporter. 
There was, however, a similar protein to the GLUT transporters, which was most like 
GLUTS. The GLUT transporters are only known to transport oxidised ascorbate 
(dehydroascorbate), and the method used by Wilkinson et al, to eliminate ascorbate fi-om 
the medium was to treat it with ascorbate oxidase, meaning that only dehydroascorbate 
would remain. Depleting the ascorbate in this way contributed to the growth defects of the 
TbALO knockout mutants, suggesting that they could accumulate ascorbate but not 
dehydroascorbate. Therefore, if trypanosomatids are able to uptake ascorbate from their 
surrounding environment, it is unlikely to be via GLUT-like transporters and may occur by 
a novel mechanism.
Ascorbate was added to a final concentration of 10 mM to L. major parasites that had just 
undergone the second transfection to knockout the LmGLO gene. This at first seemed to be 
beneficial as cultures that contained the added ascorbate grew better than those without. 
However there was no noticeable effect on growth when ascorbate was withdrawn from 
the cultures that had previously contained it, or added to the cultures that were previously 
without it. There was also no correlation between the presence of ascorbate in the media 
and successful LmGLO knockouts: all three clones were derived fi*om cultures that had 
contained ascorbate and of these only one, KOLmGLOB, proved to be a genuine LmGLO 
knockout.
The parent strain of KOLmGLOB exhibited several defects: promastigotes grew slowly in 
culture, did not reach high densities at the stationary phase of growth and were poorly 
infective to peritoneal macrophages. Moreover KOLmGLOB parasites were poorly
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infective to mice, taking several weeks longer than WT parasites to cause lesions of 4 mm 
to develop. The inability to synthesise ascorbate in these lines appears to adversely affect 
the parasites although further experimentation is required to address why the 
KOLmGLOAl clone also exhibits an in vivo infection defect. A more in-depth phenotypic 
analysis of the clones rather than the parent knockout lines, together with the creation and 
analysis of KOLmGLO parasites engineered to re-express LmGLO, will help clarify the 
role of GLO in L  major. It is also of interest that parasites over-expressing LmGLO appear 
to be more infective to both macrophages and mice than WT and control parasites. 
However, until a method can be developed to prove that the parasites do indeed over­
express LmGLO, these results must be treated with caution.
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7 Discussion
This study aimed to identify and characterise a Leishmania protein capable of reducing 
pentavalent antimonial compounds to the toxic trivalent form, and to ascertain whether any 
protein identified was involved in antimonial susceptibility in vivo. L. major TDRl was 
found and investigated due to its similarity to oGST and like this mammalian protein, 
recombinant TDRl was capable of reducing pentavalent metalloids, including antimonial 
drugs, in vitro (Denton et al, 2004). To elucidate the role of TDRl in antimonial 
metabolism in vivo, L. major TDRl knockout and over-expressing lines were generated, 
infected into macrophages and treated with pentavalent antimonials, and the effects of the 
drugs on the parasites were assessed. Due to the different macrophage infection rates 
displayed by the different parasites lines it proved difficult to compare the effects of the 
pentavalent antimonials on the different parasites. However despite being inconclusive, the 
studies suggested that altering the level of TDRl in L. major had little or no effect on the 
parasites' sensitivity to pentavalent antimonial drugs.
If the TDRl does not have an impact upon the susceptibility of L. major to pentavalent 
antimonials in vivo it is interesting to postulate why that may be. Since it is already well 
established that toxicity is dependant on reduction of the drugs to the trivalent form, the 
most obvious explanation is that in vivo the protein does not reduce pentavalent 
antimonials and there could be several reasons for this. Firstly, as discussed in the 
introductory chapter to this investigation, the site of reduction remains controversial. If 
reduction occurs in the macrophage, which could be mediated enzymatically by one of the 
classes of mammalian arsenate reductases discussed or by an as yet unidentified protein, 
TDRl may only encounter the trivalent form of the drug. It has also been demonstrated 
that pentavalent antimonials are reduced upon reaction with small thiols such as 
glutathione and cysteine (Frezard et al, 2001; Ferreira Cdos et al, 2003); this could also 
occur in the macrophage. Indeed the acidic environment of the phagolysosome where the 
parasites reside promotes this reaction (Alexander and Russell, 1992). Reduction could 
also be mediated in the macrophage by a secreted Leishmania protein and indeed, it was 
shown as part of this investigation (chapter four) that TDRl is likely to be released. This 
could also be the case for the recently identified Leishmania ACR2 protein which reduces 
pentavalent antimonials (Zhou et al, 2004): although the published account of this protein 
describes it as comprising 130 amino acids it is possible that it contains a further 100 
amino acid N-terminal region which includes a signalling peptide that is predicted to direct 
the protein to the extracellular space, as outlined in chapter three. In this situation the
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macrophage or parasitophorous vacuole could act as a reservoir for the secreted parasite 
protein meaning that although a Leishmania protein would mediate the reaction, reduction 
and therefore toxicity would be dependant on the amastigote parasites being situated in 
macrophages. This could help explain some of the controversy surromiding the site of 
reduction, specifically the observation that axenic amastigotes are not susceptible to 
pentavalent antimonials (Sereno et al, 1998). However, conflicting reports that axenic 
amastigotes are indeed sensitive to these drugs (Ephros et al, 1999) imply that the 
presence of macrophages is not necessary for reduction to occur, and that therefore this 
happens within the parasites.
The second reason that would explain TDRl not reducing pentavalent antimonials in vivo 
is that the drugs may be reduced by a different route inside the parasite. Given that there is 
scant information on the localisation of antimonials within Leishmania, it may be that 
TDRl and the pentavalent drugs do not co-localise in vivo, therefore explaining why the 
protein is not able to reduce the compounds. This would be particularly likely if the 
pentavalent antimonials were sequestered inside a parasite organelle given the likely 
cytosolic distribution of TDRl described in chapter four. In this case, pentavalent 
antimonials must be reduced by an alternative mechanism. Again, this could be mediated 
by a protein other than TDRl -  such as LmACR2 -  or could occur non-enzymatically 
upon reaction with thiols. As well as pentavalent antimonials being reduced by the thiols 
mentioned, the trypanosomatid-specific thiol trypanothione is also capable of reducing 
antimonials non-enzymatically (Ferreira Cdos et al, 2003). Indeed, reduction rates were 
greater in the presence of trypanothione than glutathione, which may go some way to 
explain why pentavalent antimonials are more toxic to parasites than the host. However, 
the rates of reduction of antimonials achieved with thiols are a fraction of those achieved 
with TDRl in vitro (Denton et al, 2004) so non-enzymatic, thiol-based reduction alone is 
unlikely to account for why TDRl does not reduce the drugs in vivo. Therefore enzymatic 
reduction by another Leishmania protein or several proteins may be a more likely 
explanation. As well as LmACR2, other arsenate reductase-like sequences are present in 
the parasite that may be capable of reducing antimonials, the most alike being similar to 
GAPDH as explained in chapter three. However, the in vivo relevance of GAPDH in 
metalloid reduction remains unclear. Three new classes of proteins with arsenate reductase 
activity have been identified in the last five years and it is likely more will be elucidated. A 
candidate could be the glutaredoxins, of which there are predicted to be several of in L. 
major. Despite the low-level sequence similarity that the proteins share, oGSTs and 
glutaredoxins exhibit comparable activities in vitro including thioltransferase and 
dehydroascorbate reductase activities. It is therefore pertinent to consider that the
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glutaredoxins may display the pentavalent arsenical reducing ability of oGST: there are no 
published accounts of these activities being looked for in glutaredoxins. It would be 
interesting to look for this activity in the predicted L. major glutaredoxins that are 
described in chapter three.
As well as the possibility that TDRl does not reduce pentavalent antimonials in vivo, it is 
possible that the protein does indeed carry out this reaction but that the experiments 
described in this investigation failed to detect this. Although knockout and over-expressing 
lines are useful tools that have been used to analyse the roles of other Leishmania proteins, 
the approach may not have been successful here. If several proteins, including TDRl, are 
able to reduce the drugs in vivo then knocking out or over-expressing TDRl may not result 
in a big difference in the parasites’ ability to reduce the pentavalent compounds and 
therefore render any changes in susceptibility to the drugs undetectable. This effect would 
be particularly pronounced if the L. major parasites were able to up- or down-regulate the 
expression of these proteins in response to the altered level of TDRl. As discussed in 
chapter three, L. major parasites are thought to possess several glutaredoxins and 
thioredoxins and degeneracy between these proteins has been reported in yeast (Potamitou 
et al, 2002): it could be the case that degeneracy between these proteins and TDRl occurs 
in Leishmania given the common activities of the proteins in vitro. It would be interesting 
to test this hypothesis by comparing the levels of glutaredoxins and thioredoxins in 
Leishmania wild type with the lines with altered TDRl levels. This could be achieved by 
individually by western blotting if the specific anti-sera to these proteins were available, or 
by a more global proteomic approach.
There are other reasons why the approach used to elucidate the role of TDRl in antimonial 
reduction and sensitivity in vivo may have failed. One possibility could be that the 
peritoneal macrophages used in the experiments may have been unsuitable for assaying the 
effects of the drug, for example if there expression profile was altered due to their artificial 
growth conditions leaving them unable to accumulate the pentavalent antimonials. This 
would also explain the lack of sensitivity to the drugs displayed by all the parasite lines 
used in the study. A problem of this nature could be circumvented by infecting live animals 
with the parasite lines and testing the efficacy of the drugs in treating the L, major 
infections in a true in vivo setting. Another potential problem could be that L  major 
parasites that were used in this study: L, major causes cutaneous leishmaniasis whereas 
visceral leishmaniasis, commonly caused by L. donovani or L. infantum, is more likely to 
be treated with pentavalent antimonials. Indeed, several studies have shown that intrinsic 
differences in species sensitivity to these drugs is common and cutaneous leishmaniasis
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isolates are generally less susceptible to these drugs than those causing visceral disease 
(reviewed in Croft et al, 2006). Creating and analysing TDRl knockout and over- 
expressing forms of a different species of Leishmania, such as L. infantum, may be 
worthwhile.
Very little is known about the enzyme(s) that mediate the reduction of pentavalent 
metalloids in mammals. There are three classes of enzymes known to display this activity 
in vitro -  GAPDH, oGSTs and PNP -  and yet evidence of the involvement of any of these 
proteins in vivo remains elusive. Construction of a knockout mouse model of any of these 
proteins may facilitate this area of investigation and help clarify whether the protein does 
mediate reduction in vivo, although this may be impossible for GAPDH and PNP due to 
their ubiquity in cells. A greater understanding of mammalian reduction of metalloids is 
required before the impact, if any, of the host metabolism on the sensitivity of Leishmania 
to pentavalent antimonials can be assessed. It is important to identify the proteins that 
regulate the reduction of pentavalent metalloids in higher eukaryotes for reasons other than 
their potential involvement in leishmaniasis chemotherapy: Arsenical compounds continue 
to contaminate drinking water in many parts of the world and are considered to be a serious 
health risk. It is distressing to think that how the body metabolises and detoxifies these 
compounds and how they exert their toxicity is still unknown. With arsenical- and 
antimonial-based drugs being proposed for the treatment of cancer (Murgo, 2001; Wyllie 
and Fairlamb, 2006), it is even more imperative that a greater insight into their metabolism 
is reached. Elucidation of how pentavalent metalloids enter cells -  both mammalian and 
parasitic -  is also required.
The recent licensing of the oral antileishmanial drug miltefosine together vrith the 
impressive cure rates quoted in several clinical studies of the drug may have prompted 
speculation that the days of antimonials in leishmaniasis chemotherapy are numbered. 
However this is a controversial view. It was outlined in the introduction to this 
investigation that miltefosine, despite its obvious advantages of being orally administrated, 
has several potential shortcomings: resistance to the drug has been easily generated in 
Leishmania in the laboratory; it may not be effective in treating some South American 
Leishmania species; patients co-infected with HIV tend to relapse when treated with 
miltefosine; and the drug is teratogenic. Although resistance to pentavalent antimonials is 
now a problem in some parts of India, these drugs have been used for decades successfully. 
Although miltefosine is no doubt a welcome addition to the arsenal of antileishmanial 
drugs, it has not stood the test of time. This, coupled with the infrastructure needed to treat 
leishmaniasis sufferers with pentavalent antimonials aheady being in place, m e^s that
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antimonials are very much still required and that research into its reduction and activation 
are valid and important. This research may also aid the understanding of additional 
metalloid-based chemotherapies.
What the endogenous role is of TDRl in the parasite is an interesting point. Unlike its T. 
cruzi homologue Tc52, TDRl was knocked out of L. major with relative ease showing that 
is it is not an essential protein. This is an intriguing difference between the two proteins. 
The different predicted active sites between TDRl and Tc52 could be indicative of 
differing functions which may explain why Tc52 is essential while TDRl is not. Whatever 
the reason, the fact that L. major can survive well without the protein implies that, as 
discussed, degeneracy between proteins may be occurring. The in vitro activities of TDRl 
coupled with the observation that the TDRl knockout lines were more susceptible to 
paraquat stress suggest that the protein has a role in protecting the parasite ffom oxidative 
stress. Maintaining the correct redox environment is of utmost importance in the cell and 
this is particularly true of parasites that have to withstand high levels of reactive oxygen 
species (ROS) generated during the oxidative burst. It would therefore make sense that the 
parasites have evolved to possess several proteins that are capable of regulating levels of 
ROS, and that partial degeneracy exists between them.
One of the potential roles of TDRl in L  major is to maintain levels of ascorbate by 
reducing dehydroascorbate which occurs in vitro. This is controversial: it has been 
described how tiypanothione alone is thought to be sufficient for performing this function 
and that an enzyme is not required (Krauth-Siegel and Ludemann, 1996). However, this 
observed activity prompted us to look for enzymes that could have a role in ascorbate 
biosynthesis in L  major and the discovery of LmGLO which, as explained in chapter six, 
is likely to have such a role. The potential involvement of TDRl in reducing ascorbate 
remains unresolved although it would be interesting to analyse this. For example, in the 
TDRl knockout lines LmGLO could be up-regulated: if the ability to recycle ascorbate 
was lost or reduced, a solution could be to produce more ascorbate. The reciprocal is true: 
in the LmGLO line TDRl could be up-regulated to promote recycling of any available 
ascorbate. This hypothesis could be tested by western blotting. Furthermore, it would be of 
interest to attempt to generate a double mutant lacking both proteins: if the hypothesis was 
correct this mutant may not be viable. Certainly, what both thèse proteins do have in 
common is that directly or indirectly they are likely to impact upon the intracellular redox 
environment of the parasite.
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